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Abstract 
 
The phosphoinositide 3-kinase / Akt / mammalian target of rapamycin (PI3-K-Akt-
mTOR) signalling pathway is a regulator of critical cellular functions including 
apoptosis, metabolism and survival. Its deregulation is involved in numerous human 
diseases. This thesis describes the synthesis and biological evaluation of a series of 
analogues of the PI3-K-Akt-mTOR inhibitor E1, a homo-dimeric diarylmethane. 
Several structurally diverse hetero-dimeric E1 derivatives were discovered that 
inhibited PI3-K-Akt-mTOR signalling in human cancer cells. 
 
Chapter 1 provides an overview of the PI3-K-Akt-mTOR signalling pathway and its 
biological significance. Chapter 2 discusses the use of small molecules for the 
investigation of PI3-K-Akt-mTOR signalling, with examples given by structural class. 
It concludes with a profile of lead compound E1. Chapter 3 outlines the proposed 
approach to analogue synthesis by the coupling of functionalised building blocks, and 
describes the development of building block compounds via the ortho-
functionalisation of phenol derivatives. Chapter 4 describes efforts towards the 
derivatisation of E1 with a linker group in order to allow the conjugation of biotin for 
affinity chromatography, or the incorporation of other groups useful for biological 
characterisation. In Chapter 5, the coupling of building blocks via C-C, C-O, C-N and 
N-S bond-forming reactions to generate homo- and hetero-dimeric E1 derivatives is 
discussed. Several of these compounds were capable of inducing cellular Akt 
inhibition. Chapter 6 focuses on the synthesis of hetero-dimeric analogues based on 
these new lead compounds. The biological evaluation of E1 derivatives in a cellular 
assay is described in Chapter 7. Finally, detailed experimental procedures are 
described in Chapter 8. 
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1. The PI3-K-Akt-mTOR Signalling Pathway 
 
1.1. Overview of PI3-K-Akt-mTOR Signalling 
The human genome is believed to consist of approximately 25,000 genes, a 
surprisingly low number, similar to that of the nematode worm Caenorhabditis 
elegans (approximately 20,000 genes).1,2 Additional biological complexity in humans 
and other mammals is enhanced by the posttranslational modification (PTM) of these 
gene products to regulate their function. One such mechanism of PTM is the 
reversible phosphorylation of proteins, which forms the basis of many cellular 
signalling networks, and imparts temporal and spatial control of protein function. Two 
classes of enzymes control this reversible phosphorylation process: kinases, which 
catalyse the transfer of phosphate groups from a phosphate donor such as 
adenosine triphosphate (ATP) to a substrate, and phosphatases, which hydrolyse 
phosphate esters. 
 
One such signalling pathway that has a central role in regulating varied cellular 
processes including metabolism, cell growth, proliferation, apoptosis, chemotaxis and 
secretion, is mediated by the phosphoinositide 3-kinase (PI3-K) family of kinases, 
predominantly through the downstream effector Akt (alternatively known as protein 
kinase B, PKB).3 Akt acts as a central node in the pathway by phosphorylating a 
plethora of substrates and coupling PI3-K with the mammalian target of rapamycin 
(mTOR) pathway.4  
 
Considerable research interest into PI3-K-Akt-mTOR signalling has been stimulated 
by its involvement in complex disease states. Deregulation of the pathway is 
prevalent in numerous human cancers,5 and it also plays a key role in the 
development of other conditions, including type II diabetes6 and neurodegenerative 
diseases.7 
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1.2. Activation of PI3-K-Akt-mTOR Signalling  
Induction of the signalling cascade begins with the activation of PI3-K in response to 
extracellular stimuli through a variety of mechanisms. Once activated, PI3-K is 
recruited to the membrane and phosphorylates the inositol phospholipid 
phosphatidylinositol-4,5-bisphosphate (PIP2 or PtdIns(4,5)P2, 1) at the 3 position of 
the inositol ring to produce the secondary messenger lipid phosphatidylinositol-3,4,5-
trisphosphate (PIP3 or PtdIns(3,4,5)P3, 2) (Figure 1.1). The synthesis of PIP3 enables 
further propagation of the signal by providing a binding site for proteins containing the 
Pleckstrin homology (PH) domain, thus bringing them into close proximity.8 
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Figure 1.1. Phosphatidylinositol-4,5-bisphosphate (PIP2, 1) is phosphorylated by PI3-
K to phosphatidylinositol-3,4,5-trisphosphate (PIP3, 2). The reverse reaction is 
catalysed by PTEN. 
 
1.2.1. Structural Characteristics of PI3-Ks 
PI3-Ks are divided into three major classes: I, II and III, although only class I PI3-Ks 
are responsible for the conversion of PIP2 to PIP3 and thus contribute to the PI3-K-
Akt-mTOR cascade.9 Class I PI3-Ks are heterodimeric proteins containing a catalytic 
and regulatory subunit.10 The 110 kDa catalytic subunit consists of a catalytic lipid 
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kinase domain, a Ras binding domain (RasB), a C-2 phospholipid binding domain 
(protein kinase C homology domain), a helical PI kinase (PIK) domain and an N-
terminal domain that forms a tight association with the regulatory subunit.11 Class I 
PI3-Ks are further subdivided depending on their structure and mechanism of 
activation: class Ia are activated primarily by growth factor receptor tyrosine kinases 
(RTKs),12 and class Ib by G-protein-coupled receptors (GPCRs).6 
 
The class Ia regulatory subunit performs an adaptor function and contains two Src-
homology 2 (SH2) domains. Class Ia PI3-Ks can encode five isoforms of the 
regulatory subunit in mammalian cells: p85α, p85β and p55γ are encoded by distinct 
genes; the shorter p55α and p50α are obtained via alternative splicing of p85α.11,6 
Additionally three isoforms of the catalytic subunit are produced: p110α, p110β and 
p110δ, which can interact with any of the regulatory subunits. The sole class Ib PI3-K 
that has been characterised to date consists of a p110γ catalytic subunit and a 
structurally distinct p101 regulatory subunit.11 A second regulatory subunit know as 
p8413 or p87PIKAP14 has also been identified. Class Ib PI3-Ks have been shown to 
play an important role in inflammatory processes.15  
 
Class I isoforms of PI3-Ks are typically referred to as α, β, γ and δ based on the 
composition of the catalytic subunit and will be referred to as such hereafter. The 
p110δ and p110γ isoforms appears to be largely restricted to leukocytes,16 whereas 
the other two isoforms typically have a broad tissue distribution.17 The factors 
governing expression of PI3-K isoforms in different tissues are currently poorly 
understood.  
 
1.2.2. Regulation of PIP3 Synthesis 
There are several mechanisms for the activation of class Ia PI3-Ks. The SH2 
domains in the p85 regulatory subunit of PI3-Ks have a high affinity for 
phosphorylated tyrosine residues found in activated growth factor RTKs, and binding 
to these motifs leads to activation. Alternatively, adaptor proteins such as Grb2-
associated binders (Gab1-3) and insulin receptor substrates (IRS1-4) can activate 
PI3-Ks when phosphorylated.12 Grb2 can also activate Ras through prior activation of 
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the GTPase son of sevenless (SOS). Association with the GTP-bound form of Ras 
via the Ras binding domain (RasB) allows direct activation of the catalytic subunit of 
class Ia PI3-Ks independent of the regulatory subunit.11,18 The p101 regulatory 
subunit of class Ib PI3-K does not contain an SH2 domain, therefore cannot be 
activated by RTKs. Activation occurs upon binding the Gβγ complex that is released 
upon GPCR stimulation.19 
 
The signalling cascade is terminated by the dephosphorylation of PIP3 at the 3-
position to regenerate PIP2 by the phosphatase PTEN (phosphatase and tensin 
homologue deleted on chromosome 10). Although the SH2-containing inositol 5'-
phosphatases (SHIP1 and SHIP2) are also capable of dephosphorylating PIP3 by 
removing the phosphate group at the 5-position to generate phosphatidylinositol 
(3,4)-diphosphate, PTEN has been shown to be primarily responsible for attenuating 
the effects of PI3-K signalling in vivo.20,21 This is presumably due to the ability of 
phosphatidylinositol (3,4)-diphosphate to recruit PH domain containing proteins to the 
membrane. 
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1.3. Signalling Downstream of PI3-K 
The presence of PIP3 in the cell membrane allows phosphoinositide-dependent 
kinase 1 (PDK1) and Akt to be translocated to the membrane by binding of their PH 
domains to PIP3. PDK1 can activate a variety of kinases from the AGC family 
including Akt, p70 ribosomal S6 kinase (S6K), and several isoforms of protein kinase 
C (PKC);22 however, only Akt phosphorylation by PDK1 is PI3-K and PIP3 
dependent.23 Three closely related isoforms of Akt are produced in mammals: Akt1, 
Akt2 and Akt3 (also known as PKBα, PKBβ and PKBγ), all of which contain a 
hydrophobic motif (HM) at the C-terminus, which forms a docking site for PDK1. They 
also contain a PH domain and a catalytic kinase domain related to that of other AGC 
family kinases.24 
 
1.3.1. Activation of Akt: the Central Signalling Node 
The activation of Akt occurs when it is localised at the membrane, and is regulated by 
two independent phosphorylation events (Figure 1.2). PDK1 phosphorylates Akt at 
threonine 308 (Thr308) located in the activation loop (T-loop) of the kinase domain.24 
PDK1 can additionally phosphorylate a variety of kinases including S6K and all PKC 
isoforms.25,26 Knock-in mice that express a mutant form of PDK1 that cannot bind 
PIP3 show reduced phosphorylation of Akt at Thr308 and as a result, are small and 
insulin resistant.27 
 
The identity of the kinase responsible for phosphorylation of the HM at serine 473 
(Ser473) was controversial until recently with numerous candidate kinases identified 
that could replicate this event in vitro, yet no convincing in vivo data. Sarbassov and 
co-workers have since provided compelling evidence that the mammalian target of 
rapamycin complex 2 (mTORC2) complex is the kinase predominantly responsible 
for Ser473 phosphorylation in vivo through extensive RNA intereference (RNAi) and 
pharmacological studies on Drosophila and human cell lines.28 Upon phosphorylation 
at Thr308 and Ser473 Akt is activated and can remain at the membrane or migrate to 
the cytosol (Figure 1.2). Both phosphorylation events are necessary for full Akt 
activation in vitro,29 yet it is unclear whether dual phosphorylation of Akt is necessary 
for phosphorylation of all of its downstream effectors in vivo. 
 
16 
 
 
Figure 1.2. Inactive Akt (red) and PDK1 are recruited to the plasma membrane via 
their PH domains. The kinase domain of Akt is phosphorylated at Thr308 by PDK1 
and the HM domain at Ser473 by mTORC2 to give activated Akt (green). 
 
The mTORC2 complex consists of mTOR, mammalian stress-activated protein 
kinase interacting protein 1 (mSIN1), mammalian counterpart of yeast LST8 (mLST8, 
also known as GβL), rapamycin-insensitive companion of mTOR (rictor) and a 
protein associated with rictor (Protor).30 mTORC2 is often referred to as the 
ʻrapamycin-insensitiveʼ complex of mTOR; however, it has since been found that in 
some cell lines, prolonged exposure to rapamycin leads to a decrease in Akt 
phosphorylation at Ser473, due to rapamycin inhibiting the formation of the mTORC2 
complex.31 The PH domain and leucine rich repeat protein phosphatases (PHLPPs) 
PHLPP1 and PHLPP2 counteract mTORC2 by dephosphorylating Akt at Ser473.32,33 
PHLPPs can also dephosphorylate all PKC isoforms.34 Hemmings and co-workers 
have shown that an alternative AGC kinase, DNA-dependent protein kinase (DNA-
PK), is responsible for Akt Ser473 phosphorylation in response to DNA damage in 
vivo.35 
 
1.3.2. Regulation of Akt Activation by mTORC1  
Once activated, Akt activates another mTOR complex known as mTORC1. mTORC1 
contains mTOR together with mLST8, the regulatory associated protein of mTOR 
(raptor), and proline-rich Akt substrate of 40 kDa (PRAS40). mTORC1 is also known 
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as the rapamycin-sensitive complex of mTOR. Akt activates mTORC1 indirectly by 
phosphorylation of tuberous sclerosis complex 2 (TSC2) in the TSC1/TSC2 dimer. 
This phosphorylation event inhibits the guanosine triphosphatase activating protein 
(GAP) activity of TSC2, and in turn leads to the activation of Rheb, which is active 
only in the guanosine triphosphate (GTP) bound form. Rheb-GTP in turn binds to 
FKBP38 (also known as FKBP8), a member of the FK506-binding protein (FKBP) 
family. The inhibited complex consists of FKBP38 bound to mTORC1; however, upon 
activation Rheb-GTP binds to FKBP38, inducing its release from mTORC1, and thus 
activating the complex (Figure 1.3).36  
 
Akt can also activate mTORC1 by direct phosphorylation of PRAS40, a component of 
the inhibited mTORC1 complex. Phosphorylation of PRAS40 generates a binding site 
for 14-3-3 proteins that enable dissociation of PRAS40.  Activated mTORC1 initiates 
a negative feedback loop that inhibits Akt by the negative regulation of IRS1 via 
activation of p70 ribosomal S6 kinase 1 (S6K) (Figure 1.3).37  
 
 
 
Figure 1.3. Overview of the relationships between PI3-K, Akt and mTOR, as well as 
selected downstream effectors. 
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1.4. Cellular Consequences of PI3-K-Akt-mTOR Signalling 
Akt acts as a central signalling node in the PI3-K-Akt-mTOR pathway, propagating 
the signal through a variety of downstream effectors (Figure 1.4). In 2007, Manning 
and Cantley published an extensive review of the literature relating to reported 
cellular targets of Akt that identified 18 substrates that had been the subject of 
multiple independent reports,4 although this may be a conservative estimate as there 
are numerous additional reports of Akt substrates supported by strong experimental 
data in the literature. 
 
 
 
Figure 1.4. Akt regulates a variety of downstream effectors by phosphorylation. 
Some key proteins regulated by Akt that are involved in cellular growth (red), 
neurological processes (purple), angiogenesis (orange), cell survival and apoptosis 
(blue), cell cycle progression (green) and metabolism (yellow) are shown. 
 
Through these numerous downstream targets, the PI3-K-Akt-mTOR signalling 
pathway plays a key role in regulating cell survival and apoptosis, cell-cycle 
progression, angiogenesis, metabolic and neurological processes. The study of PI3-
K-Akt-mTOR signalling is challenging due to the complexity of the pathway, with 
further complexity arising from cross-talk with other signalling cascades. This has 
made the development of suitable experimental tools an active area of interest. This 
will be discussed further in the following Chapter. 
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2. Pharmacological Investigation of PI3-K-Akt-mTOR 
Signalling 
 
2.1. Introduction 
The PI3-K-Akt-mTOR signalling pathway is a key regulatory mechanism for essential 
cellular processes that is deregulated in numerous complex disease states. 
Accordingly, this signalling cascade has received a vast amount of research interest 
since its initial discovery in the 1980s and has since become a popular target for 
therapeutic intervention with numerous small molecule inhibitors of the pathway 
reported at various stages of clinical development.38 
 
This review will discuss three major themes. The first section of this Chapter will 
discuss the major experimental techniques that have been harnessed to probe PI3-
K-Akt-mTOR signalling. The second section will discuss insights into understanding 
PI3-K-Akt-mTOR signalling obtained from small molecules, using specific examples 
by structural class. The final section will discuss the development of a dimeric 
diarylmethane modulator of PI3-K-Akt-mTOR signalling developed within the Hailes 
and Woscholski research groups. Finally, the objectives of the work presented in this 
thesis will be outlined. 
 
2.2. Techniques for Studying PI3-K-Akt-mTOR Signalling 
Despite recent advances in our understanding of PI3-K-Akt-mTOR signalling, the 
complexity of the network provides ample opportunity for further advances, and 
hence the development of new techniques and tools for its study is an active area of 
research. In vivo investigation of PI3-K-Akt-mTOR signalling has relied on various 
techniques, in particular: genetic knockout and knock-in to modulate protein function, 
gene silencing using RNA interference (RNAi) and pharmacological protein 
modulation with small molecules. 
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2.2.1. Genetic Knockout and Knock-in 
Gene knockout refers to the insertion of inoperative genes into an organism, typically 
resulting in the target protein not being expressed, or expression of an inactive 
analogue, whereas gene knock-in refers to the replacement of a wild-type gene with 
a target sequence. Such techniques have been instrumental for studying PI3-K-Akt-
mTOR signalling, yet have some limitations. Knockout of the p110α or p110β 
isoforms of PI3-K is embryonically lethal in model organisms due to the ubiquitous 
expression of these isoforms.39 Similarly, knockout of more than one isoform of Akt is 
embryonically or neonatally lethal in mice.40 A more fundamental disadvantage is that 
the knockout of one isoform of PI3-K can result in a compensatory increased 
expression of other isoforms, therefore it cannot be conclusively determined if the 
observed phenotype is directly related to the knocked-out gene.39  
 
2.2.2. RNA Interference (RNAi) 
RNAi is a powerful and extensively used method for the knockdown of protein 
expression. It provides an operationally simple method of altering gene expression 
relative to genetic knockout and knock-in, and avoids issues of embryonic non-
viability. RNAi is promoted by doubled-stranded RNA (dsRNA) sequences 
complementary to the gene of interest. The endoribonuclease Dicer cleaves dsRNA 
into double stranded fragments of 21-25 nucleotides containing dinucleotide 3ʼ 
overhangs known as small interfering RNAs (siRNAs). These siRNAs are recognised 
and incorporated into an RNA-induced silencing complex (RISC). The catalytic 
component of RISC is an exonuclease known as argonaute, which cleaves mRNAs 
complementary to the siRNA guide strand, thus preventing translation of the 
corresponding protein.41  
 
In mammalian cells, dsRNAs of more than 30 base pairs induce a non-specific 
antiviral response. To circumvent this issue siRNAs are chemically synthesised and 
introduced into the cell, or expressed from a plasmid, or viral vectors.42 Ensuring 
effective delivery of siRNA is one of the major limitations of RNAi, as is its slow 
response time. As RNAi inhibits transcription, effective knockdown is also dependent 
on the rate of degradation of the protein of interest.43 
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2.2.3. Small Molecules as Pharmacological Probes 
A wide variety of small molecules that modulate components of the PI3-K-Akt-mTOR 
pathway have been developed, primarily as potential therapeutic agents.  The 
discovery of potent and selective small molecule modulators is highly resource-
intensive, yet pharmacological perturbation possesses some unique advantages 
providing that development of a suitable compound is feasible. Small molecules act 
extremely rapidly (typically in a matter of minutes, as opposed to hours or days for 
RNAi), and can induce reversible effects in vivo due to metabolism; furthermore, 
varying the concentration of the small molecule allows subtle phenomena to be 
studied by the generation of a dose-reponse profile.44,45 A unique feature of small 
molecules is that they can be modified to incorporate functionalities such as organic 
dyes for imaging experiments,46 or those aiding target identification such as 
photoaffinity labelling groups that allow covalent linkage to a protein upon UV 
irradiation,47 or biotin for affinity purification with avidin or streptavidin coated 
polystyrene beads. 
 
Shokat and co-workers have developed a hybrid pharmacological and genetic 
approach that they refer to as ʻchemical geneticsʼ.48 A mutation can be introduced 
into a protein of interest that enables binding of a modified inhibitor incorporating a 
bulky sidechain, thereby precluding binding to the closely related wild-type proteins. 
This technique allows unparalleled inhibitor specificity, despite the high homology of 
the ATP-binding sites of kinases. Although this approach is potentially extremely 
powerful, it is highly labour intensive, and has yet to be successfully applied to the 
PI3-K-Akt-mTOR pathway. 
 
Genetic, RNAi knockdown and pharmacological approaches can be considered 
complementary to each other; each technique contains unique advantages and 
disadvantages that must be considered (summarised in Table 2.1).49,50 Weiss and 
Shokat have published a series of experimental guidelines to aid researchers in 
designing appropriate experiments using RNAi and small molecules.50 
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 Advantages Disadvantages 
Genetic knockdown / 
knock-in 
• In theory, any gene can be 
targeted 
 
• Mutations may be lethal. 
• Protein-protein interactions 
are disrupted. 
• May result in altered 
expression of other proteins. 
• Highly labour intensive. 
RNAi • In theory, any gene can be 
targeted. 
• siRNAs are readily available 
and inexpensive. 
• Often results in only partial 
depletion of the desired 
protein. 
• Possibility of off-target effects. 
• Slow response time. 
• Delivery may be difficult. 
Small molecules • Rapidly acting. 
• Effects are typically 
reversible. 
• Protein-protein interactions 
are preserved. 
• Can generate dose-
response profile. 
• Can incorporate useful 
functionalities (e.g. dyes). 
• Common therapeutic 
agents. 
• Development is extremely 
labour intensive. 
• May not be feasible for some 
targets. 
 
 
Table 2.1. Summary of the advantages and disadvantages of some complementary 
techniques for protein perturbation.  
 
2.2.4. The Observed Phenotype may be Technique Dependent 
Inconsistencies between phenotypes that result from protein modulation using 
different experimental techniques are a significant barrier to building a holistic 
understanding of PI3-K-Akt-mTOR signalling. These inconsistencies result from 
mechanistic differences between genetics, RNAi and perturbation of protein function 
with small molecules.50 Small molecules typically target the ATP-binding site of a 
kinase, inhibiting protein function without influencing protein abundance; knockdown 
or knock-in techniques disrupt both protein function and abundance. Accordingly, 
protein-protein interactions are typically maintained using small molecule probes, 
whereas this structural information is lost with genetics or RNAi. Examples of such 
inconsistencies will be addressed throughout this discussion. 
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A major motivation for studying PI3-K-Akt-mTOR signalling is the identification of 
novel drug targets, although genetic or RNAi techniques may not provide an accurate 
model for small molecule modulation.50 As small molecules are currently the ʻgold 
standardʼ for therapeutic agents, they provide the most suitable agents for verification 
of potential targets at present. 
 
2.3. Specific Small Molecules Modulators of PI3-K-Akt-mTOR Signalling 
Small molecules have been valuable tools for investigating PI3-K-Akt-mTOR 
signalling and will be the subject of the remainder of this discussion. Selected 
examples will be presented by structural class. 
 
2.3.1. Steroidal Furanoids 
The fungal steroid wortmannin (3) was reported to inhibit PI3-K in 1993, making it the 
first known small molecule inhibitor (Figure 2.1).51 Wortmannin irreversibly inhibits 
PI3-K by opening of the electrophilic furan ring at the C-20 position, following attack 
of a lysine residue within the ATP-binding region. Wortmannin suffers from multiple 
disadvantages in comparison to more recently developed compounds. It is a 
promiscuous inhibitor that inhibits PLK1,52 as well as numerous other kinases 
including mTOR.53 Additionally it is cytotoxic and suffers from low solubility and poor 
stability in aqueous media. 
 
Derivatives of wortmannin have been developed in an attempt to solve these 
problems. The pegylated 17-hydroxywortmannin derivative PWT-458 (4) developed 
by Wyeth resulted in reduced toxicity and improved solubility and plasma stability 
while maintaining potency.54 Similarly, the ring-opened derivative PX-866 (5) 
developed by Oncothyreon demonstrated improved stability.55 Wortmannin 
analogues incorporating fluorescent probes have also been used to image the 
localisation of PI3-Ks in a cellular context. Addition of the fluorescent carboxylic acid 
NBD-sarcosinate at the C-11 position of wortmannin gave a fluorescent conjugate (6) 
that was inhibitory towards PI3-K.56 Similarly, C-11 derivatisation has been used to 
generate biotinylated (7) and 125I labeled (8) wortmannin derivatives,57 which inhibited 
PI3-K sufficiently to enable their use as probes in vivo. 
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Figure 2.1. Wortmannin (3) and derivatives (4-8). Wortmannin was the first small 
molecule reported to inhibit PI3-K. 
 
2.3.2. Rapamycin and the ʻRapalogsʼ 
Rapamycin (9) is a macrocyclic lactone isolated from a Streptomyces hygroscopicus 
strain (Figure 2.2). Initial interest focussed on its anti-fungal properties, however it 
was later found to have immunosuppressive activity. Rapamycin has low solubility in 
aqueous media, and therefore the closely related ʻrapalogsʼ – temsirolimus (10), 
everolimus (11) and deferolimus (12) – were developed by Wyeth, Novartis and Ariad 
respectively to improve aqueous solubility.58 
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Figure 2.2. Rapamycin (9) and the ʻrapalogsʼ (10-12) inhibit mTOR. 
 
Rapamycin influences PI3-K-Akt-mTOR signalling through the formation of a complex 
with the FK506-binding protein FKBP12. mTOR was subsequently identified as the 
target of the resulting rapamycin-FKBP12 complex in 1994.59-61 The rapamycin-
FKBP12 complex binds to and inhibits the kinase activity of the mTORC1 complex 
(also known as the ʻrapamycin sensitiveʼ complex).  
 
It was initially thought that mTORC2 was insensitive to rapamycin, as the rapamycin-
FKBP12 complex does not bind to mTORC2. Sarbassov and co-workers have since 
shown that rapamycin is capable of inhibiting the assembly of mTORC2 in several 
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cell types, and thus it shows inhibitory activity in these cell types.31 In addition, 
Akcakanat, et al. have shown that treatment with rapamycin, as well as RNAi 
knockdown of mTOR, causes dephosphorylation of rictor, a component of 
mTORC2.62 The recent development of pyrazolopyrimidine-derived ATP-competitive 
mTOR inhibitors has shed further light on the downstream consequences of mTOR 
signalling.63,64 
 
2.3.3. Chromone Derived Compounds 
In 1994, one year after wortmannin was reported as a PI3-K inhibitor, Lilly Research 
Laboratories demonstrated that competitive inhibition of PI3-K with a small ʻdrug likeʼ 
molecule was feasible with the quercetin-derived compound LY294002 (13) (Figure 
2.3).65 X-Ray crystallographic studies later revealed that LY294002 binds in the ATP-
binding site via hydrogen bonding between the morpholino oxygen and the amide 
backbone of the Val882 residue, and between the ketone moiety and Lys833.66  
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Figure 2.3. Isoform specific PI3-K inhibitors (14-16) have been developed from the 
non-specific inhibitor LY294002 (13) by modification of the chromone scaffold. The 
interactions between the morpholino oxygen and ketone moieties of LY294002 and 
the Val882 and Lys833 residues of PI3-K are shown. 
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As with wortmannin, LY294002 inhibits a variety of kinases besides PI3-K. Gharbi, et 
al. have investigated the specificity of LY294002 by immobilising the compound onto 
Sepharose beads for affinity chromatography experiments using cellular extracts of 
potential target proteins.67 The exocyclic aryl group of LY294002 was substituted with 
an aniline group to provide a ʻhandleʼ for conjugation, as X-ray crystallography 
indicated that this substituent projects away from the ATP-binding site. The 
immobilised LY294002 derivative was successfully used to affinity purify a variety of 
kinases including mTOR, CK2, GSK3 and PI4-K as well as PI3-K. This study 
provides further evidence that LY294002 is unsuitable for investigating PI3-K-Akt-
mTOR signalling as compounds with an improved specificity profile are commercially 
available. 
 
Modification of the chromone scaffold in LY294002 has led to the development of 
some isoform specific PI3-K inhibitors. Replacement of the chromone oxygen with 
nitrogen, together with modification of the C8 aryl substituent led to improved potency 
and selectivity in TGX-115 (14), developed by Kinacia. TGX-115 is selective for the 
mammalian p110β and p110δ isoforms of PI3-K, exhibiting over 100-fold selectivity 
over the p110α and p110γ isoforms.68 This specificity profile was presumed to result 
from interactions between the bulky C-8 aromatic substituent and non-conserved 
residues that line the outside of the ATP-binding site. The LY294002 derivative TGX-
286 (15) exhibited similar potency to TGX-115, although it was less selective for the 
p110β and p110δ isoforms.67 
 
In a landmark study, Knight and co-workers evaluated a structurally diverse collection 
of PI3-K inhibitors using a variety of in vitro and in vivo assays and X-ray 
crystallography.69 This study showed that TGX-115 and TGX-286 were unable to 
inhibit insulin-stimulated phosphorylation of any protein associated with the PI3-K 
pathway in adipocyctes and myotubes, despite TGX-115 lowering PtdIns(3,4)P2 and 
PIP3 levels in adipocytes by approximately 50%. These results indicated that the 
p110β and p110δ isoforms were not primarily responsible for insulin signalling in 
adipocytes and myotubes. Further investigation using TGX-115 revealed a secondary 
role for these isoforms in myotubes, where they are responsible for synthesising a 
basal pool of PIP3 that lowers the threshold level of p110α neccesary for Akt 
phosphorylation. In contrast, addition of TGX-115 led to a partial reduction in PIP3 
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levels in adipocytes, but did not inhibit p110α induced Akt phosphorylation, 
suggesting this subtle effect is not at work in this tissue.69 Foukas, et al. published a 
similar study, which demonstrated that TGX-221 (16), which is over 1,000-fold 
selective for p110β over 110α, had no effect on insulin stimulated PI3-K activity.70 
Jackson and co-workers used TGX-221 to demonstrate a role for p110β in promoting 
platelet activation, suggesting a potential role for p110β inhibitors as antithrombotic 
agents.71  
 
2.3.4. Pyrimidine and Quinoline Derived Compounds 
PI-103 (17), a pyridinylfuranopyrimidine compound developed by Piramed, has 
proved a great asset for the study of PI3-K-Akt-mTOR signalling (Figure 2.4). 
Although PI-103 is a multi-target inhibitor, it inhibits the p110α isoform more 
effectively than p110β.69 As well as being a nanomolar inhibitor of PI3-K, PI-103 is a 
potent inhibitor of mTORC1 and mTORC2 (IC50s of 20 and 83 nM respectively). A 
model based on X-Ray crystallography studies of several PI3-K inhibitors bound to 
p110γ suggests that PI-103 binds in the ATP-binding pocket in a similar manner to 
LY294002 and other chromone derivatives. Its potency against PI3-K is thought to 
derive from projection of the meta-phenol moiety into a deep ʻaffinity pocketʼ.  
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Figure 2.4. Structures of isoform selective PI3-K inhibitors derived from a pyrimidine 
(17-18) or quinoline (19-20) scaffold. 
 
Knight and co-workers exploited the isoform specificity of PI-103 to show that p110α 
is primarily responsible for insulin signalling in adipocyctes and myotubes.69 
Chaussade, et al. conducted a similar study using PI-103 and a variety of other 
isoform specific inhibitors including TGX-221.72 In contrast to the earlier study by 
Knight and co-workers, they found that p110α is not necessary for insulin signalling 
as p110β and p110δ play a compensatory role in several cell lines. These results 
provide strong evidence that there is functional redundancy between PI3-K isoforms 
in vivo, and that this is highly variable over different cell types. 
 
The inhibitory activity of PI-103 has been further defined by Fan, et al.73 In glioma cell 
lines, addition of either PI-103 or TGX-286 (p110α and p110β inhibitors respectively) 
was sufficient to prevent activation of Akt, although inhibition of p110α alone blocked 
proliferation of glioma cells in vitro. Furthermore, the synergy of mTOR and PI3-K 
inhibition exhibited by PI-103 gave the compound significantly higher efficacy in 
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arresting the growth of glioma cells in vivo, in comparison to treatment with 
rapamycin or TGX-286.73 
  
The advantage of using potent and specific compounds such as PI-103 over 
promiscuous inhibitors such as LY294002 was demonstrated by Raynaud and co-
workers, who showed that treatment of a variety of cell lines with PI-103 did not lead 
to apoptosis, despite successful inhibition of Akt phosphorylation.74 While this was 
contrary to expectations, much of the evidence for associating inhibition of PI3-K-Akt-
mTOR signalling with apoptosis arises from studies employing LY294002. This 
indicates that apoptosis observed following treatment with LY294002 may result from 
other pathways or mechanisms, therefore it has been recommended that the use of 
LY294002 for inhibiting PI3-K be replaced by PI-103.53 PI-103 is commercially 
available from several sources. 
 
Yaguchi, et al. developed the pyrimidine-derived compound ZSTK474 (18) following 
screening of a library of triazines.75 ZSTK474 is a potent inhibitor of PI3-K (IC50 of 37 
nM), but is not isoform specific. Molecular modelling indicated that ZSTK474 binds to 
ATP-binding pocket of PI3-K, in a similar manner to ATP, with the benzoimidazole 
nitrogen forming a hydrogen bond to Val882 and further hydrogen bonding to Lys833 
and Ser806. The greater potency of ZSTK474 over LY294002 is presumed result 
from this additional hydrogen bond with Ser806. 
 
Yang and co-workers have identified a quinoline-derived compound known as 
quinostatin (19) from a library of approximately 20,000 compounds, using a high-
throughput assay they developed for inhibition of phosphorylation of ribosomal 
protein S6: a downstream effector of mTOR signalling.76 Structure-activity analyses 
indicated that the C-3 carbonyl group was essential for S6K inhibition, but an ethoxy 
group could replace the para-ethylphenyl substituent without affecting inhibition. The 
target of quinostatin was verified using affinity chromatography. An analogue of 
quinostatin (20) was synthesised by attachment of a polyethylene glycol chain via an 
amide bond to the C-3 carbonyl group, which in turn, could be linked to agarose 
beads via an additional amide linkage. This structural modification lead to an 
approximate 100-fold decrease in activity, although the conjugated compound 
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remained sufficiently active to be used for affinity chromatography. Incubation of 
MCF-7 cell lysate with the beads led to the identification of numerous proteins, with a 
single band that disappeared upon the addition of 100 μM quinostatin. LC-MS and 
trypsin digestion indicated this band corresponded to the p85α and p85β subunits of 
PI3-K, whereas immunoblotting with a p110-specific antibody indicated that affinity 
purification of the catalytic subunit had also occurred. In addition, quinostatin was 
found to inhibit the kinase activity of p110γ. This suggests quinostatin is targeting the 
catalytic subunit, as p110γ does not contain a regulatory subunit. 
 
2.3.5. Quinazolinone Purines 
Further modification of the LY294002 scaffold led to the development of IC87114 
(21), the first quinazolinone purine PI3-K inhibitor, by ICOS (Figure 2.5). IC87114 is a 
potent inhibitor of p110δ, (IC50 of 0.5 μM) with over 50-fold selectivity over p110γ, 
making it the most selective inhibitor of a single PI3-K isoform reported to date.77 
Interestingly, IC87114 has 100-fold selectivity over p110α and p110β-compared to 
p110γ, whereas the chromone-derived compounds are selective for both p110β and 
p110δ. IC87114 has been used to show that p110δ is primarily responsible for 
amplification of PIP3 levels and the directional component of chemotaxis in 
neutrophils.77 IC87114 has also subsequently been used to indicate the key role of 
p110δ in B cell and T cell development, indicating the anti-inflammatory potential of 
such compounds. Illustrating the phenotypic differences between pharmacological 
and genetic approaches, the use of IC87114 in wild-type mouse B cells led to 
stronger inhibition of Erk and GSK3 than observed in B cells obtained from p110δ 
D910A/D910A knock-in mice.78,79 
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Figure 2.5. Structures of the isoform selective PI3-K inhibitors 21-23 derived from a 
quinazoline purine scaffold. 
 
To determine the impressive selectivity of the quinazolinone purines for p110δ the 
crystal structure of p110γ bound to PIK-39 (22) has been studied. PIK-39 is a closely 
related analogue of IC87114 containing a thiol moiety, and has similar potency and 
specificity for p110δ.69 In order to be accommodated within the ATP-binding pocket, 
orientation of the purine differs to that of the adenine of ATP and the quinazolinone 
ring system projects out of the entrance to the ATP-binding pocket. This binding 
mode is believed to induce flipping of the Met804 residue, which induces a 
conformational change in the protein. According to this model the selectivity of the 
quinazolinone purines can be explained by the differing plasticity of PI3-K isoforms in 
the region around Met804 within the loop of the catalytic domain, and hence their 
ability to tolerate this induced conformational change. 
 
The crystallographic data were used to model IC87114 bound to p110γ and show 
that this unique binding mode is conserved among the quinazolinone purines. Aided 
by this model, Knight and co-workers designed and synthesized the IC87114 
derivative PIK-294 (23), which incorporates a meta-phenol group to project into the 
ʻaffinity pocketʼ analogously to PI-103. A 62-fold increase in potency against purified 
p110γ was achieved by exploiting this interaction, albeit with a loss in specificity.69 
The crystal structure of p110δ was disclosed during the preparation of this thesis;80 
the structures of PIK-39 and IC87114 bound to p110δ confirmed the hypothesis that 
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these quinazolinone purine compounds exploit the additional plasticity of this isoform 
by projecting substituents into the previously postulated ʻaffinity pocketʼ. 
 
2.3.6. Thiazolidinediones 
The selective ATP-competitive inhibitors of p110γ, AS-604850 (24) and AS-605240 
(25) were developed by Serono in 2005 around the thiazolidinedione scaffold (Figure 
2.6). X-ray crystallographic studies revealed that they both bind to the ATP-binding 
pocket and the thiazolidinedione nitrogen interacts either via a salt-bridge with the 
side chain of Lys833 and the quinoxalone nitrogen, or by hydrogen bonding between 
the 1,3-benzodioxole oxygen atoms and Val882.81  
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Figure 2.6. Structures of the isoform selective PI3-K inhibitors 24-27 derived from a 
thiazolidinedione scaffold. 
 
AS-604850 and AS-605240 inhibit p110γ with over 30-fold selectivity over p110β and 
p110δ. AS-604850 was more selective for p110γ over p110α than AS-605240 (18-
fold and 7.5-fold respectively), yet AS-605240 was vastly more potent (IC50 of 9 nM) 
than AS-604850 (IC50 of 10 μM) in vivo due to its high cell permeability.81 The related 
thiazolidinedione PIK-124 (26), developed by Warner-Lambert, also exhibits 
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selectivity for p110γ over p110β and p110δ, however is also twice as selective for 
p110α over p110γ. 69 
 
AS-605240 and AS-604850 are useful tools for probing p110γ function due to their 
selectivity profiles. In mouse macrophages, both compounds inhibited Akt 
phosphorylation when stimulated with C5a and chemokine MCP: cytokines that act 
through GPCRs.81 In contrast, the compounds had no effect upon stimulation in the 
presence of a ligand that activates PI3-K by activation of RTKs. AS-605240 was 
successfully used to block the progression of joint damage and inflammation in two 
different mouse models of rheumatoid arthritis. 81 
 
AS-604850 has subsequently been used in conjunction with IC87114 to show that 
p110δ and not p110γ is the PI3-K isoform primarily responsible for the activation of 
signalling components downstream of B cell antigen receptors (BCRs).82 This 
evidence supported earlier genetic studies that indicated a role for p110δ in B and T 
cell activation.81 The thiazolidindinone structure has been further modified, replacing 
the quinoxaline ring in AS-605240 with an aryl substituted furan to yield AS-252424 
(27), resulting in a greater than 20-fold selectivity for p110γ over p110α.83  
 
2.3.7. 2,3-Disubstituted Pyrazines and Related Compounds 
Merck Research Laboratories have developed selective Akt inhibitors known as the 
ʻAktisʼ (28-31) based on the 2,3-disubstitued pyrazine scaffold (Figure 2.7).84 
Characterisation of Akti-1/2a (28) shows that it is an allosteric Akt inhibitor. Akti-1/2a 
was 8-fold selective for Akt1 over Akt2 in a purified enzyme assay, and 2-fold 
selective for Akt1 over Akt2 in C33a cervical carcinoma cells. Further exploration 
around this scaffold led to compounds Akti-1 (29), Akti-2 (30) and Akti-1/2 (31). Akti-1 
was selective for Akt1 (31-fold over Akt2), whereas Akti-2 was selective for Akt2 (58-
fold over Akt1) in the purified enzyme assay, although this selectivity was less 
pronounced in C33a cells. Akti-1/2 inhibited both Akt1 and Akt2, although showed 
low selectivity for the former. None of the compounds strongly inhibit Akt3, and all 
were non-inhibitory towards a panel of related kinases.84 
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Figure 2.7. Structures of the ʻAktiʼ series of Akt inhibitors (28-31) based around a 
2,3-disubstituted pyrazine scaffold. 
 
Binding of the Aktis is PH domain dependent; however, studies with tritium-labelled 
analogues indicated that they do not bind to the isolated PH domain but require intact 
Akt, suggesting that the Aktis bind to multiple domains. In order to demonstrate their 
therapeutic potential, the Aktis were used to demonstrate the induction of TNF-
related apoptosis-inducing ligand (TRAIL) induced apoptosis in LNCaP cells, using 
caspase-3 induction as a readout.84 
 
Dual inhibition of Akt1 and Akt2 was as effective at inducing apoptosis as treatment 
with LY294002; independent inhibition of Akt1 or Akt2 was far less effective. 
Furthermore, overexpression of Akt3 was unable to rescue the LNCaP/Akt3 cells 
from caspase-3 activation upon treatment with Akti-1/2. In three out of four cell lines, 
co-treatment with Akti-1/2 was found to be more effective than treatment with 
rapamycin alone in inducing caspase-3 activity, illustrating the role of Akt in inducing 
apoptosis. The Aktis have also been used to demonstrate that Akt directly 
phosphorylates the S-phase-cyclin-dependent kinase CDK2 in vivo.85 EGF induced 
phosphorylation of CDK2 was abolished upon pretreatment with an Akti compound, 
yet CDK2 phosphorylation was maintained upon pretreatment with rapamycin.  
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Merck subsequently published a ʻsecond-generationʼ of compounds with improved 
pharmacological properties (Figure 2.8). The pyridopyrimidine compound 32 caused 
a 3-fold induction of caspase-3 activity at 0.1 μM in LnCap cells treated in 
combination with TRAIL.86 By contrast, 2 μM of Akti-1/2 is required to cause a 2-fold 
increase in activity. Further derivatisation led to the 2,3,5-trisubstituted pyridine 
compound 33, which induced an approximately 6-fold increase in caspase-3 activity 
at 2.0 μM.87 A related set of potent inhibitors, including the 2-unsubstituted 
pyridopyrimidine 34, have also recently been reported.88 
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Figure 2.8. Structures of ʻ2nd generationʼ Akt inhibitors derived from the ʻAktiʼ series 
(32-34). 
 
2.3.8. Pyrazolopyrimidines 
Since the first pan-selective PI3-K inhibitors such as wortmannin and LY294002 were 
discovered, considerable effort has been focused on the development of inhibitors for 
specific kinases or isoforms.89 Multi-targeted inhibitors were expected to exhibit 
unacceptable toxicity for therapeutics due to the fundamental nature of PI3-K-Akt-
mTOR signalling,38 yet there is evidence that such compounds exhibit poor efficacy 
due to redundancy of function within the pathway.73 This lack of efficacy is presumed 
to result from the complex feedback loops within the pathway, therefore inhibitors 
targeting multiple kinases have attracted growing interest.90  
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Compounds derived from the pyrazolopyrimidine scaffold are known to inhibit a 
variety of tyrosine kinases. Apsel and co-workers screened a variety of tyrosine 
kinases for p110α inhibition and identified the pyrazolopyrimidines S1 (35) and S2 
(36) that inhibited p110α in addition to a series of protein kinases.91 Over 200 
analogues with different substitution patterns at positions N-1 and C-3 were 
synthesised and screened against a panel of 14 PI3-Ks and tyrosine kinases, 
resulting in several compounds capable of potently inhibiting p110α and tyrosine 
kinases (Figure 2.9).  
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Figure 2.9. Structures of multi-targeted inhibitors of PI3-K and tyrosine kinases 
derived from a pyrazolopyrimidine scaffold (35-39). 
 
Crystal structures of S1 and S2 bound to p110γ indicated that the pyrazolopyrimidine 
ring system mimics the adenine of ATP in the ATP-binding site and that the aryl 
moiety projects into the affinity pocket. Crystal structures were also obtained for 
several compounds bound to the tyrosine kinase c-Src. Pyrazolopyrimidines capable 
of inhibiting c-Src such as PP121 (37) have a hydrogen bond to Glu310, which 
compensates for the helix-stabilising interaction between Lys295 and Glu310 when 
the active site is unoccupied. 
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PP121 has been used to determine the cellular consequences of dual inhibition of 
p110α and oncogenic tyrosine kinases such as Bcr-Abl, Src, Ret and the VEGF 
receptor. PP121 inhibits phosphorylation of Akt and S6K in a similar manner to PI-
103, with flow cytometry indicating that both compounds induce G0G1 cell cycle arrest 
in three different human cancer cell lines. Unlike PI-103, PP121 inhibits proliferation 
of thyroid carcinoma cells, which frequently contain mutations in the Ret tyrosine 
kinase.92 Interestingly, PP121 is able to block proliferation of cells expressing Bcr-Abl 
containing the T315I mutation. This common mutation prevents binding of inhibitors 
by increasing the size of the ʻgatekeeperʼ residue that limits the substrateʼs access to 
the ATP-binding site, limiting the efficacy of existing clinically approved tyrosine 
kinase inhibitors.93 Although binding of PP121 is also prevented, inhibition of the PI3-
K-Akt-mTOR cascade is compensatory. This study suggests multi-targeted inhibitors, 
or combination therapy with PI3-K-Akt-mTOR inhibitors, might be a useful strategy 
for oncological therapies. 
 
Further alteration of this scaffold by Feldman and co-workers identified the 
ʻTORKinibsʼ – PP242 (38) and PP30 (39). In vitro screening indicated that PP242 
and PP30 inhibitor mTOR with IC50s of 8 nM and 80 nM respectively.63 Both 
compounds are highly selective, although PP242 also inhibits PKCα with an IC50 of 
50 nM whereas PP30 is inactive. These compounds are the first reported ATP-
competitive inhibitors of mTOR. Thoreen, et al. concurrently reported the discovery of 
Torin1, a pyridinonequinoline derived ATP-competitive selective mTOR inhibitor with 
2 to 8 nM potency in vitro.64 The structure of Torin1 has not been disclosed.  
 
A model of the catalytic region of TOR has been developed based on the crystal 
structure of p110γ.94 The overlapping locations of activating mutations in TOR with 
oncogenic mutations in p110γ suggests considerable structural similarity between 
the proteins. This model has been used to rationalise the inhibitory profile of the 
pyrazolopyrimidine inhibitors. Modelling studies suggested that the 4-amino group of 
PP242 is capable of hydrogen bonding to the Gly2238 residue adjacent to the 
gatekeeper, with the 5-hydroxy group of the indole interacting with Lys2187. The 
authors suggest that PP242ʼs additional selectivity for mTOR over p110γ compared 
to S2 arises from a steric clash between p110γ and the N-1 isopropyl group of 
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PP242. However, in the original study by Apsel, et al., S1 was reported to inhibit 
p110γ, despite also containing an N-1 isopropyl group. Furthermore, the binding 
modes of the pyrazolopyrimidine rings of S1 and S2 appeared identical by X-ray 
crystallography.91 
 
PP242 and PP30 inhibit Akt phosphorylation at Ser473, and inhibits Thr308 at higher 
doses, providing further evidence that mTORC2 is responsible for Ser473 
phosphorylation. In order to investigate the relationship between the Ser473 and 
Thr308 phosphorylation events, cells containing S473A mutant Akt and cells unable 
to express mTORC2 were treated with PP121. In both cases, phosphorylation of 
Thr308 was unaffected by PP121 treatment, indicating that these two 
phosphorylation events are linked through mTOR.  
 
The necessity of dual Akt phosphorylation in vivo is unclear.29 Treatment with PP242 
did not lead to the significant inhibition of phosphorylation of downstream substrates 
of Akt, such as GSK3, TSC2 and FOXO1/O3a. In contrast, treatment with Akti-1,2 led 
to complete inhibition of phosphorylation of Akt and its downstream substrates. 
Despite this, PP121 was a more potent anti-proliferative agent in mouse embroyonic 
fibroblasts (MEFs) than rapamycin, even in cells lacking mTORC2. PP121 inhibits 
translation by fully inhibiting phosphorylation of the mTORC1 substrate 4EBP1, which 
is partially resistant to treatment with rapamycin. These findings suggest that 
mTORC1 may play a more critical role in regulating the PI3-K-Akt-mTOR cascade 
than was previously thought. 
 
2.4. General Features of Kinase Inhibitors 
Eukaryotic protein and lipid kinases contain a highly conserved ATP-binding site. 
This motif is located in the catalytic domain, which is folded into two lobes that are 
connected by a peptide chain known as the ʻhinge regionʼ. ATP binding occurs 
through the formation of hydrogen bonds between the adenine ring and the hinge 
region, as well as between the ribose ring and C-terminal residues. In addition, the 
phosphate groups are coordinated to two magnesium ions, which are in turn bound to 
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an aspartate that forms part of the conserved ʻDFG-motifʼ. The phosphates also 
interact with a glycine-rich loop in the ATP-binding site.152 The majority of kinase 
inhibitors are ATP-competitive and contain an adenine-mimic. Despite the homology 
of the ATP-binding site, selectivity for particular kinases can be imparted by 
exploiting binding interactions outside of the ATP-binding site, or by targeting the 
structurally distinctive inactive conformation of the kinase. The rational design of such 
inhibitors typically relies on the availability of X-ray crystallographic data.  Non-ATP 
competitive compounds such as the ʻAktisʼ and rapamycin and its analogues have 
also been successfully employed as kinase inhibitors by targetting allosteric sites or 
disrupting protein-protein interactions required for catalytic activity. 
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2.5. Development of a Dimeric Diarylmethane Modulator of PI3-K-Akt-mTOR 
Signalling 
2.5.1. Compound 48/80 (c48/80): an Oligomeric Modulator of PI3-K-Akt-mTOR 
Signalling 
Compound 48/80 (c48/80) (40) is an oligomeric mixture, produced by the 
condensation of N-methyl-para-methoxyphenethylamine and formaldehyde, that is 
known to influence a variety of cell signalling pathways (Scheme 2.1).95 c48/80 is a 
potent hypotensive agent due to its ability to mediate the release of histamine by 
promoting mast cell degranulation.96 This histamine-releasing activity is thought to 
result either from c48/80ʼs ability to directly activate the α subunit of the 
heterotrimeric G-protein Gi3, thereby stimulating GTPase activity;97 or be due to the 
activation of phospholipase D (PLD).98  
 
In the last decade the influence of c48/80 on PI3-K-Akt-mTOR signalling has been 
recognised. Treatment with the PI3-K inhibitor wortmannin (3), as well as the PKC 
inhibitors K252a and GF1090203X, led to inhibition of c48/80 promoted release of 
the secondary messenger arachidonic acid.99 PKC is activated by PDK1 following 
activation of PI3-K (Figure 1.3). c48/80 is known to raise calcium levels in mast cells. 
An increase in calcium levels is associated with the accumulation of PIP3 following 
PI3-K activation, which can be reversed upon treatment with the PI3-K inhibitor 
LY294002 (13).100 Furthermore, expression of the SHIP phosphatases that 
dephosphorylates PIP3 to PIP2 arrests c48/80 induced mast cell degranulation.101 
 
Strong evidence for c48/80 promoting activation of PI3-K-Akt-mTOR signalling led to 
further investigation by Byrne and co-workers.95 c48/80 was found to have a dose 
dependent influence on Akt activation. At concentrations of between 3 and 10 μg/ml 
c48/80 induced phosphorylation of Akt at Thr308 and Ser473 and its translocation to 
the membrane in NIH-3T3 cells; at concentration above 10 μg/ml Akt inhibition was 
observed. In contrast, S6K phosphorylation was preserved at doses of greater than 
30 μg/ml and abolished upon addition of rapamycin or LY294002, indicating PI3-K 
activation. Additionally, treatment with the PKC inhibitor bisindoylmaleimide I reduced 
S6K phosphorylation. 
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Treatment with the PKC activator phorbol-12-myristate-13-acetate (PMA) inhibited 
Akt activation, which could be partially rescued upon addition of bisindoylmaleimide I. 
Further evidence for the inhibition of Akt by activation of PKCs was provided by 
fluorescence microscopy studies, demonstrating that c48/80 induces the 
translocation of PKCα to the membrane at a dose of 30 μg/ml. Treatment with the 
PKCα/β selective inhibitor Gö6976 rescued Akt phosphorylation. As NIH-3T3 cells 
primarily express PKCα, it was concluded that activation of PKCα is responsible for 
Akt inhibition induced by c48/80 at does of above 10 μg/ml via the activation of S6K. 
 
This study indicated that c48/80 can uniquely activate and inhibit PI3-K-Akt-mTOR 
signalling in a dose-dependent manner, making it a useful pharmacological tool for 
future investigations. 
 
2.5.2. Structural Characterisation of Compound 48/80 
The utility of c48/80 as a pharmacological tool is limited by its availability as a poorly 
defined mixture of oligomer(s) and the unknown composition of the oligomer(s) 
responsible for its biological activity. Variations in the composition of batches of 
c48/80, both in terms of degree of polymerisation and distribution, could have a 
detrimental effect on the reproducibility of studies employing c48/80. The 
heterogeneity of c48/80 may be partially responsible for its varied effects on cellular 
processes, which have previously been reported to include antimicrobial activity,102 
impairment of cell division,103 apoptosis and tumour progression,104,105 as well as 
promoting mast cell degranulation.97,98  
 
The discovery of c48/80 was preceded by the studies of Ide and Buck who, in 1937, 
investigated the synthesis of a range of N-methyltetrahydroisoquinolines by 
cyclisation of the respective N-methylphenethylamines with formaldehyde in acid 
(Scheme 2.1a).106 Analysis of the hypertensive effects of these compounds in dogs 
showed that 6-ethoxy-N-methyltetrahydroisoquinoline exhibited far higher potency 
than other analogues in the series. Subsequently 6-ethyoxy-N-
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methyltetrahydroisoquinoline was prepared by a different procedure and found to 
have low potency, indicating that an impurity was the hypotensive agent.107 
 
Encouraged by these findings, Baltzly et al. investigated this impurity, which they 
deduced to be an acyclic oligomer linked by methylene groups (Scheme 2.1b).108 
Further synthesis and biological testing revealed that the condensation of 4-methoxy-
N-methylphenylethylamine with formaldehyde in acid yielded a condensation product 
that had enhanced blood pressure depressor action. This product was named 
compound 48/80 after its internal code number ʻBW 48/80ʼ.  
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Scheme 2.1. a) Pharmacological studies by Hjort, et al. showed that the biological 
activity of the compounds reported by Ide and Buck was due to acyclic oligomer 
byproducts; b) Synthesis of compound 48/80 (40). 
 
Although Baltzly, et al. were successful in defining the ʻbackboneʼ structure of c48/80, 
their determination of the oligomer(s) responsible for biological activity was 
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inconclusive; counter-current distribution suggested that the active components were 
probably trimeric (n=3) and tetrameric (n=4) oligomers. 
 
DeGraw, et al. successfully prepared the dimer (n=2) of c48/80, and the trimer of its 
N,N-dimethyl derivative in 1966, concluding that both compounds were inactive.109,110 
In 1972, Read and Lenney used a combination of dialysis, gel-filtration 
chromatography and mass spectrometry to determine the active components of 
c48/80.111 They concluded that the active species range in composition from 
tetramers (n=4) to octamers (n=8), however the accuracy of this approach is poor 
due to the considerable variation in determination of molecular weight depending on 
the calibration method employed. 
 
Ortner, et al. used gel-filtration chromatography and NMR to separate and identify the 
active component(s) of c48/80.112 NMR analysis of c48/80 synthesised from 13C 
enriched formaldehyde provided further evidence for the presence of methylene 
linkers in c48/80, and contradicted the assertion by Read that c48/80 contains cyclic 
species.113 Analysis of the separated fractions suggested the most active component 
corresponds to a hexamer (n=6), yet the individual components could not be 
completely separated by chromatography. 
 
Katsu, et al. successfully synthesised and isolated the monomeric, dimeric and 
trimeric components of c48/80 in 1984. They concluded that the trimer has similar 
activity to the commercially available mixture of oligomers, whereas the monomer 
and dimer exhibited much lower activity.114 Koibuchi, et al. reported separation of the 
components of c48/80 by thin-layer chromatography (TLC). The most biologically 
active components were determined to be tetradecameric (n=14), tridecameric 
(n=13) and nonameric (n=9) following gel-filtration chromatography. 
 
The inconclusive nature of these studies may be partly due to the heterogeneous 
nature of c48/80, as multiple biologically active oligomers may be present, and their 
abundance may vary between batches. 
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2.5.3. Compound 48/80 Derivatives and Compound E1 
A previous research project within the Hailes group led to the development of solid 
phase synthetic methodology to enable the iterative synthesis of specific oligomeric 
components of c48/80. The monomeric, dimeric and trimeric components of c48/80 
were synthesised and found to be unable to induce inhibition of Akt phosphorylation 
in insulin stimulated NIH-3T3 cells at a dose of 50 μg/ml for 15 minutes.115 In the 
course of this study, a series of c48/80 analogues were tested for their ability to 
inhibit Akt phosphorylation.116 An intermediate, diarylmethane 41, was identified that 
was an effective inhibitor of Akt phosphorylation (Figure 2.10).116,117 In contrast to 
c48/80, diarylmethane 41 was unable to induce activation of PI3-K-Akt-mTOR 
signalling at low doses, suggesting that it acts via a different mechanism. The 
monomeric analogue, phenol 42 was a much less effective Akt inhibitor.  
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Figure 2.10. a) Structures of lead diarylmethane 41 and its monomeric analogue, 
phenol 42; b) Western blot analysis indicating the ability of 41 (third lane) to inhibit 
phospho-Ser473 and phospho-Thr308 Akt in serum-deprived NIH-3T3 cells treated 
with 50 μg/ml of compound for 15 minutes, followed by 1 μg/ml insulin for 15 minutes. 
Cells treated with 1 μg/ml insulin (+, first lane) and untreated serum-deprived cells (-, 
second lane) are shown for comparison. Total Akt levels were unaffected by 
treatment with diarylmethane 41.116 
 
Further development of diarylmethane 41 led to the development of the diphenyl 
acetate – compound E1, 43 (Figure 2.11a).118 E1 was a marginally more potent 
inhibitor of PI3-K-Akt-mTOR signalling than diarylmethane 41 in the cellular assay, 
and was also easier to handle and purify on account of its improved solubility in 
organic solvents. The masking of alcohols as their corresponding esters to create a 
membrane-crossing prodrug is a popular strategy in the development of bioactive 
compounds. Spontaneous or esterase-mediated ester cleavage reveals the active 
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species, although this can be complicated by the variable distribution and selectivity 
of esterases in the cellular environment. As a result, ester cleavage may be less 
rapid than is often assumed, enabling esters to persist in vivo.119,120  
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Figure 2.11. a) Structures of diarylmethane E1 (43) and its trimeric analogue 44; b) 
Western blot analysis indicating the ability of E1 to inhibit phospho-Ser473 and 
phospho-Thr308 Akt in serum-deprived NIH-3T3 cells treated with 2.5-10.0 μg/ml of 
E1 for 15 minutes, followed by 1 μg/ml insulin for 15 minutes; c) Western blot 
analysis indicating the effect of E1 on various components of the PI3-K-Akt-mTOR 
signalling pathway in serum-deprived PC-3 and MCF-7 cells treated with 10-60 μg/ml 
of E1 for 15 minutes, followed by 1 μg/ml insulin for 15 minutes. Serum-starved (first 
lane) and insulin stimulated (second lane) cells are shown for comparison.116 
 
Further analysis of E1 indicated that it was capable of dose- and time-dependently 
inhibiting Akt phosphorylation in human prostrate (PC-3) and breast (MCF-7) cancer 
cell lines, inducing cell death (Figure 2.11b).116 Down-regulation of both Akt and 
mTOR activity was demonstrated by the reduced phosphorylation of the downstream 
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substrates of mTORC1 (S6K) and Akt (FOXO3a) respectively (Figure 2.11c). E1 was 
unable to reduce insulin stimulated production of PIP3 in MCF-7 cells and it inhibited 
Akt Ser473 phosphorylation more effectively than Akt Thr308 phosphorylation in PC-
3 cells, suggesting that E1 acts downstream of PI3-K. In addition, E1 did not inhibit 
mTOR directly in an in vitro assay and appears to have a different mechanism of 
action to rapamycin in MCF-7 cells.116 The simultaneous inhibition of Akt and mTOR 
induced by E1 may be advantageous over the individual inhibition of Akt or mTOR, 
as it prevents the feedback activation of PI3-K-Akt-mTOR signalling upon mTOR 
inhibition.  
 
In addition to inducing the dual blockade of mTOR and Akt activation, treatment with 
E1 resulted in elevated c-Jun N-terminal kinase (JNK) phosphorylation. The 
activation of JNK has previously been associated with inhibition of Akt activity leading 
to apoptosis, thus JNK acts as a negative regulator of PI3-K-Akt-mTOR 
signalling.121,122 In order to further investigate the relationship between the PI3-Akt-
mTOR pathway and JNK, MCF-7 and PC-3 cells were pre-treated with the JNK1/2 
inhibitor SP600125. This partially prevented the inhibitory effect of E1 on Akt and 
mTOR in MCF-7 cells; however, following the addition of E1 to PC-3 cells partial Akt 
inhibition was observed, but mTOR activity was unaffected.  
 
The cancer therapeutic paclitaxel also inhibits Akt through the activation of JNK, 
suggesting that both compounds might be acting through an overlapping mechanism 
of action.122,121 The addition of a combined suboptimal dose of E1 and paclitaxel 
increased the anti-proliferative effect relative to addition of either compound 
independently.  
 
Compound 48/80 derivatives, such as E1, represent a novel class of PI3-K-Akt-
mTOR inhibitors, and have potential for further development as pharmacological 
tools for the exploration of this signalling pathway. 
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2.6. Project Objectives 
The diarylmethane E1 (43) represents a promising lead compound for the 
development of novel PI3-K-Akt-mTOR signalling modulators, although prior to this 
study, very little structure-activity relationship data existed for this class of 
compounds. Furthermore, the cellular target(s) of E1 and its mechanism of action 
were unknown. The primary objective of this project was to develop synthetic 
methodology that would enable the synthesis of both homo- and (previously 
inaccessible) hetero-dimeric analogues of E1, as well as allowing variation of the 
ʻlinkerʼ group between the two aromatic units, which was previously restricted to a 
methylene group. The biological evaluation of these novel analogues of E1 in a 
cellular assay was intended, in order that new modulators of PI3-K-Akt-mTOR 
signalling might be found.  
 
Additionally, the identification of the cellular target(s) of E1 would be of great benefit, 
potentially enabling new insights into the PI3-K-Akt-mTOR signalling pathway, as 
well as providing useful information for the rational design of further analogues. To 
this end, the derivitisation of E1 with a linker such that it could be conjugated to 
functionalities such as biotin for affinity chromatography was envisaged. 
 
49 
3. Synthesis of Functionalised Building Block 
Monomers 
 
3.1. Introduction 
Lead compound E1 (43) is a dimeric diarylmethane, where both aromatic units 
contain a para-(2-chloroethyl) functionality on the phenolic ring. In order to investigate 
the relationship between E1ʼs effect on PI3-K-Akt-mTOR signalling and its structure, 
the synthesis and testing of new analogues was required. Of particular interest were 
two structural features: the methylene linker between the aromatic groups, and the 
homo-dimeric relationship of the aromatic rings in E1. By probing these unexplored 
regions of chemical space a more potent analogue might be identified after iterative 
cycles of synthesis and testing. 
 
E1 was prepared in an earlier study by reacting monomeric phenol 42 with 
formaldehyde and heating in concentrated sulfuric acid (Scheme 3.1).118 The 
coupling is thought to proceed through two electrophilic aromatic substitution 
reactions and elimination of water to form diarylmethane 41. 
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Scheme 3.1. Proposed mechanism for the formation of diarylmethane 41 from 42 
and formaldehyde under acidic conditions. 
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Similar acid- or base-induced processes are typically used to form calixarenes: the 
cyclic equivalents of diarylmethanes.123,124 Typically these syntheses produce 
complex mixtures of oligomeric products; extensive experimentation is often required 
to produce the particular species of interest. Solubility plays an important role in 
determining the product mixture. Both monomeric phenol 42 and diarylmethane 41 
are insoluble under the reaction conditions, however if a small amount of 
tetrahydrofuran (THF) is added to form a homogeneous solution, a complex mixture 
of higher oligomers is isolated.  
 
The acid-induced dimerisation method provides an expedient route to E1 following 
acetylation of diarylmethane 41, but suffers from multiple disadvantages: the 
inclusion of acid-sensitive functional groups is precluded, and the separation of the 
desired dimeric product from other higher oligomers is non-trivial – preparative high 
performance liquid chromatography (HPLC) is necessary to ensure complete removal 
of traces of other oligomers. Furthermore, this one-pot approach is likely to be an 
inadequate technique for the synthesis of hetero-dimeric diarylmethanes derived from 
two different precursors, due to the capricious nature of the oligomerisation process. 
 
3.2. Strategies for the Synthesis of Diarylmethanes 
A number of approaches are frequently used for the synthesis of diarylmethanes. 
These include the reduction of diarylketones (typically formed by Friedel-Crafts 
acylation) or diarylmethanols (typically formed by Grignard or orthanolithium addition 
to benzylic aldehydes), Friedel-Crafts alkylation reactions or, in recent years, by the 
transition metal-mediated coupling of benzyl haildes or pseudohaldies and aryl metal 
species (or vice versa) (Scheme 3.2). 
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Scheme 3.2. Common strategies for the synthesis of diarylmethane compounds by: 
a) acid- or base-induced coupling; b) reduction of diarylketones or diarylmethanols; c) 
Friedel-Crafts acylation, or; d) palladium-catalysed cross-coupling reactions. 
 
This study required that both homo- and hetero-dimeric analogues were accessible in 
a concise fashion. A literature search revealed only one example of a phenolic 
hetero-dimeric diarylmethane containing para-(2-haloethyl) functionalisation, which 
was prepared by scientists at Glaxo as an intermediate towards a series of 
quinazolines.125 
 
This seven-step synthesis proceeded via ortho-bromination of the starting diol 45 
followed by protection of the alcohol as its corresponding tetrahydropyranyl (THP) 
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ether. The key C-C bond-forming step is accomplished in moderate yield by lithium-
halogen exchange followed by addition of benzaldehyde. Subsequent acetylation, 
decarboxylation, deprotection, and bromination yielded the desired diarylmethane 46 
in 4% overall yield (Scheme 3.3).  
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Scheme 3.3. Glaxo synthesis of hetero-dimeric diarylmethane 46.125 
  
In this study, a route that allowed diversification of the diarylmethane at a late stage 
through introduction of the second aromatic unit was desired. The route shown in 
Scheme 3.3, based on diarylmethanol reduction, was considered unsuitable due to 
the numerous additional steps required after the second aromatic unit is incorporated 
and its poor overall yield. Similarly, the reduction of diarylketones requires additional 
steps after the C-C bond-forming step. Approaches based on reduction after the 
installation of the second aromatic also preclude the incorporation of some functional 
groups, and so were discounted for the formation of diarylmethanes in this study. 
Friedel-Crafts alkylation was also ruled out, due to the possibility of multiple 
substitution and the expected difficulties in incorporating electron-poor arenes. 
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In light of the these limitations, transition metal mediated cross-coupling reactions 
were considered the most preferable method for installing the second aromatic unit, 
as this approach would enable structural diversification in the final step under 
conditions that are tolerant of many functional groups. The transition metal catalysed 
cross-coupling of organotin (Stille cross-coupling),126 organozinc (Negishi cross-
coupling),126 organoboron (Suzuki cross-coupling),126 organoindium,127 organosilyl,128 
or Grignard129 reagents (Kumada cross-coupling) with organohalides or pseudo-
halides have all been employed for the synthesis of diarylmethanes. The Suzuki and 
Negishi cross-coupling reactions were particularly appealing, due to the large variety 
of inexpensive aryl halide and aryl boronic acid or aryl boronate coupling partners 
that are commercially available. The use of the Stille cross-coupling reaction in the 
final step was unattractive because of the high toxicity of organotin compounds. 
 
3.3. Building Blocks Strategy 
E1 derivatives containing alternative linker groups between the two aromatic units 
were required in addition to diarylmethane analogues. For synthetic efficiency, these 
analogues were designed to be accessible from common intermediates where 
possible, therefore a strategy involving the synthesis of analogues by coupling of 
ortho-functionalised building blocks was envisaged. The building blocks could then 
be coupled using a variety of carbon-carbon, carbon-oxygen, carbon-nitrogen or 
nitrogen-sulfur bonds to produce homo-dimeric analogues, or combined with 
commercially available compounds containing orthogonal functionality to yield hetero-
dimeric variants (Scheme 3.4). 
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Scheme 3.4. Strategy for the synthesis of homo- and hetero-dimeric E1 derivatives 
by coupling monomeric building blocks compounds. 
 
With no structural information on the target(s) of E1 (43) available, a series of target 
linkages for joining the two aromatic units were initially identified containing a diverse 
collection of functional groups to probe unchartered regions of chemical space. 
Several factors influenced the selection of these targets. E1 contains a one-carbon 
methylene linker group, therefore the ʻfirst generationʼ analogues of E1 were 
designed to contain zero to two atoms linking the two sub-units, as it was thought 
likely that a certain distance between the sub-units would be optimal for the 
preservation of biological activity. The analogues were also designed so that they 
could be obtained from a reasonably small library of building blocks, which in turn 
were to be obtained from common intermediates. 
 
Two readily available starting materials, phenyl methyl ether 47 and phenol 42, were 
identified from which all the required building block compounds containing the 
desired para-(2-chloroethyl) functionality could be synthesised (Scheme 3.5).  
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Scheme 3.5. Envisaged synthesis of building block compounds from the common 
precursors, phenyl methyl ether 47 and phenol 42. 
 
The phenyl methyl ether 47 was commercially available, whereas phenol 42 was 
accessed in high yield from the commercially available diol 48 by chlorination with 
thionyl chloride in toluene.118 This reaction was performed routinely on scales of up to 
16 grams with no depletion in yield (Scheme 3.6) 
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Scheme 3.6. Formation of alkyl chloride 48 from diol 42. 
 
3.4. The Synthesis of Building Blocks Incorporating an ortho-Methylene Group 
The introduction of an ortho-methylene group was required for the building block 
precursors required for the synthesis of E1 analogues containing a one-carbon unit 
between the aromatic groups. Previous studies had indicated that Friedel-Crafts 
acylation of phenyl methyl ether 47 with acetyl chloride to produce the ketone 49 was 
a high-yielding method for the introduction of a one-carbon methylene unit. Additional 
methylation and oxidation steps were required to produce the ester 50.118 Reduction 
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of 50 to yield alcohol 51, a useful intermediate for the synthesis of several building 
blocks, looked to be a viable strategy (Scheme 3.7). 
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Scheme 3.7. Proposed strategy for the one-carbon homologation of phenyl methyl 
47 via a Friedel-Crafts acylation approach. 
 
Nevertheless, a more concise strategy was identified. This involved directed ortho-
metallation of phenyl methyl ether 47, followed by addition of carbon dioxide and 
subsequent reduction of the carboxylic acid 52 to the alcohol 51 (Scheme 3.8).  
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Scheme 3.8. Proposed strategy for the formation of 51 via an ortho-lithiation 
approach. 
 
Directed ortho-metallation involves deprotonation at the position in an aromatic ring 
ortho to a heteroatom containing functional group, known as a Direct Metallation 
Group (DMG) or ortho-director. DMGs are typically Lewis basic moieties that provide 
a point of co-ordination for the alkyl lithium species. The starting material 47 contains 
a DMG in the form of a methyl ether group. 
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Initially, the methyl ether 47 was reacted with n-butyllithium and N,N,Nʼ,Nʼ-
tetramethylethylenediamine (TMEDA). When dissolved in hexane, n-butyllithium 
forms – typically hexameric – aggregates. The use of a co-ordinating solvent such as 
diethyl ether, THF, or TMEDA leads to a lower degree of aggregation, increasing the 
reactivity of the organolithium.130 After three hours carbon dioxide was bubbled 
through the reaction mixture for one hour, but none of the desired product 52 was 
isolated after workup. Thin layer chromatography (TLC) and proton nuclear magnetic 
resonance (NMR) analysis indicated the presence of starting material, as well as 
other unidentified side-products (Scheme 3.9). 
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Scheme 3.9. Failed ortho-lithiation of methyl ether 47. 
 
Due to this competing decomposition pathway, a more efficacious DMG was sought. 
Sulfone, sulfonamide, amide, carbamate, and oxazoline functional groups are 
reported to be particularly effective DMGs.130,131 Accordingly, diethyl carbamate 53 
was synthesised from phenol 42 in high yield by treatment with diethylcarbonyl 
chloride and potassium carbonate in refluxing acetonitrile (Scheme 3.10).132 
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Scheme 3.10. Synthesis of carbamate 53 from phenol 42. 
 
58 
Trial reactions were conducted with carbamate 53, TMEDA and sec-butyllithium in 
TMEDA and THF at -78 °C. To determine the degree of ortho-lithiation that was 
occurring, a highly reactive electrophile (methyl iodide) was added to the reaction 
mixture after three hours to provide a ʻhandleʼ for analysis of the reaction mixture by 
proton NMR spectroscopy, yet only the starting material, carbamate 53, was 
observed (Scheme 3.11).  
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Scheme 3.11. Failed ortho-lithiation of carbamate 53. 
 
To establish whether the failure of this reaction was due to unsuccessful lithiation of 
the aromatic ring, or unsuccessful nucelophilic attack of the arylorganolithium, 
carbamate 53 was treated with sec-butylithium in TMEDA and THF at -78 °C, 
followed by quenching of the reaction after three hours with an excess of deuterated 
water. Proton NMR analysis following workup indicated that no incorporation of 
deuterium had occurred, and that ortho-lithiation was unsuccessful. Due to the failure 
of the ortho-lithiation reaction, an alternative route where the aryl metal species is a 
Grignard reagent was identified. This could be accessed from the corresponding alkyl 
halide, following bromination or iodination of phenyl methyl ether 47. The high polarity 
of the carbon-magnesium bond makes Grignard reagents strong carbon 
nucleophiles.  
 
To synthesise aryl bromide 54, phenyl methyl ether 47 was treated with 1 equivalent 
of molecular bromine and 1 equivalent of aluminium chloride in 1,4-dioxane at room 
temperature. Bromine forms a complex with 1,4-dioxane in situ that acts a mild 
brominating agent due to halogen bonding between bromine and oxygen.133 A 
reaction time of three days was necessary for complete conversion of 47 to the aryl 
bromide 54, which was isolated in 97% yield (Scheme 3.12). 
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Scheme 3.12. Synthesis of aryl bromide 54. 
 
The corresponding aryl iodide 55 was synthesised according to the modified 
procedure of Stavber and co-workers by treatment with molecular iodine and 
Selectfluor® (56) in acetonitrile at room temperature (Scheme 3.13). Selectfluor® is 
most commonly used as an electrophlilic source of fluorine, however it can also be 
used as an oxidising agent, which enables the generation of iodonium (I+) ions when 
mixed with molecular iodine.134 Molecular iodine alone is insufficiently electrophilic to 
react with aromatic species.  
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Scheme 3.13. Selectfluor® (56) mediated iodination of phenyl methyl ether 55. 
 
Alkyl magnesium Grignard reagents are typically made by reacting alkyl halides with 
magnesium metal in an aprotic solvent (typically diethyl ether or THF). Aryl halide 
substrates 54 and 55 contain an alkyl chloride motif, which might also be reactive 
under these conditions, therefore exclusive formation of the aryl Grignard reagent by 
magnesium-halogen exchange was attempted.135 The magnesium-halogen exchange 
equilibrium is dependent on the stability of the carboanion intermediates, therefore 
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only the aryl bromide would be expected to undergo magnesium-halogen exchange. 
Treatment of aryl halides 54 and 55 with isopropyl magnesium chloride (i-PrMgCl) for 
five hours, followed by carbon dioxide, led to exclusive recovery of the starting 
materials (Scheme 3.14).  
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Scheme 3.14. Failed Grignard reagent formation from aryl halides 54 and 55. 
 
Krasovskiy and Knochel have reported that the rate of Br/Mg exchange can be 
enhanced by the addition of lithium chloride.136 This may be due to its ability to 
disaggregate i-PrMgCl, resulting in the formation of the reactive complex 57, followed 
by transmetallation to form 58 (Scheme 3.15). Similar heterometallic 
organomagnesium complexes containing bridging halogens have been previously 
been synthesised and characterised by X-ray crystallography.137 
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Scheme 3.15. Deaggregation of i-PrMgCl by formation of the reactive complex 57, 
followed by transmetallation to form complex 58. 
 
Unfortunately, treatment of aryl iodide 55 with the preformed i-PrMgCl.LiCl complex, 
followed by addition of carbon dioxide, gave none of the desired product, after seven 
hours at room temperature (Scheme 3.16). 
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Scheme 3.16. Unsuccessful one-carbon homologation of aryl iodide 55 via Grignard 
addition of carbon dioxide. 
 
Due to the difficulties encountered in metallating the aromatic ring, attention was 
switched to alternative methods of installing the one-carbon unit. A classical method 
for the one-carbon homologation of phenols is treatment with chloroform in aqueous 
sodium hydroxide at high temperature (the Reimer-Tiemann reaction). This leads to 
the formation of a dichlorocarbene, which reacts with a phenol to form the ortho-
formyl product.138 This procedure was deemed unsuitable for one-carbon 
homologation of phenol 42, due to the opportunity for these compounds to 
decompose under the reaction conditions.  Decomposition of para-(2-haloethyl) 
compounds, such as phenol 59, under basic conditions is believed to proceed via 
nucleophilic attack of the activated spirocylic intermediate 60 formed under basic 
conditions (Scheme 3.17). These species have been isolated and characterised by 
Winstein, et al.139,140 
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Scheme 3.17. Proposed mechanism for the decomposition of phenol 59 under basic 
conditions via the spirocylic intermediate 60.139,140 
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Another well-established method for one-carbon homologation of activated aromatic 
compounds is the Vilsmeir-Haack formylation.138 The one-carbon electrophile, know 
as a Vilsmeier reagent, is prepared in situ by reaction of phosphoryl chloride with 
dimethylformamide (DMF). Upon introduction of the activated aromatic substrate, an 
iminium salt is formed, which upon aqueous workup reveals the corresponding 
aldehyde. The attempted Vilsmeir-Haack formylation of phenyl methyl ether 47 
yielded none of the desired aldehyde 61 (Scheme 3.18). 
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Scheme 3.18. The attempted Vilsmeir-Haack formylation of phenyl methyl ether 47 
was unsuccessful. 
 
Following these setbacks, it was decided to revert to the proposed route outlined in 
Scheme 3.7, where the one-carbon homologation of phenyl methyl ether 47 proceeds 
by Friedel-Crafts acylation. Previous studies had shown that protection of the phenol 
group as its methyl ether was necessary for the oxidation of ketone 49 to ester 50.118 
Methyl ethers are highly robust, and are resistant to the various conditions required 
for coupling the building blocks units to form analogues of E1.  E1 contains phenyl 
acetate groups, therefore it was also essential to ensure that the methyl ether group 
could be successfully removed to unmask the phenol before embarking on the 
synthesis of methyl ether protected building block compounds.  
 
Treatment of phenol 42 with trimethylphenyl ammonium chloride and sodium hydride 
in DMF at 90 °C to form methyl ether 47 led to decomposition of the starting material. 
Alternatively, treatment with trimethylsilyldiazomethane and DIPEA in a 9:1 mixture of 
acetonitrile and methanol at room temperature provided phenyl methyl ether 47 in 
49% yield. Increasing the reaction time and equivalents of trimethylsilyldiazomethane 
enabled this to be increased to 96%. Alternatively phenyl methyl ether 47 could be 
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accessed by treating phenol 42 with potassium carbonate and methyl iodide in 
acetone at 55 °C (Scheme 3.19). 
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Scheme 3.19. Interconversion between phenol 42 and phenyl methyl ether 47. 
 
Typical cleavage protocols employ tribromoborane, which upon coordination to the 
ethereal oxygen promotes scission of the carbon-oxygen bond to form methylbromide 
and an alkyoxyborane that is hydrolysed upon aqueous workup.141 Experiments were 
performed using tribromoborane-dimethyl sulfide complex, which was unable to 
cleave 47 at room temperature in dichloromethane. Changing the solvent to 1,2-
dichloroethane allowed the reaction to be performed at elevated temperature, forming 
the corresponding phenol 42. Addition of a further excess of tribromoborane-dimethyl 
sulfide after 17 hours enabled a modest improvement in yield (Scheme 3.19).  
 
Once a successful protection and deprotection protocol had been established, 
attention was again turned to the preparation of alcohol 51. Methyl ketone 49 was 
prepared by Friedel-Crafts acylation in quantitative yield.118 The phenolic group of 
methyl ketone 49 was methylated to phenyl methyl ether 62 by Williamson 
etherification, but initial yields were low (Table 3.1, entries 1-2). Adding a large 
excess of volatile methyl iodide enabled this to be increased (Table 3.1, entry 3), 
although 49 and 62 could not be separated by basic workup, distillation, or flash 
chromatography, so the complete consumption of phenol 49 was necessary to 
provide analytically pure 62. The use of a sealed pressure tube reduced evaporation 
of methyl iodide over the course of the reaction (Table 3.1, entries 6-7). Five 
equivalents of potassium carbonate was necessary for the reaction to go to 
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completion, as the use of larger quantities reduced stirring efficiency (Table 3.1, entry 
8). Due to the small volume of commercially available pressure tubes, multiple 
reactions were carried out in parallel on a two mmol scale to provide sufficient 
quantities of phenyl methyl ether 62. 
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Entry Reaction Vessel Equiv 
MeI 
Equiv 
K2CO3 
Scale 
(mmol) 
% Conversion  
(by 1H NMR, ±5%) 
1 RB Flask 5 5 70 10 
2 RB Flask 10 5 30 50 
3 RB Flask 10 3 3 90 
4 Carousel Tube 10 3 2 10 
5 Carousel Tube 10 5 3 10 
6 Pressure Tube 5 5 2 70 
7 Pressure Tube 10 10 3 90 
8 Pressure Tube 10 5 2 100 
(97% isolated yield) 
 
Table 3.1. Optimisation of the methylation of phenol 49 via Williamson etherification. 
 
The subsequent one-pot oxidation of the ketone side-chain of 62 to form methyl ester 
50 proceeded successfully by treatment with a methanolic solution of 13% aqueous 
sodium chlorite at 0 °C in moderate yield (Scheme 3.20).142 
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Scheme 3.20. Oxidation of ketone 62 to methyl ester 50. 
 
Conducting the reaction in methanolic solution enabled isolation of the methyl ester 
50 rather than the free carboxylic acid, aiding extraction during workup and 
chromatographic purification. The formation of methyl hypochlorite in this procedure 
is potentially hazardous. While methyl hypochlorite can be prepared, isolated, and 
stored without incident,143 it is unstable at high concentrations, it is light sensitive and 
has a low boiling point (12 °C). To reduce the associated risks the sodium 
hypochlorite was added dropwise at 0 °C, the reaction was run at high dilution (5.4 
mmol scale), light was excluded and a blast shield employed. Any hypochlorite 
remaining after the reaction was complete was destroyed using a large quantity of 
aqueous sodium bisulfite solution. The source of the aqueous sodium hypochlorite 
solution was found to be critical: only solutions purchased from Acros Organics 
enabled this transformation to occur. Sodium chlorite solutions obtained from other 
suppliers induced complete decomposition of the starting material.  
 
Treatment of methyl ester 50 with lithium aluminium hydride (LAH) reduced the side 
chain ester to the corresponding alcohol, but also led to formation of side-product 63 
resulting from reductive dehalogenation of the alkyl chloride group, which could not 
be separated from the desired product by flash chromatography. Diisobutylaluminium 
hydride (DIBAL-H) was chosen as an alternative reducing agent and allowed 
successful reduction of methyl ester 50 to alcohol 51 in good yield with none of the 
undesirable side dehalogenated side-product observed (Scheme 3.21). 
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Scheme 3.21. Synthesis of alcohol 51 from methyl ester 50. 
 
The synthesis of the key intermediate alcohol 51 enabled the production of several 
other methylene-containing building blocks using various functional group inter-
conversions. Aldehyde 61 was successfully obtained in high yield by an alternative 
procedure involving oxidation of alcohol 51 with manganese dioxide in diethyl ether at 
room temperature. One-carbon homologation of aldehyde 61 to the alkyne 64 
(Corey-Fuchs reaction) via the intermediate dibromoalkene was accomplished by 
treatment with two equivalents of carbon tetrabromide and four equivalents of 
triphenylphosphine in dichloromethane (Scheme 3.22).  
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Scheme 3.22. Synthesis of aldehyde 61 and alkyne 64 from alcohol 51. 
 
Alcohol 51 was converted to the corresponding benzylic bromide 65 via the 
intermediate oxyphosphonium species by the addition of triphenylphosphine and 
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carbon tetrabromide in dichloromethane (Scheme 3.23). Heating at 55 °C was 
required to ensure complete consumption of alcohol 51. On several occasions, a 
coloured impurity was observed following chromatographic purification that had could 
not be determined by proton NMR. The presence of this impurity caused significant 
decomposition of bromide 65 to a dark coloured tar after ten days of storage 
according to proton NMR analysis. Fortunately, this impurity could usually be 
removed after repeated chromatographic purification to obtain bromide 65 as a pale 
yellow oil. 
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Scheme 3.23. Synthesis of benzylic bromide 65 from alcohol 51. 
 
In order to synthesise diarylmethanes via Suzuki cross-coupling, a boronic acid or 
boronate precursor was required. Due to the problems previously encountered with 
ortho-metallation of the aromatic ring, it was decided to synthesise the organoboron 
coupling partner by a Miyaura borylation of benzylic bromide 65, rather than attempt 
the synthesis of an aryl organoboron compound; however, a literature search 
revealed only two examples of the borylation of benzylic halides, both using similar 
conditions.144,145 The borylation of bromide 65 according to the procedure of Giroux 
produced boronate ester 66 in low yield (Scheme 3.24).144 
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Scheme 3.24. Synthesis of boronate 66 from bromide 65. 
 
In an attempt to improve the low yield of this transformation, the Suzuki coupling 
conditions optimised by Flaherty, et al. for the coupling of B-benzyl-9-borabicyclo-
[3.3.1]nonane (B-benzyl-9-BBN) with aryl and heteroaryl halides were employed.146 
This procedure uses the hindered phosphine ligand 2-(2′,6′-dimethoxybiphenyl)-
dicyclohexylphosphine (SPhos, 67), developed by Barder and co-workers.147 SPhos 
is reported to be a highly active catalyst for the Suzuki coupling reaction, yet under 
these conditions only 8% of the desired boronate 66 was obtained (Scheme 3.25).  
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Scheme 3.25. Synthesis of boronate 66 from bromide 65 using an SPhos-based 
catalytic system. 
69 
Additionally, the azide 68 was synthesised from benzyl bromide 65, by treatment with 
sodium azide in DMF at 60 °C. A reaction time of 3 days was required to ensure that 
bromide 65 was entirely consumed. This was necessary for purification as bromide 
65 and azide 68 were inseparable by flash chromatography (Scheme 3.26).  
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Scheme 3.26. Synthesis of azide 68 from bromide 65. 
 
3.5. Building Blocks Containing Heteroatoms 
Functionalised building block compounds containing heteroatoms were required for 
the synthesis of E1 derivatives not containing a methylene linker. 
 
Aryl ketone 62 was subjected to a Baeyer-Villiger oxidation by treatment with meta-
chloroperoxybenzoic acid (m-CPBA) to produce ester 69. As expected, the more 
electron rich aromatic group migrated preferentially (Scheme 3.27).  
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Scheme 3.27.  Synthesis of ester 69 from ketone 62 via Baeyer-Villiger oxidation. 
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The introduction of an ortho-sulfonic acid group was first attempted by reacting 
phenol 42 with concentrated sulfuric acid at room temperature, with proton NMR 
analysis indicated a mixture of the desired monosulfonic acid and unwanted 
disulfonic acid compound. Such compounds are highly polar and were not separable 
by normal phase flash chromatography. By contrast, when the phenyl methyl ether 
47 was used as the substrate, none of the disulfonic acid was observed by proton 
NMR, although the removal of residual solvent and trace impurities from the desired 
product proved to be problematic. The crude product was isolated as an oil and 
attempted precipitation of the desired product as a crystalline solid proved 
unsuccessful. The corresponding sodium sulfonate salt was formed by dissolving the 
crude product in methanol and adding saturated sodium chloride solution. The 
resulting solid was collected by filtration after slurrying in chloroform to remove 
starting material, yet still contained impurities that included the corresponding 
dehalogenated compound. Purification of this mixture by recrystallisation proved to 
be unsuccessful.  
 
As a alternative approach, phenyl methyl ether 47 was treated with chlorosulfonic 
acid, which enabled isolation of the mono-sulfonyl chloride 70 in high yield (Scheme 
3.28). None of the impurities previously obtained were observed using this 
procedure. 
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Scheme 3.28. Synthesis of sulfonyl chloride 70 from methyl ether 47. 
 
The formation of a compound containing an ortho-amino functionality had been 
previously synthesised within the Hailes research group by the nitration of phenyl 
methyl ether 47 using nitrous acid generated in situ, followed by reduction of nitro 
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compound 71 using tin (II) chloride and hydrochloric acid in refluxing ethanol, to form 
amino compound 72 (Scheme 3.29).148 
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Scheme 3.29. Synthesis of aryl amine 72 by nitration of phenyl methyl ether 47 and 
reduction of nitro compound 71.148 
 
This route was constrained by the low conversion of phenyl methyl ether 47 to the 
nitro compound 71. The conversion could be improved by raising the reaction 
temperature to 15 °C, however this was reported to lead to production of the 
corresponding di-nitro compound, as well as various other side-products that could 
not be separated from 71. Another disadvantage was the low stability of amine 72, 
which decomposes upon standing. Additionally, the reduction of 71 to 72 using this 
protocol generated various side-products that were difficult to remove by flash 
chromatography.148 
 
Mono-nitration of activated aromatic compounds is often low yielding due to the 
formation of over-nitrated side-products, as well as the competing decomposition of 
the starting material.149 In order to overcome these limitations, an alternative nitration 
protocol was chosen that suppresses the formation of unwanted di-nitro compounds 
by using a biphasic system containing a dilute nitic acid combined with the phase-
transfer catalyst tetrabutylammonium bromide (TBAB).150 This enabled mono-
nitration of phenol 42 in good yield, with none of the di-nitrated product isolated. 
Nitrophenol 73 was subsequently protected as its corresponding methyl ether 71 by 
Williamson etherification (Scheme 3.30).  
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Scheme 3.30. Synthesis of nitro-compound 71 from nitrophenol 73. 
 
The nitro compound 71 was reduced using 10% activated palladium on carbon in 
methanol under a hydrogen atmosphere, but the resulting amine 72 rapidly 
decomposed upon standing, presumably due to polymerisation. In an attempt to 
suppress this decomposition process, hydrochloric acid was added to the methanol 
to protonate the aryl amine. The resulting hydrochloride salt 74 was isolated, yet 
decomposition products was still evident. A related strategy to trap amine 72 as its 
tert-butoxycarboyl (Boc) protected derivative 75 by reduction in the presence of di-
tert-butyl dicarbonate and triethylamine was unsuccessful, as the reduction of the 
nitro group failed under these conditions (Scheme 3.31).  
 
73 
OMe
Cl
OMe
Cl
NH3
71 74
NO2
OMe
Cl
NBoc2
75
10% Pd/C, 
H2, MeOH,
r.t. OMe
Cl
NH2
72
Cl
10% Pd/C, H2, 
MeOH, 1M HCl, r.t.
10% Pd/C, 
H2, Boc2O,
NEt3, MeOH, r.t.
 
 
Scheme 3.31. Unsuccessful synthesis of amine 72 and the hydrochloride salt 74 and 
di-Boc protected analogue 75. 
 
As an alternative approach to preventing the polymerisation of the desired aryl 
amine, nitrophenol 73 was converted to the corresponding phenyl acetate 76 by 
treatment with acetic anhydride, triethylamine and catalytic 4-dimethylaminopyridine 
(4-DMAP). Substitution of the electron-donating methyl ether with an electron-
withdrawing acetate group should reduce the reactivity of the aniline resulting from 
reduction of 76. Unfortunately, after treatment with 10% activated palladium on 
carbon in methanol under a hydrogen atmosphere, decomposition of 76 was 
observed and none of the desired amine 77 was isolated (Scheme 3.32). 
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Scheme 3.32. Attempted synthesis of aryl amine 77 via reduction of nitro compound 
76. 
 
Due to the difficulties in preventing decomposition of aryl amine 72 and the 
unsuccessful reduction of the phenyl acetate derivative 77, it was decided to revert to 
the previous reduction procedure and synthesise aryl amine 72 in small batches 
when required for immediate use. 
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3.6. Summary 
In summary, a series of ortho-functionalised building block compounds were 
synthesised, some incorporating a methylene group, and others containing 
heteroatoms (Figure 3.1).  
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Figure 3.1. Structures of the ortho-functionalised building block compounds 
synthesised. 
 
The synthesis of these compounds used a divergent strategy and contained a 
maximum of six linear steps from commercially available starting materials. The 
compounds were designed so that they could be assembled to generate novel homo- 
and hetero-dimeric analogues of E1.  
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4. Progress Towards the Identification of the Cellular 
Target(s) of E1 
 
4.1. Introduction 
Prior to this study, the cellular target(s) of E1 were unknown; however, the successful 
identification of the target species could provide new insights into the PI3-K-Akt-
mTOR signalling pathway.151 Such studies could potentially lead to the identification 
of previously unknown components of this cascade. Alternatively, target verification 
can provide the basis for conducting modelling and X-ray crystallography studies, 
aiding the development of new analogues.152 Despite an array of techniques 
available to the experimentalist, identification of the target(s) of small molecules from 
a cellular assay remains an extremely challenging task. Many of these methods, 
such as the analysis of transcription products are laborious, requiring specialist 
knowledge and automated equipment.153,45  
 
If some indication of the target is already available – such as is the case for 
compounds that are structurally similar to a well-characterised molecule – the 
judicious use of in vitro assays can be an effective approach for target discovery, 
however, this approach is inherently unsuitable if the target species is a previously 
undiscovered protein, or if the compound targets a protein-protein interaction. 
External analysis of E1 using a commercially available fluorescence-based coupled-
enzyme assay (Invitrogen SelectScreen™) indicated that the compound was inactive 
against a panel of 79 kinases. 
 
4.2. Pharmacological Tools for Determining the Cellular Target(s) of E1 
Several target identification techniques require additional functionalisation or 
immobilisation of the active small molecule, thus requiring the input of the synthetic 
chemist. A widely used technique involves attachment of the compound to a solid 
support via a functionalised linker group for affinity chromatography (alternatively 
referred to as a ʻpull-downʼ experiment). The immobilised conjugate is incubated with 
cell lysate and washed to remove any non-specifically bound protein. An excess of 
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the lead compound is then added to elute the target protein(s), which are typically 
analysed by Western blotting and mass spectrometry. Although this is a powerful 
approach, a strong interaction between the compound and its target(s) is required, 
due to the deleterious effect that attachment to a solid matrix typically has on 
biological activity.154 Despite the difficulties involved in this approach, it has been 
successfully employed to shed light on the specificity of, among others, PI3-K and 
BCR-ABL inhibitors.67,155 
 
Alternative approaches requiring derivatisation include the attachment of a group that 
covalently binds with the protein upon UV irradiation (photoaffinity labeling)47 and the 
incorporation of a fluorescent moiety to enable visualisation of the distribution of the 
compound within the cells. Such spatial information can provide valuable evidence to 
the compoundʼs mechanism(s) of action.156 
 
The results presented in this chapter document the attempted synthesis of an 
analogue of E1 containing a functionalised linker group. This would enable 
attachment to a biotin group for immobilisation on streptavidin coated polystyrene 
beads for affinity chromography, or coupling with other useful functionalities such as 
a fluorescent dye (Figure 4.1). 
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Figure 4.1. a) Derivatisation of E1 with a functionalised alkyl linker enables 
attachment of, b) a biotin group for immobilisation on streptavidin coated beads for 
affinity chromatography, or, c) a fluorescent dye for microscopy studies. 
 
4.3. Introduction of a Linker via Heck Coupling  
The initial strategy for derivatisation of E1 was based around the introduction of a 
suitably protected functionalised alkyl chain through a palladium cross-coupling 
based approach. Studies during an earlier research project had indicated that 
incorporation of an acetylene containing side-chain by Sonogashira coupling was 
feasible, albeit with limitations. Aryl iodide 78 and alkyne 79 could be successfully 
coupled, however, the resulting product cyclised in situ to form the benzofuran 80 in 
low yield (Scheme 4.1).118 Although it should be possible to suppress the undesired 
cyclisation reaction by protection of the phenol, the coupling was low yielding. A 
further disadvantage of this route was the lack of commercial availability of suitable 
alkyne coupling partners. The three-carbon functionalised alkyne 79, derived from 
propargylamine, was readily available; however, coupling partners containing longer 
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alkyl chains would have required additional synthesis. As a result of these limitations, 
alternative palladium catalysed cross-coupling strategies were investigated.  
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Scheme 4.1. Synthesis of benzofuran 80 by Sonogashira coupling of aryl iodide 78 
and alkyne 79.118  
 
The feasibility of using a palladium catalysed cross-coupling approach was confirmed 
upon consulting the literature, which revealed that Schädel and Habicher had 
developed a protocol for the Heck coupling of monobromohydroquinone 81 with α-
methylstyrene 82, which they later applied to various alkenes using ligandless 
(Jefferey) conditions.118 Using the optimised conditions a mixture of isomers 83 and 
84 was obtained in 92% yield (Scheme 4.2). 
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Scheme 4.2. Heck coupling of monobromohydroquinone 81 with α-methylstyrene 82 
using ligandless conditions.118  
 
A synthetic strategy was envisaged where a protected alkyl amine chain would be 
attached to the aryl iodide 85 by Heck coupling with alkene 86, which would be 
synthesised by the amination of commercially available 6-bromohex-1-ene (Scheme 
4.3). Boc protection of the primary amine functionality was deemed necessary to 
avoid any potential undesired side reactions with the Pd(0) catalyst. Deprotection of 
80 
the Boc groups under acidic conditions would reveal conjugate 87. 
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Scheme 4.3. Retrosynthetic scheme for synthesis of conjugate 87 via Heck coupling. 
 
Tandem amination and protection of 6-bromohex-1-ene by treatment with di-
tertbutyliminodicarboxylate and caesium carbonate in 2-butanone at 90 °C proceeded 
in quantitative yield (Scheme 4.4), enabling investigation of the key Heck coupling 
step. 
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Scheme 4.4. Synthesis of alkene 86. 
 
In order to preserve supplies of the valuable aryl iodide 85, the coupling was initially 
attempted using alkene 86 and bromobenzene using the previously identified 
ligandless conditions; however, no reaction was observed. Switching the aryl halide 
coupling partner to the more reactive iodobenzene produced the coupled alkene 88 
in 97% yield under identical conditions (Scheme 4.5). 
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Scheme 4.5. Model Heck coupling using ligandless conditions. 
 
Following the successful model reaction, the coupling of aryl iodide 89 and alkene 86 
under these conditions was attempted. This resulted in a mixture of the desired 
coupling product 90 and diacetate 91, in addition to unidentified decomposition 
products (Scheme 4.6). The isolation of significant amounts of diacetate 91 was 
surprising, but presumably could be suppressed by using an alternative palladium 
source. 
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Scheme 4.6. The attempted Heck coupling of aryl iodide 89 and alkene 86 under 
ligandless conditions produced an inseparable mixture of alkenes 90 and 91. 
 
With these results in hand, attention was turned towards the coupling of the iodo-
diarylmethane 85 with alkene 86. The synthesis of 85 proceeded by iodination of 
phenol 41 followed by acetylation, as described previously;118 however, the 
attempted Heck coupling of iodo-diarylmethane 85 and alkene 86 to produce alkene 
92 produced a complex mixture of products that could not be chromatographically 
separated (Scheme 4.7). 
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Scheme 4.7. The attempted Heck coupling of aryl iodide 85 and alkene 86 under 
ligandless conditions was unsuccessful. 
 
Heck coupling of the iodo-diarylmethane 85 with 86 is likely to be more challenging 
than that of its monomeric equivalent 89 and 86, as the diarylmethane is more 
electron rich. Accordingly, optimising the Heck coupling of monomeric 89 and 86 was 
necessary before returning to the coupling of the dimeric species. Several trial 
reactions were performed using the electron-rich bulky phosphine ligands SPhos (67) 
and XPhos (93) developed by Prof Stephen Buchwaldʼs research group,147,157 as well 
as the air-stable alkylphosphonium salt tri-tert-butyl-phosphonium tetrafluoroborate158 
and triphenylphosphine (Scheme 4.8). Bulky phosphine ligands increase the rate of 
palladium cross-coupling reactions through a combination of steric and electronic 
effects. Their presence enhances the rates of the oxidative addition, transmetallation 
and reductive elimination steps of the catalytic cycle, as well as preventing 
palladacycle formation.159 
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Scheme 4.8. The attempted optimisation of the Heck coupling of aryl iodide 89 and 
alkene 86. 
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In all cases an only partially chromatographically separable mixture of species was 
obtained. Despite the difficulties in separation, the coupling reaction could be 
followed by proton NMR, as the allyl proton signal shifts from 2.04 in 86 to 2.24 in the 
coupled alkene 90. When triphenylphosphine, XPhos or tri-tert-butyl-phosphonium 
tetrafluoroborate were employed as ligands, no coupling was observed and the 
starting materials were recovered. On the other hand, when SPhos was used as the 
ligand, NMR indicated approximately 25% conversion of aryl iodide 89 to the coupled 
alkene 90, the presence of which was further confirmed by mass spectrometry of the 
relevant fraction. Despite this limited success, these conditions were considered 
unsuitable for the coupling of the dimeric species due to the low yield and 
troublesome purification. 
 
The formation of side-products resulting from palladium insertion at either the alkyl 
chloride or acetate groups was found to be a limitation of this strategy. As palladium-
catalysed cross coupling reactions were expected to play a key role in several 
components of this project, this merited further investigation. An analogue of aryl 
iodide 89 where the chloro and acetate groups were replaced with ethers was 
synthesised in two steps from alcohol 45 by ortho-iodination to produce aryl iodide 
94, followed by benzyl protection of the primary alcohol on the upper rim to yield 
ether 95 (Scheme 4.9).  
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Scheme 4.9. Synthesis of ether 95 for model studies. 
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Ether 96 was initially synthesised by etherification of alcohol 45, though the 
subsequent iodination step was problematic. Iodination was attempted using the 
procedure that had previously been effective for the mono-iodination of the 
analogous methyl phenyl ether 47 (see Chapter 3). Unfortunately conversion was 
low, and the resulting mixture of products was chromatographically inseparable. 
Changing the solvent system, or addition of surfactants, could not rectify this 
situation, necessitating a reversal in the order of the synthesis. Modification of the 
iodination protocol to include Brij 30, a non-ionic surfactant, enabled the synthesis of 
aryl iodide 94 in 56% yield. As aryl iodide 94 is an amphiphilic compound it is likely to 
form micelles in solution, which will be disrupted by the addition of Brij 30. The 
subsequent etherification was straightforward, producing ether 95 in moderate yield. 
 
Detailed experimental investigations of the Heck reaction have shown that the 
catalytic cycle proceeds via either ʻneutralʼ or ʻcationicʼ mechanistic pathways, so-
called due to the charge present at the palladium centre following oxidative addition 
(Figure 4.2).160  
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Figure 4.2. The Heck reaction can proceed by a) ʻcationicʼ, or, b) ʻneutralʼ 
mechanistic pathways. 
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The use of additives can influence the reaction in proceeding via a particular 
mechanistic pathway, and potentially altering the resulting product mixture. The 
cationic pathway was first identified for the Heck coupling of aryl triflates.161,162 The 
addition of silver or titanium salts enables halide abstraction following the oxidative 
addition step (Figure 4.2a). The Heck coupling of aryl or vinyl halides in the absence 
of silver salts is postulated to proceed by a neutral mechanism, although the details 
of this catalytic cycle still remain unclear (Figure 4.2b). 
 
To investigate whether these different catalytic cycles would result in a different 
product mixture for the Heck coupling of aryl iodide 95 and alkene 86, the reaction 
was attempted under two sets of conditions (Scheme 4.10). The reaction conducted 
under ʻcationicʼ conditions yielded only starting materials; conversely, the reactions 
conducted under ʻneutralʼ conditions produced a similar inseparable mixture of 
products to that obtained earlier. Proton NMR analysis indicated that some 
successful coupling had taken place, suggesting that the competing side-reactions 
resulting from palladium insertion into either the acetate or chloroethyl groups that 
were observed previously were unlikely to be a significant factor in the poor efficiency 
of the coupling reaction. 
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Scheme 4.10. The Heck coupling of 95 and 86 was attempted under conditions 
designed to force the reaction to proceed through each of the two possible 
mechanistic pathways. 
 
As these control experiments indicated that the desired Heck coupling on this 
scaffold would be problematic, and with no literature precedent to provide 
encouragement, the route was not pursued further. 
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4.4. Introduction of a Linker via Claisen Rearrangement  
Following the difficulties encountered in attempting to introduce a linker via Heck 
coupling, an alternative route was devised where the linker could be introduced by 
etherification of the phenol 41, followed by Claisen rearrangement of ether 97 to 
produce alkene 98. The resulting alkene could then be further elaborated by cross-
metathesis, or alternative methods such as epoxidation (Scheme 4.11). 
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Scheme 4.11. Retrosynthetic scheme for the synthesis of alkene 98 via Claisen 
rearrangement. 
 
The monomeric model compound 99 was synthesised in high yield from phenol 42 by 
etherification with allyl bromide (Scheme 4.12).163  
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Scheme 4.12. Synthesis of the Claisen rearrangement substrate, allyl ether 99. 
 
The heating of neat allyl ether 99 at 190 °C for 18 hours did not induce Claisen 
rearrangement. Raising the temperature to 250 °C for a further 13 hours led to the 
formation of alkene 100, albeit in a synthetically unacceptable yield. Claisen 
rearrangements can be induced either thermally, or by the addition of a Lewis acid. In 
an attempt to increase conversion to a synthetically useful degree a variety of 
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conditions were employed (Table 4.1).  
 
OH
Cl
O
Cl
99                                                             100  
Entry T (°C) t Solvent Additive Heating 
Type 
Isolated 
Yield (%) 
1 r.t. 20 h CH2Cl2 AlCl3 - - 
2 r.t. 20 h CH2Cl2 AgOTf - - 
3 r.t. 20 h CH2Cl2 ZnCl2 - - 
4 r.t. 20 h CH2Cl2 TiCl4 - - 
5 r.t. 20 h TFA - - - 
6 250 24 h - - Thermal - 
7 190-250* 31 h - - Thermal 6 
8 210 24 h N,N-diethylaniline - Thermal 10 
9 250 10 m - - Microwave - 
10 250 2 m DMF - Microwave - 
11 250 10 m DMF - Microwave - 
12 250 12 m DMF - Microwave - 
* Temperature was increased to 250 °C after 18 hours. 
 
Table 4.1. Optimisation of the Claisen rearrangement of allyl ether 99 to phenol 100. 
 
The Lewis acid-induced Claisen rearrangement was unsuccessful in all cases (Table 
4.1, entries 1-4). Equally ineffective was the addition of trifluoroacetic acid (TFA), 
which is reported to be particularly useful for promoting the Claisen rearrangement of 
aryl allyl ethers containing a para-electon donating substituent.164 Heating at a high 
temperature for prolonged periods was necessary for any reaction to take place 
(Table 4.1, entries 7-8). As the yield for this reaction could not be raised beyond 10% 
this route was not considered synthetically viable and an alternative was sought. 
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4.5. Introduction of a Linker via Selective Nitration of E1 
In parallel with the attempted development of the Claisen rearrangement based 
route, an effective method for the selective mono-nitration of monomeric equivalents 
of E1 was developed. These compounds can be reduced to the corresponding 
amines in high yield (see Scheme 3.29, Chapter 3). This approach appeared to offer 
a concise route to the selective introduction of an amine at the ortho-position of one 
of E1ʼs aromatic rings to form amine 101 via the nitro compound 102, thus enabling 
subsequent conjugation of a linker group (Scheme 4.13). 
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Scheme 4.13. Retrosynthetic scheme for the synthesis of amine 101 via the nitration 
of phenol 41. 
 
The nitration of phenol 41 was attempted using the protocol previously employed for 
the synthesis of the mono-nitro building block 73.150 Due to the poor solubility of 41 in 
both water and dichloromethane it was necessary to conduct the reaction in 
acetonitrile. Treatment with dilute aqueous nitric acid in acetonitrile produced the di-
nitro species 103 in 41% yield, although none of the desired mono-nitro species was 
obtained (Scheme 4.14). Treatment with sub-stoichiometric quantities of nitric acid 
and dilution of the reaction mixture similarly led to exclusive production of the di-nitro 
compound 103. 
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Scheme 4.14. Nitration of phenol 41 led to exclusive formation of the di-nitro 
compound 103. 
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This synthetic route was not pursued further due to the difficulties involved in 
selective mono-nitration.  
 
4.6. Introduction of a Linker via Friedel-Crafts Acylation  
Another tactic for the introduction of the functionalised linker group was identified, 
utilising a key Friedel-Crafts acylation step. The diol 104 had previously been 
synthesised within the group via partial reduction of the corresponding ketone 105;117 
however, 104 was unable to induce cellular Akt inhibition (Scheme 4.15).  
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Scheme 4.15. Synthesis of diol 104 via Friedel-Crafts acylation 
 
In order to ascertain whether Friedel-Crafts acylation would be a viable method for 
the introduction of a linker, it was first necessary to discern whether reduction of the 
secondary alcohol group could rescue biological activity. The precursor ketone 105 
was synthesised by reaction of phenyl methyl ether 47 with acyl chloride 106 and 
aluminium chloride in nitrobenzene at 60 °C in moderate yield. The attempted 
reduction of ketone 105 to 107 by hydrogenation at atmospheric pressure with 5% 
activated palladium on carbon in THF led to the exclusive recovery of the starting 
material. Similarly, treatment with aluminium chloride and sodium borohydride 
according to the method of Maeyama, et al. was unsuccessful,165 as was treatment 
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with aluminium hydride (alane) generated in situ from lithium aluminium hydride and 
aluminium chloride (Scheme 4.16). 
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Scheme 4.16. Attempted reduction of ketone 105.  
 
In both cases a complex mixture of products was obtained upon workup. Although 
proton NMR analysis suggested that none of the desired fully reduced species was 
obtained, this analysis was hindered by the presence of numerous signals from the 
alkyl sidechain, therefore the readily available methyl ketone 49 was chosen as a 
model substrate for further investigation of this reaction (Scheme 4.17). 
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Scheme 4.17. Reduction of a model substrate, ketone 49.  
 
Treatment of 49 with aluminium hydride exclusively produced alcohol 108. Due to the 
difficulties encountered in the reduction of the benzyl ketone moiety, and the 
moderate yield obtained for the early stage Friedel-Crafts acylation step (Scheme 
4.15), this route was discontinued. 
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4.7. Introduction of a Linker via Wittig Coupling and Late-stage Acid-induced 
Coupling  
In parallel with this work, the synthesis of heterodimeric analogues of E1 by Suzuki 
coupling, or the acid-induced coupling of functionalised monomeric building block 
compounds, was developed (see Chapters 3 and 5). The success of this approach 
led to its adoption in an alternative approach for the synthesis of a conjugate, 
involving the coupling of suitably functionalised monomeric compounds at a late 
stage to form the desired diarylmethane (Scheme 4.18). 
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Scheme 4.18. Synthesis of linker containing conjugates based on: a) a late stage 
Suzuki cross-coupling based strategy; b) a late stage acid-induced coupling strategy. 
 
 
A sequence utilising the acid-induced coupling was thought to be optimal, as unlike 
the Suzuki cross-coupling, it does not require substrate specific optimisation. 
Furthermore, a Suzuki cross-coupling based strategy would require functionalisation 
of both monomeric coupling partners, whereas the proposed acid-induced coupling 
could be achieved in relatively few steps from previously synthesised intermediates 
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(Scheme 4.19). 
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Scheme 4.19. Retrosynthetic scheme for the synthesis of conjugate 110 by a late 
stage acid-induced dimerisation of functionalised monomers. 
 
It was envisaged that the linker component of the desired conjugate could be 
incorporated by a Wittig coupling between aldehyde 61 and ylid 112, which could be 
synthesised from 1,6-hexanediol through sequential mono protection, bromination 
and ylid formation steps (Scheme 4.20). 1,6-hexanediol was succesfully mono 
triisopropylsilyl (TIPS) protected to give silyl ether 113,166 although the subsequent 
bromination with triphenylphosphine-bromine complex led to a chromatographically 
inseparable mixture of bromide 114 and other side-products. To circumvent this 
problem, the bromination and protection steps were reversed. Bromination of 1,6-
hexanediol using hydrobromic acid in toluene proceeded to give bromide 115 in high 
yield.167 
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Scheme 4.20. Attempted formation of the linker component of the conjugate by 
bromination of 1,6-hexanediol and ylid formation. 
 
This synthesis was not pursued further due to the parallel development of a 
conjugate using a related strategy developed within the group. 
 
4.8. Introduction of a Linker via Sonogashira Cross-coupling 
In parallel to the development of conjugate 110 via Wittig homologation followed by 
acid-induced dimerisation, Dr Mark Smith, developed a successful method for the 
addition of a functionalised alkyl linker to the ortho position of E1 within the Hailes 
research group. Installation of the linker by Negishi or Kumada cross-coupling 
reactions was unsuccessful, however, the conjugate 116 could be successfully 
synthesised by Sonogashira cross-coupling of aryl iodide 85 and mono-Boc 
protected alkyne 117 at room temperature in moderate yield (Scheme 4.21). 
Protection of the phenol groups avoided cyclisation to the corresponding benzofuran, 
as observed previously. Furthermore, the alkyne 117 is less sterically hindered than 
its dibenzyl equivalent, which may improve the yield of the Sonogashira coupling 
reaction at room temperature. 
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Scheme 4.21. Synthesis of conjugate 118 by Dr Mark Smith via a Sonogashira 
cross-coupling based approach. 
 
Removal of the Boc group unmasked the reactive amine, which was ʻcappedʼ with an 
acetate group to provide an analogue of the biotin/dye labelled amide conjugate for 
biological testing. Using a similar strategy, conjugate 119 where the alkyne moiety of 
120 was reduced by hydrogenation was prepared via the Sonogashira cross-coupling 
of aryl iodide 85 and alkyne 121 (Scheme 4.22).  
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Scheme 4.22. Synthesis of conjugate 119 by Dr Mark Smith via a Sonogashira 
cross-coupling based approach. 
 
Unfortunately, biological testing of conjugates 118 and 119 indicated that the 
additional substitution abolished Akt inhibition in the cellular assay. As a result, the 
related conjugates 122 and 123 were synthesised by Dr Mark Smith using a hybrid 
strategy, where the hetero-dimeric diarylmethane 124 was formed using the acid-
induced coupling method described earlier, and the functionalised alkyl linker was 
installed via Sonogashira cross-coupling (Scheme 4.23). Removal of the Boc group 
in 125, followed by acetylation gave conjugate 122 for biological evaluation. 
Additionally, reduction of the alkyne by hydrogenation gave conjugate 123 for 
biological evaluation. Finally, the biotin-containing conjugate 126 was synthesised for 
affinity chromatography studies. 
 
97 
O
O
1) 42, H2SO4, 100 °C
2) Ac2O, py, 4-DMAP, r.t.
Cl
O
O
57%
124
I
OH
OH
I
NHBoc
Pd(PPh3)4, CuI, 
NEt3, r.t.
117
70% O
O
Cl
O
O
125
NHBoc
O
O
Cl
O
O
122
1) TFA, CH2Cl2, 0 °C
2) Ac2O, py, 4-DMAP,
    r.t
57%
125
O
O
Cl
O
O 126
1) TFA, CH2Cl2, 0 °C
2) Biotin X-SE, EDC,
    CH2Cl2/DMF, r.t.
72%
125
H
N
O
N
H
O
S
HN NH
O
H
H
quant
H2, Pd/C, MeOH
O
O
Cl
O
O
123
H
N
O
H
N
O
 
 
Scheme 4.23. Synthesis of biotin-labelled conjugate 126 by Dr Mark Smith via a 
Sonogashira cross-coupling based approach. 
 
 
Affinity chromotagraphy experiments using conjugate 126 by Evelyn Rosivatz in the 
Woscholski research group did not identify any target proteins, suggesting that 
extensive derivatisation of E1 leads to an unacceptable loss of biological activity. The 
successful application of this technique is likely to require a significantly more active 
compound than E1 in order to overcome the resulting loss of activity upon 
derivitisation. Accordingly, the remainder of this thesis is focussed upon the 
identification of an analogue of E1 with greater biological activity. 
 
4.9. Summary 
Several synthetic strategies for the incorporation of a functionalised alkyl chain into 
lead compound E1 were investigated, based around Heck coupling, Claisen 
rearrangement, Friedel-Crafts acylation and Wittig homologation / late stage acid-
98 
induced coupling steps; however, synthesis of the desired conjugates using these 
approaches was unsuccessful. Conjugate 126 was successfully synthesised within 
the Hailes research group by Dr Mark Smith, but appeared to be insufficiently active 
for affinity chromatography. This suggests that the development of a more potent 
PI3-K-Akt-mTOR modulator might be required to make target identification using this 
technique viable.  
  
99 
5. Assembly of Homo- and Hetero-dimeric Analogues 
of E1 
 
5.1. Introduction 
Following the synthesis of a number of functionalised monomeric building blocks 
compounds (see Chapter 3), the next objective of the project was to complete their 
assembly into homo- and hetero-dimeric analogues of E1, thus allowing testing of the 
compounds to determine the role that the linker group between aromatic units 
contributes towards biological activity. During the planning stage of the project a 
number of target linker groups had been identified (Scheme 3.4). This chapter 
describes the synthesis of these analogues and their biological evaluation. 
 
5.2. Initial Investigation of Hetero-dimeric E1 Analogues  
To determine whether additional substitution at one of the aromatic rings of E1 would 
lead to a reduction in biological activity, the E1 derivative 127 containing an ortho-
ethyl side-chain was synthesised in parallel with the development of the building 
block compounds. Consultation of the literature revealed that ortho-
(hydroxymethyl)phenols can be reacted with phenols in the presence of strong acids 
to yield diarylmethanes.123,168 Although such conditions are typically low yielding and 
have not been applied to phenyl methyl ethers, this method represented a extremely 
concise route to diarylmethane 127, as the phenyl methyl ether precursors 128 and 
51 were readily accesible (Scheme 5.1).  
 
Cl
O
O
O
Cl
O
Cl
OMe
Cl
OMe
OH
127
128 51
+
 
 
Scheme 5.1. Retrosynthetic analysis for the formation of diarylmethane 127 by acid-
induced coupling.  
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The ortho-ethyl precursor 128 was synthesised via Wittig homologation of aldehyde 
61 in moderate yield, although the reaction was not optimised as it provided a 
sufficient quantity of 128 for the subsequent acid-induced coupling reaction (Scheme 
5.2). 
 
OMe
Cl
OMe
Cl
O
61 128
1) MePPh3Br, NaH, 
    THF, r.t.
2) H2, Pd/C, THF, r.t.
66%H
 
 
Scheme 5.2. Synthesis of ortho-ethylphenyl methyl ether 128 by Wittig 
homologation. 
 
The attempted coupling of alcohol 51 and ortho-ethylphenyl methyl ether 128 by 
suspension in aqueous sulfuric acid resulted in the formation of complex mixture of 
products (Scheme 5.3). Analysis of the crude product mixture by proton NMR 
indicated that it consisted predominately of recovered starting materials, as well as a 
mixture of oligomers (determined by the multiple bridging methylene peaks between 
3.7 ppm and 4.1 ppm). Similarly, the attempted coupling of 51 and 128 in the 
presence of formaldehyde according to the method developed for the synthesis of E1 
generated a complex mixture of oligomers. Separation of this mixture by flash 
chromatography was unsuccessful. 
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Scheme 5.3. The attempted synthesis of diarylmethane 129 by coupling of alcohol 
51 and ortho-ethylphenyl methyl ether 128 was unsuccessful. 
 
Typically, free phenols are required for the analogous acid-induced synthesis of 
calixarenes, which are cyclic analogues of E1,123,124 therefore a potential factor in the 
failure of this reaction was the masking of the phenol groups as their respective 
phenyl methyl ethers. To investigate whether this was the case, it was decided to 
attempt the coupling on the phenolic analogues of phenyl methyl ethers 51 and 128. 
The ortho-ethylphenol 130 was accessible by demethylation of ortho-ethylphenyl 
methyl ether 128 (Scheme 5.4).  
 
OMe
Cl
OH
Cl
128 130
BBr3.S(CH3)2, 
ClCH2CH2Cl, 85 °C
43%
 
 
Scheme 5.4. Synthesis of ortho-ethylphenol 130 by Wittig homologation and 
demethylation. 
 
The attempted deprotection of phenyl methyl ether 51 using tribromoborane-dimethyl 
sulfide complex led to complete decomposition of starting material (Scheme 5.5). In 
contrast, the deprotection of methyl ether 50 was successful, giving the carboxylic 
acid 131. A small amount of the corresponding thioether 132 was also isolated from 
this reaction. Carboxylic acid 131 was converted to the corresponding methyl ester 
102 
133 to facilitate reduction with DIBAL-H. Treatment of 133 with DIBAL-H gave diol 
109 in low yield (due to the addition of only one equivalent in error), yet produced 
enough of the diol to attempt the subsequent coupling reaction.  
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OH
Cl
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Scheme 5.5. Synthesis of the diol coupling partner 109. 
 
The acid-induced coupling of diol 109 and ortho-ethylphenol 130 proceeded 
successfully to give diarylmethane 134 in 41% yield. A small sample of 
diarylmethane 134 was acetylated and purified by reverse phase HPLC to give the 
diacetate 127 for biological evaluation (Scheme 5.6).  
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Scheme 5.6. Synthesis of diarylmethane 129 via acid-induced coupling of diol 109 
and ortho-ethylphenol 130. 
 
Biological evaluation of hetero-dimeric diarylmethane 127 in the Woscholski research 
group indicated that it could inhibit Ser473 Akt phosphorylation in MCF-7 cells, albeit 
with reduced potency in comparison to E1. These results provided some evidence 
that hetero-dimeric analogues of E1 are tolerated, yet the degree of variation from the 
homo-dimeric structure of E1 that would be tolerated was still not known. 
 
5.2. Assembly of Building Blocks by C-C Bond Forming Reactions 
5.2.1. Synthesis of a Hetero-dimeric Diarylmethane by Suzuki Cross-Coupling 
In order to determine whether more significant alterations to the E1 scaffold could be 
tolerated, the synthesis of the corresponding diarylmethane where all substitution 
was removed from one of the aromatic units was desirable. Retrosynthetic analysis 
of diarylmethane revealed two possible disconnections that would allow its synthesis 
via Suzuki cross-coupling, where the methylene group can be incorporated into either 
the ʻfunctionalisedʼ fragment containing the para-(2-chloroethyl) functionality, or the 
ʻunfunctionalisedʼ fragment (Scheme 5.7). Additionally, for each of the two possible 
disconnections the boronate or halide moieties can be contained in either the  
ʻfunctionalisedʼ or ʻunfunctionalisedʼ coupling partner. 
 
104 
Cl
O
O
OMe
B(pin)2
Cl
I
+
OMe
Br
Cl
(HO)2B
+
OMe
B(pin)2
Cl
+
OMe
X
Cl
+
I
or or
B
65
66
13655, X = I
54, X = Br
135
 
 
Scheme 5.7. Retrosynthetic analysis for the formation of a hetero-dimeric 
diarylmethane by Suzuki cross-coupling.  
 
Aryl halides 55 and 54 were readily available, and their syntheses more 
straightforward than that of the benzylic halide 65 and benzylic boronate 66 (see 
Chapter 3). The synthesis of aryl boronate 135 was considered likely to be 
troublesome, due to the difficulties previously encountered with ortho-lithiation of 
phenol 42 (see Chapter 3). As B-benzyl-9-borabicyclo[3,3,1]nonane (B-benzyl-9-
BBN, 136) was commercially available, the Suzuki cross-coupling of aryl iodide 55 or 
aryl bromide 54 with B-benzyl-9-BBN was considered the preferred route.  
The Suzuki cross-coupling reaction typically involves the coupling of aryl and vinylic 
species, although in recent years it has been extended to the coupling of sp3-
hybridised species. Since 1999 there have been several examples of cross-coupling 
of benzylic halides,169-173 benzylic acetates,174 benzylic carbonates175 and benzylic 
phosphates176 with aryl boronic acids or potassium aryltrifluoroborates to form 
diarylmethanes.  
 
Conversely, the Suzuki cross-coupling of interest in this case between benzylic boron 
species and aryl halides has attracted far less attention. Prior to 2005, when Flaherty 
and co-workers reported a high-yielding method using an SPhos-based catalytic 
system,146 there were only two reports describing the cross-coupling of aryl halides 
with B-benzyl-9-BBN. One of these studies was low yielding, the other did not 
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disclose a yield.177,178 Molander and Ito later reported a related cross-coupling of aryl 
triflates and potassium benzyltrifluoroborate that was similarly low yielding.179 
 
Suzuki cross-coupling of aryl bromide 54 and B-benzyl-9-BBN according to the 
protocol of Flaherty et al. was successful (Scheme 5.8). The low isolated yield of 
diarylmethane 137 from this reaction was primarily thought to be a consequence of 
the problematic chromatographic separation of diarylmethane 137 from various 
decomposition products. As sufficient material was obtained to continue with the 
synthesis, this reaction was not optimised further. 
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Cl
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Cl
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OH
Cl
138
26% 65%
O
Cl
139
O
40%
Ac2O, 4-DMAP,
NEt3, r.t.
BBr3.S(CH3)2, 
ClCH2CH2Cl, 85 °C
B-benzyl-9-BBN (136),
Pd(OAc)2, SPhos (67),
K3PO4, THF, 60 °C
138
 
 
Scheme 5.8. Synthesis of hetero-dimeric diarylmethane 139 via a Suzuki cross-
coupling based approach. 
 
Deprotection of methyl ether 137 with tribromoborane-dimethyl sulfide complex, 
followed by acetylation produced acetate 139 in an adequate quantity for biological 
evaluation. Biological evaluation of diarylmethane 139 by Evelyn Rosivatz in the 
Woscholski research group indicated that it had a similar inhibitory effect on cellular 
Akt Ser473 phosphorylation to E1 in MCF-7 human breast cancer cells (Figure 5.1). 
A discussion of this cellular assay is provided at the end of this chapter.  
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Figure 5.1. Western Blot analysis indicating the ability of E1 (43) and diarylmethane 
139 to inhibit Akt Ser473 phosphorylation at doses of above 20.0 μg/ml in MCF-7 
human breast cancer cells. Untreated starved (-, first lane) and untreated cells 
treated with 1 μg/ml insulin (+, second lane) are shown for comparison (Evelyn 
Rosivatz). 
 
This result demonstrated that alterations to the homo-dimeric E1 scaffold could be 
made without a detrimental effect on the compoundʼs activity. Consequently, it was 
decided to prioritise the synthesis of hetero-dimeric compounds where one aromatic 
ring contains the para-(2-chloroethyl)phenol functionality present in E1 and the other 
aromatic ring is unsubstituted. Biological evaluation of these compounds to determine 
their ability to inhibit cellular Akt phosphorylation would thus enable the contribution 
of different linker groups towards activity to be determined. 
 
5.2.2. Synthesis of a Hetero-dimeric Biaryl by Suzuki Cross-coupling 
With a successful protocol for the formation of 139 via Suzuki cross-coupling 
established, attention was turned towards the synthesis of a biaryl analogue. The 
Suzuki cross-coupling of aryl iodide 89 and phenylboronic acid was indeed 
successful, although aryl iodide 89 and biaryl 140 were inseparable by flash 
chromatography (Scheme 5.9). Purification by reverse phase HPLC gave a pure 
sample of biaryl 140 for biological evaluation. 
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Scheme 5.9. Synthesis of hetero-dimeric biaryl 140. 
 
5.2.3. Synthesis of a Hetero-dimeric Diarylketone and Diarylmethanol by Friedel-
Crafts Acylation 
The diarylketone 141 was synthesised from 47 by Friedel-Crafts acylation, using the 
conditions previously developed for the synthesis of the monomeric building block 49. 
The corresponding methyl ether 142 was also isolated from the reaction. Acetylation 
of 141 provided 143 for biological evaluation (Scheme 5.10). 
 
OMe
Cl
OH
Cl
O
Cl
47 141
143
50%
PhCOCl, AlCl3,
CH2Cl2, 55 °C
35%
O
+
OMe
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142
141
O O
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71% O
 
 
Scheme 5.10. Synthesis of hetero-dimeric diarylketone 143. 
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With diarylketone 143 in hand, the reduction of the ketone group to produce the 
corresponding diarylmethanol analogue was investigated. Diarylketone 141 was 
reduced to the corresponding diol 144 by treatment with borane-dimethyl sulfide 
complex. Partial purification of 144 by flash chromotagraphy yielded material that 
was approximately 90% pure. Acetylation of 144 using one equivalent of pyridine and 
acetic anhydride in dichloromethane at room temperature gave a complex mixture of 
products, of which the sole product isolated following flash chromatography was the 
diacetate 145 (Scheme 5.11).  
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141 144
O OH O
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NEt3, CH2Cl2, r.t.
1% O
O O
BH3.S(CH3)2, 
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Scheme 5.11. Synthesis of hetero-dimeric diarylmethanol derivative 145. 
 
An alternative route to the desired diarylmethanol 146 was via reduction of 143 using 
borane. Borane reduces ketones more rapidly than esters, thus enabling a selective 
reduction.180 No reaction was observed upon treatment of 143 with borane-dimethyl 
sulfide complex at 0 °C or room temperature. Increasing the temperature to 60 °C led 
to decomposition of the ketone 143 (Scheme 5.12). 
 
O
Cl
O
Cl
143 146
O OH
BH3.S(CH3)2, 
THF
OO
 
 
Scheme 5.12. The attempted synthesis of hetero-dimeric diarylmethanol 146 by 
reduction of diarylketone 143 was unsuccessful. 
109 
Selective acetylation of the secondary alcohol is likely to be problematic due to 
migration of the acetate moiety between the two hydroxyl groups under acidic or 
basic conditions, (for example during chromatography on silica gel). Since the 
acetate group may be liable to esterase-mediated cleavage in vivo, the synthesis of 
diarylmethanol 146 was not pursued further. 
 
5.2.4. Synthesis of a Hetero-dimeric Alkyne by Sonogashira Cross-coupling 
The synthesis of a hetero-dimeric E1 analogue linked by an alkyne group by 
Sonogashira cross-coupling was also investigated. This could theroretically be 
achieved either by cross-coupling of alkyne 64 with iodobenzene, or by cross-
coupling of aryl iodide 89 with phenylacetylene (Scheme 5.13). 
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Scheme 5.13. Retrosynthetic analysis for the formation of hetero-dimeric alkyne 147 
by Sonogashira cross-coupling. 
 
The former approach would require additional deprotection and acetylation steps, 
which was not considered a viable strategy due to the potential for cyclisation to the 
corresponding benzofuran upon deprotection of the phenyl methyl ester.181 To avoid 
these extra steps, the alternative Sonogashira cross-coupling of aryl iodide 89 and 
phenylacetylene was employed to produce alkyne 147 in high yield (Scheme 5.14). 
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Scheme 5.14. Synthesis of hetero-dimeric alkyne 147 by Sonogashira cross-coupling 
of aryl iodide 89 and phenylacetylene. 
 
5.2.5. Attempted Synthesis of Hetero-dimeric Alkenes  
The Wittig reaction of aldehyde 61 and the ylid generated in situ from 
benzyltriphenylphosphonium bromide was attempted to generate the corresponding 
hetero-dimeric alkene 148 (Scheme 5.15). 
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PhCH2PPh3Br,
NaH, THF, r.t.
H OH
Cl
149
BBr3.S(CH3)2,
ClCH2CH2Cl, 85 °C
 
 
Scheme 5.15. The attempted synthesis of hetero-dimeric alkene 148 via a Wittig 
coupling based approach. 
 
As the benzyltriphenylphosphonium ylid could be considered to be ʻsemi-stablisedʼ 
because of the ability of the benzyl group to stablise the negative charge on the 
adjacent carbon atom, a mixture of (Z)- and (E)-alkenes might have been 
expected.138 Suprisngly, analysis of the resulting reaction mixture by proton NMR 
indicated the exclusive presence of the (Z)-alkene 148, with two doublet peaks 
observed at 6.46 ppm and 6.69 ppm (J = 12.1 Hz) that correspond to the alkenyl 
peaks in the (Z)-alkene 148. Unfortunately the attempted deprotection of the crude 
111 
product to phenol 149 using tribromoborane-dimethylsulfide complex led to complete 
decomposition of the material.  
 
Fortunately, the troublesome deprotection step could be circumvented by employing 
aldehyde 150 as the substrate in the Wittig reaction (the synthesis of aldehyde 150 is 
described in Chapter 6). No reaction was observed upon conducting this reaction at 
room temperature, but increasing the temperature to 60 °C led to successful 
formation of (Z)-alkene 151 (Scheme 5.16). The partial purification of 151 by flash 
chromatography, followed by reverse phase HPLC, yielded material of approximately 
90% purity according to proton NMR analysis. As these unidentified impurities could 
not be removed, this method was considered unacceptable for producing (Z)-alkene 
151 for biological evaluation. 
 
O
Cl
O
Cl
O
150 151
PhCH2PPh3Br, 
NaH, THF, 60 °C
O O
H
 
 
Scheme 5.16. Synthesis of hetero-dimeric (Z)-alkene 151. 
 
The synthesis of alkyne 147 provided an alternative route to the desired alkene by 
stereoselective reduction; however, no reaction was observed upon treatment of 147 
with Lindlarʼs catalyst (Pd(CaCO3)/Pb) under an atmosphere of hydrogen (Scheme 
5.17). 
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Scheme 5.17. The attempted synthesis of (Z)-alkene 151 by reduction of alkyne 147 
was unsuccessful. 
 
5.2.6. Attempted Synthesis of a Hetero-dimeric Diarylethane.  
The reduction of alkyne 147 could also be exploited for the synthesis of the 
corresponding diarylethane. Treatment of 147 with Pearlmanʼs catalyst (Pd(OH)2) 
under a hydrogen atmosphere led to a mixture of products. Further NMR analysis 
after partial chromtographic separation of the mixture suggested the formation of 
trace amounts of alkane 152 due to a multiplet signal at 2.90-2.75 ppm containing 
four protons relative to the characteristic CH2Cl and ArCH2 triplet signals at 3.64 ppm 
and 3.00 ppm respectively (Scheme 5.18).  
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Scheme 5.18. Synthesis of alkane 152 by reduction of alkyne 147. 
 
Due to the poor conversion of this reaction and the difficulties encountered in 
separating the reaction products, this route was not considered suitable for providing 
152 for biological testing.
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5.3. Assembly of Building Blocks by C-O Bond Forming Reactions 
5.3.1. Synthesis of a Hetero-dimeric Ether  
The synthesis of the hetero-dimeric ether 153 was also explored. Benzyl ether 153 
was formed by treatment of Williamson etherification of bromide 154 (the synthesis of 
bromide 154 is described in Chapter 6) and phenol (Scheme 5.19). Analysis of the 
reaction by TLC indicated that the addition of a catalytic amount of sodium iodide was 
required to induce conversion of 154 to 153. Complete separation of 153 from 
unidentified side-products presumed to result from decomposition was unsuccessful 
by flash chromatography, although these impurities were removed by reverse phase 
HPLC prior to biological testing. 
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Scheme 5.19. Synthesis of hetero-dimeric ether 153 via Williamson etherification. 
 
5.4. Assembly of Building Blocks by C-N Bond Forming Reactions 
5.4.1. Synthesis of a Hetero-dimeric Amide by Reductive Amination  
E1 derivatives containing an amine linker were accessible by reductive amination of 
aldehyde 150. The amine 155 was prepared by reductive amination of 150 with 
aniline. Once TLC analysis had indicated the complete consumption of 150, the 
reaction mixture was concentrated under vacuum. Experience gathered from 
synthesising the monomeric building blocks suggested that resuspension of the 
residue in dichloromethane, followed by washing with saturated sodium hydrogen 
carbonate solution would leave the acetate moiety intact, but the phenol 155 was the 
sole product, isolated in 23% yield (Scheme 5.20). 
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Scheme 5.20. Synthesis of hetero-dimeric amide 155 by reductive amination of 
aldehyde 150 and aniline. 
 
In an effort to improve the isolated yield, the procedure was modified so that the 
crude amine was isolated by precipitation as its corresponding sodium phenoxide salt 
156 during workup, which was used without additional purification. Additionally, the 
reductive amination was carried out using aldehyde 159 (the synthesis of aldehyde 
159 is described in Chapter 6). Treatment of 156 with acetic anhydride produced a 
mixture of mono- and di-acetylated products 157 and 158 (Scheme 5.21). 
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Scheme 5.21. Synthesis of hetero-dimeric amides 157 and 158 via a reductive 
amination based strategy. 
 
The selective O-acetylation of 156 was potentially problematic due to the possibility 
of intra-molecular acetate transfer, but was briefly investigated. Typically such an 
approach would require the use of an orthogonal protecting group strategy, but an 
alternative biocatalytic strategy was proposed. Lipases are a subclass of esterases 
that have found extensive use in synthetic chemistry due to their high tolerance 
towards heat and organic solvents, and their relative promiscuity towards non-natural 
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substrates.182 Phenoxide 156 was incubated with C. antarctica lipase – a lipase with 
high tolerance for bulky substrates183 – and an excess of vinyl acetate in 1,2-
dichloroethane at 40 °C, but no conversion was observed by TLC or proton NMR 
(Scheme 5.22). 
 
O-Na+
Cl
156
H
N
O
Cl
H
N
160O
C. antarctica lipase
vinyl acetate, 
ClCH2CH2Cl, 40 °C
 
 
Scheme 5.22. Attempted biocatalytic synthesis of hetero-dimeric amine 160. 
 
Following the failure of the biocatalytic approach, a more conventional orthogonal 
protecting group strategy was adopted. Protection of the amine as its carboxybenzyl 
(Cbz) derivative would allow acetylation of the phenol, followed by removal of the Cbz 
group by hydrogenation, unmasking the free amine (Scheme 5.23). Accordingly, 
phenol 155 was treated with benzyl chloroformate and triethylamine. The crude 
product was acetylated to give the benzyl carbamate 161, which was obtained in 
approximately 90% purity following flash chromatography, as determined by proton 
and carbon NMR spectroscopy. Hydrogenation of 161 successfully removed the Cbz 
group, but also reduced the chloroethyl group at the upper rim. The amide 162 was 
isolated in 17% yield over two steps, supporting the possibility that intra-molecular 
acetate transfer might be occurring. Accordingly, the synthesis of the free amine was 
not pursued further. 
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Scheme 5.23. Synthesis of hetero-dimeric amide 162 via a Cbz-protection strategy. 
 
5.4.2. Attempted Synthesis of a Hetero-dimeric Triazole by Copper Catalysed 
Huisgen [3+2] Cycloaddition 
1,2,3-Triazoles are frequently employed as metabolically stable peptide isosteres in 
biological systems.184 Two options were identified for the concise synthesis of 
regioisomeric hetero-dimeric 1,2,3-triazoles by the copper catalysed Huisgen [3+2] 
cycloaddition reaction that would utilise the monomeric building block compounds. 
Triazole 163 could be formed by cyclisation of azide 164 (which could be synthesised 
from bromide 154) and phenylacetylene. Alternatively, triazole 165 could derive from 
alkyne 64 and benzyl azide (Scheme 5.24). 
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Scheme 5.24. Retrosynthetic analysis for the formation of regiosiomeric 1,2,3-
triazoles 163 and 164 by the copper catalysed Huisgen [3+2] cycloaddition reaction. 
 
Since its discovery in 2002, the copper catalysed variant of the Huisgen [3+2] 
cycloaddition has attracted much interest due to its tolerance of oxygen and moisture, 
operational simplicity and broad substrate tolerance.185,186 Two catalytic systems are 
typically used: an ʻaqueousʼ system where the substrates are dissolved in aqueous 
tert-butanol and copper (I) is generated in situ by reduction of copper (II) sulfate by 
sodium ascorbate; or a when organic solvents are employed, copper (I) in the form of 
copper iodide and a stabilising nitrogen ligand are added.187 
 
As bromide 154 was already available, it was determined that conversion of 154 to 
the corresponding azide 164 would be more efficient than conducting deprotection 
and acetylation steps post cyclisation. Accordingly, the azide 164 was prepared to 
enable investigation of the cyclisation reaction. However, no reaction was observed 
for the reaction of 164 and phenylacetylene under ʻaqueousʼ conditions. In contrast, 
when the ʻorganicʼ protocol was used, NMR analysis indicated that decomposition 
occured (Scheme 5.25). 
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Scheme 5.25. Attempted synthesis of 1,2,3-triazoles 163 and 166 by a Huisgen 
[3+2] cycloaddition based strategy. 
 
To prevent the possibility of decomposition occurring following cleavage of the phenyl 
methyl ether, methyl ether 68 was reacted under the same conditions, however a 
similar complex NMR spectrum resulting from decomposition was obtained. 
Alternatively, cyclisation of alkyne 64 and benzyl azide could be used to produce the 
1,2,3-triazole 165 (Scheme 5.26). Benzyl azide was synthesised according to the 
procedure of Alvarez and Alvarez.188 The subsequent cyclisation reaction was 
similarly unsuccessful, leading solely to decomposition of the material. 
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Scheme 5.26. The attempted synthesis of 1,2,3-triazole 165 by Huisgen [3+2] 
cycloaddition of alkyne 68 and benzyl azide was unsuccessful. 
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To investigate this reaction further, a series of small-scale control reactions where 
the starting materials were independently exposed to individual reagents were run. 
Analysis of these reactions by TLC indicated that none of the individual reaction 
components were capable of promoting decomposition, suggesting that side-
reactions might be occurring following formation of the desired 1,2,3-triazole. 
Consequently, the synthesis of 1,2,3-triazoles 163 and 165 were not pursued further. 
 
5.5. Assembly of Building Blocks by N-S Bond Forming Reactions 
5.5.1. Synthesis of a Hetero-dimeric Sulfonamide  
Condensation of sulfonyl chloride 70 with aniline yielded sulfonamide 167 in 
moderate yield. Deprotection of 167 using the previously developed method was 
straightforward, giving phenol 168. Phenol 168 was subsequently acetylated to give 
acetate 169 (Scheme 5.27). 
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Scheme 5.27. Synthesis of hetero-dimeric sulfonamide 169 via the condensation of 
sulfonyl chloride 70 and aniline. 
 
5.6. Biological Evaluation of Hetero-dimeric E1 Analogues 
To determine the effect of the functional group linking the two aromatic units on 
biological activity, the hetero-dimeric E1 analogues 157, 143, 145, 169, 127 and 139 
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were tested for their ability to inhibit Akt Ser473 phosphorylation in MCF-7 cells in 
comparison to E1 by Evelyn Rosivatz in the Woscholski research group (Figure 5.2). 
Compounds 140, 147 and 153 were not included in this experiment, as they had not 
been synthesised at the time.  
 
MCF-7 cells that were deprived of growth serum overnight, were treated with a 50 
μg/ml solution of the relevant compound dissolved in DMSO. After a one-hour 
incubation period, the cells were stimulated with 1 μg/ml of insulin for 15 minutes to 
promote activation of PI3-K-Akt-mTOR signalling. Insulin stimulated (+) and serum 
starved (-) cells were included as controls. Following stimulation the cells were lysed 
and the samples subjected to Western blotting analysis with antibodies specific for 
Akt (Figure 5.2a) and phospho-Ser473 Akt (Figure 5.2b). The experiments were 
repeated twice with consistent results.  
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Figure 5.2. Immunoblot analysis showing the effect of treatment of a 50 μg/ml DMSO 
solution of E1 (43) and the hetero-dimeric compounds 157, 143, 145, 169, 127 and 
139 on: a) total cellular Akt; b) Akt Ser473 phosphorylation (Evelyn Rosivatz); c) 
structures of hetero-dimeric E1 analogues. 
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The total amount of Akt remained relatively consistent for all the compounds (data 
not shown for compounds 127 and 139), suggesting that they had similar levels of 
cytotoxicity (Figure 5.2a). Compounds 157, 145, 169 and 127 showed little or no 
inhibitory activity towards Akt Ser473 phosphorylation. As discussed previously in 
this Chapter, diarylmethane 139 showed similar Ser473 phospho-Akt inhibitory 
activity to E1 in a dose-response study (Figure 5.1). Furthermore, diarylketone 143 
showed similar inhibitory activity to E1 and was also selected for further 
development. 
 
5.7. Summary 
The synthesis and biological evaluation of the hetero-dimeric diarylmethane 127 
acted as a proof-of-concept that variation of the homo-dimeric structure of E1 was 
tolerated, albeit with a reduction in potency. Gratifyingly, the removal of functional 
groups from one of the aromatic rings of E1 resulted in a hetero-dimeric 
diarylmethane, 139, that inhibited cellular Akt Ser473 phosphorylation to a similar 
degree to E1. 
 
Following this promising result, the functionalised building block compounds were 
assembled using a variety of C-C, C-O, C-N and N-S bond-forming reactions to 
generate hetero-dimeric compounds containing a para-chloroethyl phenol group 
linked to an unsubstituted phenyl ring. Biological evaluation of these compounds 
gave the first indication of how the functional group linking the two aromatic units 
influences Akt inhibition. In addition to diarylmethane 139, diarylketone 143 inhibited 
Akt phosphorylation in the cellular assay, hence both compounds were considered 
suitable leads for further development. 
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6. Second Generation Hetero-dimeric PI3-K-Akt-mTOR 
Modulators  
 
6.1. Introduction 
Previously, a series of hetero-dimeric compounds containing two aromatic units 
linked by various functional groups had been screened for inhibitory activity towards 
Akt. Diarylmethane 139 and diarylketone 143 inhibited Ser473 Akt phosphorylation in 
MCF-7 cells to a similar degree as lead compound E1 (43) (Scheme 6.1), making 
them suitable leads for further development (see Chapter 5).  
 
Cl
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O
O
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E1, 43 139 143  
 
Scheme 6.1. Structures of lead compounds: E1 (43), diarylmethane 139 and 
diarylketone 143. 
 
To explore the structure-activity relationships of these hetero-dimeric scaffolds 
further, additional diarylmethane and diarylketone analogues were required for 
biological testing. Substitution of the phenyl ring with electron-withdrawing and 
electron-donating substituents at various positions, as well as replacement of the 
phenyl group with heterocyclic or aliphatic cyclic groups, was planned in the first 
instance. As no structural information was available to guide the rational design of 
analogues, a shortlist of eleven substituents were chosen that could be incorporated 
into both scaffolds using readily available starting materials. Although these 
analogues were intended to make relatively small deviations from the structures of 
the two lead compounds, the goal was to develop versatile synthetic routes that could 
be used for further iterations of this process. 
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6.2. Synthesis of a Series of Hetero-dimeric Diarylmethanes 
The hetero-dimeric diarylmethane 139 had previously synthesised by Suzuki cross-
coupling of aryl bromide 54 with B-benzyl-9-BBN, followed by deprotection and 
acetylation steps (Scheme 5.8). However, this route possessed several limitations 
that made it unattractive for analogue synthesis: in addition to the low yielding Suzuki 
cross-coupling step, functionalised benzylic boronate derivatives or boronic acids 
were not commercially available, necessitating additional steps for their synthesis 
from the corresponding benzyl alcohols (Scheme 6.2a). Although this limitation could 
be circumvented by Suzuki cross-coupling of benzylic bromide 65 with commercially 
available aryl boronic acids (Scheme 6.2b), both routes were considered to be non-
optimal as they required additional deprotection and acetylation steps for each 
analogue.  
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Scheme 6.2. a,b) Suzuki cross-coupling approaches utilising readily avaliable 
precursors were non-optimal, as they required additional deprotection and acetylation 
steps for each analogue; c) to avoid these steps installation of the phenyl acetate is 
necessary in advance of the Suzuki cross-coupling step 
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6.2.1. Synthesis of a Benzylic Bromide for Suzuki Cross-coupling 
A more suitable approach for analogue generation involved preparation of the phenyl 
acetate group prior to the Suzuki cross-coupling step (Scheme 6.2c). Consequently, 
the first task was to develop a synthesis of benzylic bromide 154 that could provide 
sufficient amounts of material for investigation of the key Suzuki cross-coupling step. 
 
The analogous methoxy-protected benzyl bromide 65 had previously been 
synthesised from phenyl methyl ether 47 via Friedel-Crafts acylation, protection, 
oxidation, reduction and bromination steps (Scheme 6.3, see Chapter 3). 
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Scheme 6.3. Synthesis of benzyl bromide 65 from phenyl methyl ether 47. 
 
The deprotection of phenyl methyl ether 65 using tribromoborane-dimethylsulfide 
complex was anticipated to be problematic, due to the likelihood of elimination and 
polymerisation occurring upon unmasking of the phenol. This hypothesis was 
supported by the attempted deprotection of the commercially available model 
substrate 170 under these conditions, which led to decomposition of the material 
(Scheme 6.4). 
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Figure 6.4. The deprotection of model substrate 170 was unsuccessful. 
 
Further attempts to synthesise benzylic bromide 154 also presented an opportunity to 
remove the inefficient oxidation and reduction steps present in the synthesis of 
bromide 65. Accordingly, the addition of formaldehyde to phenol 42 via a 
magnesium-mediated ortho-formylation reaction proceeded to form aldehyde 159 in 
excellent yield (Scheme 6.5).189 A sample of aldehyde 159 was acetylated to provide 
a substrate for a Wittig coupling that was conducted in parallel (see Chapter 6). 
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Scheme 6.5. Synthesis of aldehyde 159 and its acetylated derivative 150 by 
magnesium-mediated ortho-formylation of phenol 42 with formaldehyde. 
 
Consultation of the literature identified a tandem reduction and bromination 
procedure for a range of substituted benzylic aldehydes mediated by 
polymethylhydroxysilane (PHMS) and N-bromosuccinimide (NBS).190 This procedure 
was attempted using aldehyde 159, but TLC analysis indicated that no reaction had 
occured (Scheme 6.6). 
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Scheme 6.6. Attempted synthesis of bromide 171 by tandem reduction and 
bromination of aldehyde 159. 
 
Aldehyde 159 was converted to the corresponding diol 109 by reduction using borane 
(Scheme 6.7). Purification of diol 109 by flash chromatography was successful, albeit 
with reduced mass recovery. During scale-up of this procedure, the crude diol was 
used in the next step without chromatographic purification to avoid loss of material.  
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Scheme 6.7. Synthesis of diol 109 by reduction of aldehyde 159. 
 
The bromination of diol 109 using the conditions previously developed for the 
bromination of the analogous methoxy ether 65 was attempted, but the desired 
bromide 171 could not be isolated from the reaction mixture (Scheme 6.8). In order to 
avoid the potential decomposition of 171 during the removal of triphenylphosphine 
oxide using chromatographic methods, the reaction was repeated using polymer-
bound triphenylphosphine. Unfortunately, a complex mixture of products was again 
obtained. Bromination of 109 using phosphorous tribromide was similarly 
unsuccessful. 
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Scheme 6.8. The attempted bromination of diol 109 was unsuccessful. 
 
An alternative strategy involving the acetylation of the phenolic group of diol 109 prior 
to bromination was pursued. Acetylation of 109 was attempted with single 
equivalents of acetic anhydride and pyridine. NMR analysis following partial 
separation of the reaction mixture by flash chromatography indicated that the major 
product was the di-acetylated species 172. Additionally, small quantities of the 
phenolic acetate 173 were observed, although none of the desired phenyl acetate 
was isolated (Scheme 6.9). The structure of acetate 173 was confirmed using proton 
NMR, which showed an aromatic doublet signal at 6.90 ppm (J = 8.2 Hz), indicative 
of an aromatic proton adjacent to a phenolic hydroxyl group. Predominant formation 
of di-acetate 172 under these conditions was consistent with the literature precedent 
for the acetylation of phenols containing an ortho-benzyl alcohol group. Upon initial 
deprotonation of the phenol group of 109, the proton of the benzylic alcohol could be 
shuttled between the two sites via a cyclic intermediate. Similarly, the acetate group 
could be transferred between the two positions following mono-acetylation of 109. 
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Scheme 6.9. The acetylation of diol 109 produced a mixture of the di- and mono-
acetylated species 172 and 173. 
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The development of a ʻone-potʼ tandem bromination and acetylation procedure 
presented a potentially attractive solution for the formation of the desired bromide 
154, by circumventing the need to isolate potentially unstable intermediates and the 
troublesome selective mono-acetylation of diol 109. Treatment of vicinal diols with 
hydrogen bromide in glacial acetic acid allows the formation of the corresponding 
acetoxy bromide products via nucleophilic opening of an acetoxonium intermediate 
derived from a cyclic orthoacetate.191 This procedure is frequently employed for the 
synthesis of glycosyl bromides.192 Accordingly, treatment of diol 109 with hydrogen 
bromide (33% weight) in glacial acetic acid successfully produced the desired 
bromide 154, albeit in only 7% yield (Scheme 6.10). 
 
OH
Cl
O
Cl
154
HBr (33% wt), AcOH, r.t.
7%
109
OH Br
O
 
 
Figure 6.10. Synthesis of bromide 154 by a tandem acetylation-bromination 
approach. 
 
Further consultation of the literature revealed a similar tandem procedure employing 
trimethyl orthoacetate and acetyl bromide in dichloromethane at 0 °C.193 
Unfortunately the attempted reaction of diol 109 under these conditions was 
unsuccessful, with no reaction observed by TLC analysis (Scheme 6.11). Similarly, 
no reaction was observed upon raising the reaction temperature to room 
temperature. 
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Scheme 6.11. Attempted tandem acetylation-bromination of diol 109 to form bromide 
154. 
 
Modification of the successful, albeit low yielding, one-pot bromination-acetylation 
reaction was investigated in order to raise the yield of bromide 154. Dilution of the 
reaction mixture increased the conversion of 109 to 154 to a negligible degree, but 
none of the desired product was isolated upon addition of dichloromethane as a co-
solvent. The use of acetyl bromide and acetic acid at room temperature allowed the 
isolated yield of the bromide 154 to be increased to 56%. Reduced yields were 
obtained when this reaction was run on a scale of greater than 1.2 mmol. 
 
Although this synthetic sequence was sufficiently concise and high yielding to provide 
adequate quantities of bromide 154 for analogue synthesis (four steps, in 23% overall 
yield from phenol 42), an alternative and concise route consisting of a Clemmensen 
reduction of aldehyde 159 to ortho-methylphenol 174, followed by radical bromination 
and acetylation, was briefly investigated (Scheme 6.12). 
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Scheme 6.12. Alternative route to bromide 154 via a Clemmensen reduction and 
radical bromination strategy. 
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Before embarking on this sequence, it was necessary to ensure that the radical 
bromination step would be sufficiently selective and not result in a mixture of 
polybrominated products. A literature search revealed an example of radical 
bromination of an ortho-methyl substituted phenol derivative that led to exclusive 
formation of the corresponding benzylic bromide in high yield.194 No reaction was 
observed upon treatment of phenol 42 under these conditions, suggesting that this 
route was feasible (Scheme 6.13) 
 
OH
Cl
NBS, AIBN, PhMe, 85 °C
42  
 
Scheme 6.13. No reaction occurred upon exposure of phenol 42 to radical 
bromination conditions. 
 
The Clemmensen reduction of aldehyde 159 by treatment with zinc powder (particle 
size >45 μm) and a solution of acetic acid and hydrochloric acid in ethanol was 
attempted (Scheme 6.14).195 Partial chromatographic separation of the reaction 
mixture yielded a residue with proton and carbon NMR data consistent with a mixture 
of aryl alkanes 174 and 175, as well as other unidentified side-products. A 
Heteronuclear Multiple Quantum Coherence (HMQC) NMR experiment indicated that 
the mixture contained a singlet proton signal at 4.65 ppm that correlated with a 
carbon signal at 72.3 ppm, suggesting the presence of an ether-linked cyclic species. 
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Scheme 6.14. The attempted Clemmensen reduction of aldehyde 159 led to the 
production of a mixture of products. 
 
In any case, given the low mass recovery from the reaction and troublesome 
separation of the reaction products, this route was abandoned in favour of the 
previously described synthesis of bromide 154 via diol 109. 
 
6.2.1. Optimisation of the Suzuki Cross-coupling Reaction 
With an adequate route established, several grams of the benzylic bromide 154 was 
synthesised, and attention was turned to the subsequent Suzuki cross-coupling 
reaction.a The coupling of benzyl bromide 154 and phenylboronic acid was chosen 
for the screening of suitable reaction conditions as the resulting diarylmethane 139 
had previously been synthesised and characterised, aiding interpretation of the 
results. Monitoring of the reaction was frustrated by the inability to separate 154 and 
139 by TLC using various solvent systems. Furthermore, liquid chromatography-
mass spectrometry (LC-MS) was unsuitable for monitoring reaction progress as 
neither the molecular ion or any recognisable fragments were observed. Ultimately, 
aliquots of the reaction mixture were removed, filtered, evaporated and analysed by 
proton NMR spectroscopy to determine the conversion of benzyl bromide 154 to the 
desired diarylmethane 139. Several sets of conditions were trialed with varying 
degrees of conversion observed (Table 6.1). 
 
                                                
a Diarylmethane and diarylketone analogues of E1 were synthesised in the laboratories of 
Prof Herbert Waldmann at the Max-Planck-Institut für molekulare Physiologie in Dortmund. 
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O
Cl
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Cl
154 139O
Br
B(OH)2
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Entry Catalyst 
System 
Base 
 
Solvent Type of 
heating 
T 
(°C) 
t 
(hours) 
% Conversion to 
139 
(1H NMR ±5%) 
1 1 mol%  
trans-PdBr(N-
Succ)(PPh3)2 
Na2CO3  THF Thermal 60 21 32 
2 4 mol% SPhos 
67, 2 mol% 
Pd(OAc)2 
Cs2CO3 THF Thermal 60 23 20 
3 4 mol% SPhos 
67, 2 mol% 
Pd(OAc)2 
Cs2CO3 THF Thermal 60 96 25 
4 10 mol%  
trans-PdBr(N-
Succ)(PPh3)2 
Na2CO3 DMF µwave 150 0.5 - 
5 10 mol%  
trans-PdBr(N-
Succ)(PPh3)2 
Na2CO3 THF Thermal 60 16 90 
6 10 mol%  
trans-PdBr(N-
Succ)(PPh3)2 
Na2CO3 THF Thermal 60 88 93 
 
Table 6.1. Optimisation of the Suzuki cross-coupling between benzyl bromide 154 
and phenylboronic acid to form diarylmethane 139. 
 
Low conversions were observed with catalytic systems employing 1 mol% of trans-
PdBr(N-Succ)(PPh3)2 or the SPhos (67) / Pd(OAc)2 system that was previously 
employed for the synthesis of the analogous methoxyphenol-substituted 
diarylmethane (Table 6.1, entries 1-4). The trans-PdBr(N-Succ)(PPh3)2 catalyst was 
initially evaluated for this reaction as it exhibits unique selectivity for benzylic 
substrates in palladium cross-coupling reactions.196-199 The N-succinimide ligand acts 
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a pseudohalide that can bind to palladium in a monodentate or bidentate manner, 
potentially stabilising intermediates in the catalytic cycle, although it is unclear why 
unactivated benzylic substrates are preferred to activated aryl species.198,200 
Increasing the reaction temperature to 150 °C using microwave heating led to 
decomposition of the starting material after 30 minutes (Table 6.1, entry 5). 
 
Burns and co-workers reported that a catalyst loading of 1 mol% of trans-PdBr(N-
Succ)(PPh3)2 was optimal for Suzuki cross-coupling reactions, however in this case, 
increasing the catalyst loading to 10 mol % improved the conversion of benzyl 
bromide 154 to diarylmethane 139 to 90% after 16 hours (Table 6.1, entry 6). 
Extending the reaction time did not improve the degree of conversion further (Table 
7.1, entry 6). The requirement for a high catalyst loading, together with the 
observation that the conversion did not increase following an extended reaction time, 
suggests that diarylmethane 139 may be inhibiting the catalyst. No colour change 
(from bright yellow) occurred over the duration of the reaction, suggesting that the 
catalyst did not decompose; furthermore, no decomposition of the benzyl bromide 
was observed under these conditions. 
 
6.2.2. Synthesis of a Series of Diarylmethanes 
These optimised conditions were then used to synthesise a series of diarylmethanes 
from benzyl bromide 154 (Table 6.2, entries 1-6). Yields were low, yet sufficient 
material was generated for biological testing in all cases. Diarylmethanes 176 and 
179 were successfully purified by flash chromatography, but further purification by 
reverse phase HPLC was necessary to separate the remaining diarylmethanes from 
benzyl bromide 154. 
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O
Cl
O
Cl
Ar
154O
Br
O
Ar-B(OH)2
10 mol% transPdBr(N-Succ)(PPh3)2,
Na2CO3, THF, 85 °C
 
Entry Boronic Acid t (hours) Product, yield 
1 
(HO)2B
Cl  
17  
176, 11% 
2 
Cl(HO)2B  
17 177, 33% 
3 
(HO)2B
CF3
 
17 178, 21% 
4 
(HO)2B
 
17 179, 47% 
5 
(HO)2B
O
 
17 180, 25% 
6 
(HO)2B OMe
OMe
OMe
 
17 181, 9% 
7 
(HO)2B
OMe  
17 - 
8 
(HO)2B OMe  
17 - 
9 
(HO)2B
OMe
 
17 - 
10 
(HO)2B
N
 
41 - 
 
Table 6.2. A series of diarylmethanes were synthesised via Suzuki cross-coupling 
with benzyl bromide 154. 
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Several of the attempted couplings did not yield the desired diarylmethanes (Table 
6.2, entries 7-10). Initial attempts to couple benzyl bromide 154 with aryl boronic 
acids containing ortho-, meta- or para-methoxy substituents were unsuccessful 
(Table 6.2, entries 7-9): a surprising result considering the successful coupling of the 
analogous 1,2,3-methoxyboronic acid (Table 6.2, entry 6). These reactions were 
repeated using a newly acquired batch of the trans-PdBr(N-Succ)(PPh3)2 catalyst,b 
but again failed to yield the desired diarylmethanes. The attempted coupling of 4-
pyridinylboronic acid with benzyl bromide 154 (Table 6.2, entry 10) produced a black 
viscous residue, which did not yield any UV active species following attempted 
purification by flash chromatography. 
 
To evaluate the biological significance of replacing the planar benzyl ring in lead 
diarylmethane 139 with an aliphatic substituent, the synthesis of analogue 182 
incorporating a cyclohexyl group was intended. Due to the challenging nature of sp3-
sp3 palladium catalysed cross-coupling reactions,201 the acid-induced coupling of an 
aryl species and a primary alcohol that was discussed in Chapter 5 appeared to offer 
a more straightforward route to 182. No coupling between phenol 42 and 
cyclohexylmethanol was observed using this method (Scheme 6.15). This may be 
due to the competing polymerisation of cyclohexylmethanol due to its solubility in 
aqueous sulfuric acid. Similar coupling reactions were found to be unsuccessful upon 
formation of a homogeneous solution (see Chapter 3). 
 
Cl
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O
Cl
OH
OH
18242
25% H2SO4 (aq), 100 °C
 
 
Scheme 6.15. Attempted synthesis of 182 by acid-induced coupling of phenol 42 and 
cyclohexylmethanol.  
                                                
b Kindly donated by Prof Richard Taylor, University of York. 
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6.3. Synthesis of a Series of Hetero-dimeric Diarylketones 
In parallel to the synthesis of the diarylmethane compounds, a series of analogous 
diarylketones incorporating the same substituent on the aromatic ring were prepared 
via Friedel-Crafts acylation of methyl ether 47 with the corresponding acyl chloride 
(either commercially sourced or synthesised in situ from the corresponding carboxylic 
acids), followed by acetylation (Table 6.3, entries 1-9). Reactions were conducted in 
parallel using a Radleys Carousel reaction station, enabling a convenient one-pot 
procedure that avoided the isolation of any intermediate species. 
 
OMe
Cl
47
O
Cl
O
Ar/Cy
O
Ar/Cy
O
Cl
Ac2O, py, 4-DMAP (cat), r.t.
, AlCl31)
2)
 
Entry Acyl chloride t (hours) Solvent T 
(°C) 
Product, yield 
(after acylation) 
1 
O Cl
Cl
 
17 CH2Cl2 55 183, 59% 
2 
O
Cl Cl
 
17 1,2-dichloroethane 85 184, 24% 
3 
O
Cl
OMe  
16 1,2-dichloroethane 85 185, 56% 
4 
O
Cl OMe
 
17 1,2-dichloroethane 85 186, 15% 
5 
O
Cl
OMe
 
16 1,2-dichloroethane 85 187, 75% 
6 
O
Cl OMe
OMe
OMe
 
17 1,2-dichloroethane 85 188, 60% 
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7 
O
Cl
 
16 1,2-dichloroethane 85 189, 97% 
8 
O
O
Cl
 
19 CH2Cl2 55 190, 40% 
9 
O
Cl
 
17 CH2Cl2 55 191, 61% 
10 
O
Cl
CF3
 
19 1,2-dichloroethane 85 - 
11 
O
N.HCl
Cl
 
64 1,2-dichloroethane 85 - 
 
Table 6.3. A series of diarylketones were synthesised by Friedel-Crafts acylation of 
47, followed by acylation. 
 
The Friedel-Crafts acylation protocol developed previously (see Chapter 5) led to 
incomplete deprotection of the resultant diarylketones (Scheme 6.16). This limited the 
quantity of the desired phenyl acetate obtained and necessitated a challenging 
separation of the phenolic and phenyl methyl ether containing diarylketones. 
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Scheme 6.16. The previously developed Friedel-Crafts acylation procedure led to a 
mixture of diarylketones containing phenol and phenyl acetate groups. 
 
Changing the solvent from dichloromethane to 1,2-dichloroethane allowed the 
reaction temperature for the Friedel-Crafts acylation to be raised from 55 °C to 85 °C. 
Accordingly, demethylation of the resulting diarylketones progressed to completion, 
enabling successful purification of the final product by flash chromatography. This 
procedure failed when 4-(trifluoromethyl)benzoyl chloride (Table 6.3, entry 10) and 
isonicotinoyl chloride hydrochloride (Table 6.3, entry 11) were employed as 
substrates. Friedel-Crafts acylation with 4-(trifluoromethyl)benzoyl chloride was 
presumably unsuccessful due to the electron-poor nature of the substrate. 
Isonicotinyl chloride hydrochloride was found to be insoluble in 1,2-dichloroethane 
and did not undergo any reaction. Carson and co-workers reported several low 
yielding Friedel-Crafts acylation reactions employing isonicotinyl chloride 
hydrochloride under similar conditions and concentrations.202  
 
6.4. Synthesis of a Series of Hetero-dimeric Biaryls 
With the desired diarylketones and diarylmethanes synthesised, attention was turned 
to their biological evaluation (see Chapter 7). In parallel with the preparation of MCF-
7 cells for the assay, several hetero-dimeric biaryl compounds were prepared from 
aryl bromide 192 and the corresponding commercially available boronic acids (Table 
6.4). The Suzuki cross-coupling protocol used previously for the synthesis of biaryl 
140 (see Chapter 6) was successfully employed.  
 
140 
O
Cl
Br
O
Cl
192
Pd(OAc)2, SPhos 67,
K3PO4, THF, 85 °C
OO
R
B(OH)2
R
 
Entry Boronic Acid t (hours) Product, yield 
1 
(HO)2B
Cl  
16 193, 43%* 
2 
Cl(HO)2B  
16 194, 59%† 
3 
(HO)2B
CF3
 
16 195, 73%‡ 
4 
(HO)2B
OMe  
16 196, 45% 
5 
(HO)2B OMe  
16 197, 51% 
6 
(HO)2B
OMe
 
16 198, 57% 
  * Product isolated as a 2.5:1 mixture of 193 to aryl bromide 192. 
  † Product isolated as an 8:1 mixture of 194 to aryl bromide 192. 
  ‡ Product isolated as a 5.5:1 mixture of 195 to aryl bromide 192. 
Table 6.4. A series of diarylmethanes were synthesised via Suzuki cross-coupling 
with aryl bromide 192. 
 
Separation of the biaryls containing halogenated substituents (Table 6.4, entries 1-3) 
from aryl bromide 192 could not be achieved using flash chromatography or reverse 
phase HPLC using a methanol-water gradient. The earlier separation of biaryl 140 
and aryl iodide 89 by HPLC used an identical method employing an acetonitrile-water 
gradient, but due to the global shortage of acetonitrile at the time the experiments 
were being conducted this could not be attempted. 
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6.5. Summary 
Following the earlier discovery that the hetero-dimeric diarylmethane 139 and 
diarylketone 143 were inhibitory towards Akt phosphorylation (see Chapter 5), a 
series of hetero-dimeric diarylmethanes, diarylketones and biaryls were synthesised 
for biological evaluation. For the diarylmethane analogues this involved developing a 
route to precursor benzylic bromide 154 and the establishment of a suitable Suzuki 
cross-coupling protocol. The hetero-dimeric compounds contained various electron-
withdrawing and electron-donating groups at different positions on the phenyl ring. 
Analogues in which the phenyl ring was replaced with a heterocycle or cyclohexyl 
group were also synthesised. 
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7. Biological Evaluation of Compounds  
 
7.1. Introduction 
Byrne and co-workers previously showed that the oligomeric mixture c48/80 was 
capable of dose-dependently activating or inhibiting Akt phosphorylation in NIH 3T3 
fibroblasts.95 Further development of this scaffold within the Woscholski and Hailes 
research groups led to the development of E1 (43), which also inhibits PI3-K-Akt-
mTOR signalling through the inhibition of Akt phosphorylation at Thr308 and Ser473 
in several cell lines, inducing cell cycle arrest and death (see Chapter 2).  
 
A series of homo- and hetero-dimeric E1 analogues were synthesised with the aim of 
discovering more potent lead compounds (see Chapter 5). Such compounds might 
provide a basis for the development of probes for target identification via affinity 
chromatography and other useful pharmacological tools for investigating PI3-K-Akt-
mTOR signalling. Evaluations of these analogues indicated that hetero-dimeric 
diarylketones and diarylketones were suitable leads for further development, and a 
ʻsecond generationʼ series of compounds were synthesised (see Chapter 6). Once 
the synthesis of these analogues had been achieved, attention was turned to their 
biological evaluation. 
 
7.2. Biological Evaluation of Hetero-dimeric E1 Analogues 
To enable comparison with the E1 derivatives that had already been tested within the 
Woscholski research group (see Chapter 5), an identical cellular assay to that used 
previously to measure total Akt and phospho-Ser473 levels was employed. 
Measurement of Akt phosphorylation is a convenient marker of PI3-K-Akt-mTOR 
signalling as Akt forms a central node of the pathway, regulating a broad spectrum of 
essential cellular functions through its downstream effectors (Figure 1.3).  
 
Cultured MCF-7 cells were deprived of serum overnight prior to the experiment. The 
cells were treated with a DMSO solution of the E1 derivatives, or E1, (50 μg/ml) for 
60 minutes. Two control samples were left untreated. The cells were then treated 
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with insulin for a further 15 minutes to activate PI3-K-Akt-mTOR signalling, except for 
the negative control sample. Increasing the dose of insulin from 1 μg/ml (as used 
previously) to 2 μg/ml of insulin was required to rescue post-starvation Ser473 Akt 
phosphorylation in the positive control sample. The cells were lysed, the lysate 
separated by SDS-PAGE and the proteins analysed by Western blotting (Figure 7.1). 
In addition, the n-octanol-water partition ratio (CLogP) and topological polar surface 
area (TPSA) values were calculated using CambridgeSoft ChemBioDraw Ultra 
software. These values relate to the hydrophilicity of the compounds and provide a 
measure of how ʻdrug likeʼ they are. A CLogP value of less than five, and TPSA of 
less than 140 Å2 are generally considered to be necessary for acceptable 
bioavailability. Experimental results suggest that compounds with a TPSA of less 
than 60 Å2 are typically more than 90% absorbed.203  
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Figure 7.1. a) Western blot analysis indicating the ability of E1 (lane 3) and hetero-
dimeric E1 analogues 122, 123, 140, 147 and 153 (lanes 4-8) to inhibit phospho-
Ser473 Akt in serum-deprived MCF-7 cells treated with 50 μg/ml of compound for 60 
minutes, followed by 2 μg/ml insulin for 15 minutes. Untreated starved cells (-, first 
lane) and untreated cells treated with 2 μg/ml insulin (+, second lane) are shown for 
comparison; b) structures of the hetero-dimeric E1 analogues with topological polar 
surface area (TPSA) and calculated n-octanol-water partition ratio (CLogP) values 
(calculated using CambridgeSoft ChemBioDraw Ultra software). Consistent results 
were observed upon repeating the experiment with an alternative sample of MCF-7 
cells, but the activation of phospho-Ser473 Akt induced by 140 was not reproducible. 
 
As anticipated, E1 inhibited Akt Ser473 phosphorylation, as observed by the reduced 
band density compared to the positive control sample (untreated insulin stimulated 
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cells). The level of phospho-Ser473 Akt observed upon treatment with 50 μg/ml E1 
for 60 minutes was similar to that of the negative control sample (untreated starved 
cells). Conjugates 122 and 123 were synthesised by Dr Mark Smith in the Hailes 
research group as probes for target determination by affinity chromatography (see 
Chapter 5), but were unable to inhibit Akt Ser473 phosphorylation in the cellular 
assay. This result suggested that extensive derivatisation of E1 at the para-position 
of one of the aromatic units caused a significant loss of biological activity. 
Accordingly, the development of a more potent analogue of E1 might be a prudent 
strategy before further efforts to identify the target(s) of E1 using affinity 
chromatography are made, in order to compensate for the loss of activity 
encountered upon addition of the linker group. On the other hand, the TPSA values 
for conjugates 122 and 123 are higher than those for E1 and the other analogues 
showing inhibitory activity in this assay, therefore the observed lack of biological 
activity may be due to the lack of cell permeability of these conjugates. Affinity 
chromatography experiments involve the use of cell lysate, so this cellular assay 
might not be a useful predictor of the viability of these conjugates for affinity 
chromatography studies. 
 
The alkyne 147 and ether 153 both induced inhibition of Akt Ser473 phosphorylation 
in comparison to the untreated insulin stimulated cells. Alkyne 147 was a weaker 
inhibitor than E1; however, treatment with ether 153 caused complete abolition of 
phosphorylation. Ether 153 has lower CLogP and TPSA values than E1, so this 
apparent increase in potency may be due to improved membrane permeability. 
Interestingly, treatment with biaryl 140 appeared to have an activating affect on Akt, 
as a more intense band was observed than for the positive control sample, although 
this observation was not reproduced upon repeating the experiment.  
 
In addition to the determination of Akt Ser473 phosphorylation, the measurement of 
total Akt levels is necessary to determine whether the compounds are specifically 
inhibiting Akt activation, or whether they are acting non-specifically as cytotoxic 
agents. Quantification of the ratio of total Akt and phospho-Ser473 Akt would then 
allow comparison between the compounds. Numerous attempts were made to 
measure total Akt by Western blotting, yet in all cases no signals were observed, 
despite obtaining an alternative batch of the relevant antibody. Similarly, the 
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attempted determination of α–tubulin levels – a structural component of microtubules 
that is frequently used as a control to ensure equal loading of samples – was 
unsuccessful. Given the successful determination of phospho-Ser473 Akt by Western 
blotting from the same lysate samples, it is probable that this was due to degradation 
of the primary antibodies. 
 
In this exploratory screening experiment, relatively high doses of the compounds 
were used (50 μg/ml). E1 has been shown to inhibit Ser473 Akt phosphorylation at 
doses of above 10 μg/ml in MCF-7 cells,116 therefore further dose-response studies 
are required in order to determine whether ether 153 is a more effective inhibitor than 
E1. 
 
7.3. Preliminary Biological Evaluation of Second Generation E1 Analogues 
The ʻsecond generationʼ series of hetero-dimeric E1 analogues based on 
diarylketone, diarylmethane and biaryl scaffolds described in Chapter 7 were similarly 
evaluated for their ability to modulate phospho-Ser473 Akt levels in MCF-7 cells 
(Figure 7.2).c 
                                                
c The precursor aryl bromide 192 was also evaluated, as biaryls 193, 194 and 195 were 
isolated as an inseparable mixture of the biaryl and aryl bromide 192. 
147 
a) 
 
 
b) 
O
O
Cl Cl
O
O  
E1 (43) 
TPSA: 52.6 Å2 
CLogP: 5.21 
Cl
O
O
O
Cl
 
184 
TPSA: 43.4 Å2 
CLogP: 4.33 
O Cl
O
Cl
O
 
183 
TPSA: 43.4 Å2 
CLogP: 4.07 
O
O
Cl
O
OMe
 
186 
TPSA: 52.6 Å2 
CLogP: 3.58 
O OMe
O
Cl
O
 
185 
TPSA: 52.6 Å2 
CLogP: 3.58 
O
O
Cl
O
OMe
 
187 
TPSA: 52.6 Å2 
CLogP: 3.58 
OO
O
Cl
 
189 
TPSA: 43.4 Å2 
CLogP: 4.74 
OO
O
O
Cl
 
190 
TPSA: 52.6 Å2 
CLogP: 2.75 
OO
OMe
OMe
OMe
O
Cl
 
188 
TPSA: 71.1 Å2 
CLogP: 2.78 
OO
O
Cl
 
191 
TPSA: 43.4 Å2 
CLogP: 4.00 
O
Cl
O
Cl
 
177 
TPSA: 43.4 Å2 
CLogP: 4.33 
O Cl
O
Cl
 
176 
TPSA: 43.4 Å2 
CLogP: 4.07 
148 
O
CF3
O
Cl
 
178 
TPSA: 43.4 Å2 
CLogP: 4.57 
O
O
Cl
 
179 
TPSA: 26.3 Å2 
CLogP: 5.47 
O
O
O
Cl
 
180 
TPSA: 35.3 Å2 
CLogP: 3.48 
O
OMe
OMe
OMe
O
Cl
 
181 
TPSA: 54.0 Å2 
CLogP: 3.60 
Br
O
O
Cl
 
192 
TPSA: 26.3 Å2 
CLogP: 3.01 
O
O
Cl
Cl
 
194 
TPSA: 26.3 Å2 
CLogP: 4.30 
O
O
Cl
Cl
 
193 
TPSA: 26.3 Å2 
CLogP: 4.05 
O
O
Cl
CF3
 
195 
TPSA: 26.3 Å2 
CLogP: 4.49 
O
O
Cl
OMe
 
196 
TPSA: 35.3 Å2 
CLogP: 2.95 
O
O
Cl
OMe
 
197 
TPSA: 35.3 Å2 
CLogP: 3.51 
O
O
Cl
OMe
 
198 
TPSA: 35.3 Å2 
CLogP: 3.51 
 
 
Figure 7.2. a) Western blot analysis indicating the ability of E1 (third lane) and 
several second generation hetero-dimeric E1 analogues to inhibit phospho-Ser473 
Akt in serum-deprived MCF-7 cells treated with 50 μg/ml of compound for 60 
minutes, followed by 2 μg/ml insulin for 15 minutes. Untreated starved cells (-, first 
lane) and untreated cells treated with 2 μg/ml insulin (+, second lane) are shown for 
comparison; b) Structures of second generation hetero-dimeric E1 analogues based 
on diarylmethane, diarylketone and biaryl scaffolds with topological polar surface 
area (TPSA) and calculated n-octanol-water partition ratio (CLogP) values (calculated 
using CambridgeSoft ChemBioDraw Ultra software). 
 
As before, attempts to measures total Akt levels were unsuccessful. Furthermore, 
validation of this experiment by further repetitions would be required before selecting 
analogues for further development. These preliminary results indicated that several of 
the second generation analogues were capable of suppressing phospho-Ser473 Akt. 
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Diarylketones containing ortho- (183) and meta-chloro substituents (184) on the 
benzylic ring were inhibitory, as were those incorporating para-methoxy (187) and 
2,3,4-methoxy (188) groups. The latter was surprising in view of the lack of inhibition 
exhibited by the ortho- (185) and meta-methoxy (186) substituted analogues. 
Interestingly, the naphthoyl (189), furanyl (190) and the diarylketone derived 
cyclohexyl (191) analogues also acted as phospho-Ser473 Akt inhibitors, indicating 
that this series offers the potential to make substantial deviations from the E1 
scaffold while preserving biological activity.  
 
In contrast, the only diarylmethane analogues that showed similar inhibitory active to 
E1 at 50 μg/ml were those incorporating ortho- (176), meta- (177) or para-halo (178) 
substituents. Those analogues containing methoxy groups (181), napthyl (179) or 
furanyl (180) rings were inactive. The napthyl compound 179 has a higher CLogP 
value than the other analogues and the low inhibitory activity in the cellular assay 
may be related to its hydrophobicity. The restricted rotation of diarylketones 
compared to diarylmethanes may explain why more of the analogues containing a 
ketone linker were inhibitory to phospho-Ser473 Akt than the diarylmethane 
compounds,204 as they may adopt an optimal conformation for interaction with the 
compoundʼs target(s). Biologically active diarylketone analogues of E1 might provide 
the opportunity to develop probes for target identification through a photoaffinity 
labelling.47 
 
Evaluation of the biaryl series of E1 analogues revealed striking variations in 
biological activity. Incorporation of para-trifluoromethyl (195) or para-methoxy (198) 
groups led to inhibition of phospho-Ser473 Akt, as did the addition of a meta-chloro 
substituent (194). Conversely, the compounds containing ortho-chloro (193), ortho-
methoxy (196) and meta-methoxy (197) substituents induced increased 
phosphorylation of Akt at Ser473 with respect to the positive control sample. Similar 
results were previously obtained for biaryl 140 (Figure 7.1a). This apparent activation 
of Akt may be a result of the compounds possessing a concentration dependent 
activity profile similar to that exhibited by c48/80.95 Further dose response studies are 
required to determine whether these compounds inhibit Akt phosphorylation at 
alternatives concentrations, potentially providing valuable information on the 
mechanism of action. 
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7.4. Conclusions and Future Perspectives 
The biological evaluation of a series of hetero-dimeric analogues of E1 identified 
several compounds capable of modulating PI3-K-Akt-mTOR signalling in MCF-7 
cells. The ether 153 completely abolished Ser473 Akt phosphorylation at a dose of 
50 μg/ml and merits further investigation through dose-response studies. The 
incorporation of an oxygen atom into the linker group of ether 153 improved the 
hydrophilicity in comparison to E1 and the hetero-dimeric diarylmethane 139. This 
may contribute to the observed inhibitory activity of ether 153, which represents a 
promising lead for further development as a pharmacological probe.  
 
Preliminary screening of a series of second generation hetero-dimeric E1 analogues 
identified several compounds based around diarylketone, diarylmethane and biaryl 
scaffolds that were capable of inhibiting Ser473 Akt phosphosphorylation at 50 μg/ml. 
Further evaluation of these hetero-dimeric analogues to determine whether they 
show improved potency over E1 would be of interest. Intriguingly, biaryls 193, 196 
and 197 appeared to induce activation of Akt at this concentration, as an increase in 
Ser473 Akt phosphorylation was observed; however, repetition of this experiment is 
necessary to ensure these observations were not artifacts. Additionally, the 
determination of total Akt or α-tubulin levels is necessary before selection of these 
analogues to ensure that the compounds are not unacceptably cytotoxic.  
 
At present the mechanism of action and target(s) of E1 and its related analogues are 
unknown. Para-(2-haloethyl) compounds are known to undergo elimination under 
basic conditions to form activated spirocyclic intermediates (see Chapter 3), 
suggesting that these compounds could result in irreversible inhibition of proteins 
following esterase mediated cleavage in the cellular environment. However, studies 
within the Woscholski research group have previously indicated that cells treated with 
E1 recover rapidly upon washing out of the compound, suggesting that reversible 
inhibition is occurring.  Although previous attempts to isolate the target(s) of E1 using 
a biotin-linked conjugate proved unsuccessful, the identification of a more potent 
analogue might allow a conjugate with the necessary biological activity to be 
synthesised. Alternatively, diarylketone analogues could be suitable for photoaffinity 
labelling approaches. The identification of the target(s) of these compounds might 
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provide new insights into the mechanism of PI3-K-Akt-mTOR signalling, as well as 
aiding the rational design of further generations of analogues. 
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8. Experimental 
 
8.2. Chemical Synthesis 
8.2.1. General Remarks 
All commercially available starting materials and reagents were used as supplied 
unless otherwise stated. The concentrations of Grignard and alkyl lithium reagents 
were determined using the methods of Love and Jones205 and Kofron and 
Backlawski206 respectively, prior to use. All water or oxygen sensitive reactions were 
conducted under an atmosphere of argon, using oven or flame-dried glassware. 
Solvents used in palladium catalysed cross-coupling reactions were degassed by 
purging with argon under sonication for 15 minutes. 
 
Dichloromethane, THF, acetonitrile, chloroform and toluene were purified by passing 
through activated alumina columns using an Anhydrous Engineering solvent 
purification system.207 Water refers to deionised water, and brine to saturated sodium 
chloride solution. Solvents were removed under vacuum using a Büchi rotary 
evaporator connected to a Büchi diaphragm pump, or a high vacuum pump where 
necessary to remove solvents with a high boiling point. Reactions requiring 
microwave heating were carried out using a CEM Discover microwave system. 
 
Reaction progress was followed by thin-layer chromatography (TLC) using 
Macherey-Nagel TLC plates pre-coated with silica gel. Visualisation of plates was 
performed using an ultraviolet lamp, and/or staining with phosphomolybdic acid (5 g 
phosphomolybdic acid, 100 ml ethanol, 5 ml concentrated HCl) or potassium 
permanganate (1 g KMnO4, 2 g Na2CO3, 200 ml H2O). Flash column chromatography 
was carried out using VWR silica gel (33-70 μm particles), Zeochem silica gel (40-63 
μm particles), and Merck silica gel (40-60 μm particles) using compressed air. 
 
1H and 13C NMR spectra were recorded on a Bruker Avance AMX-300, a Bruker 
Avance 500, a Bruker Avance III or a Bruker DRX 400 spectrometer. Chemical shift 
values are quoted in parts per million (ppm) relative to residual solvent signals 
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calibrated as: CDCl3: δH CHCl3 = 7.26 ppm and (CD3)2CO: δH (CH3)2CO = 2.17 
ppm.208 Values of coupling constants (J) are given in values of Hz. Multiplicities are 
reported as: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, dd = 
doublet of doublets, m = multiplet or overlap of non-equivalent resonances. NMR 
spectra were recorded at 298 K, unless otherwise stated. 
 
Infrared spectra were recorded neat on a Shamadazu FTIR-8700, a PerkinElmer 
Spectrum 100 or a BrukerTensor 27 infrared spectrometer. Melting points were 
determined on a Gallenkamp melting point apparatus and are uncorrected. 
Electrospray (ES) mass spectra (MS) were recorded using a Waters Acquity SQD 
Liquid Chromatography/Mass Spectrometry (LC/MS) system. Electron Ionisation (EI), 
Chemical Ionisation (CI), and Fast Atom Bombardment (FAB) high-resolution mass 
spectra (HRMS) were obtained using a Thermo Finnigan MAT 900 XP mass 
spectrometer at the Department of Chemistry, University College London; a Thermo 
Electron LTQ Orbitrap mass spectrometer at the Fakultät Chemie, Technische 
Universität Dortmund or a Thermofisher LTQ Orbitrap XL mass spectrometer at the 
EPSRC National Mass Spectrometry Service Centre, Swansea. Ion mass/charge 
ratios (m/z) ratios are reported as values in atomic mass units. HRMS values for 
compounds containing chlorine refer to the 35Cl isotope. 
 
Analytical reverse phase HPLC was conducted using a Varian ProStar system 
(Supelco Discovery BIO Wide Pore C18-10 column); detection: 254 nm, flow rate: 0.7 
ml/min. The following method was used: (solvent A: water with 0.1 % TFA; solvent B: 
acetonitrile): 0 min: 10% B, 30 min: 90% B, 5 min constant. Semi-preparative reverse 
phase HPLC was conducted using a Varian ProStar system (Supelco Discovery BIO 
Wide Pore C18 column), detection: 210 and 254 nm, flow rate: 4.0 ml/min. The 
following method was used: (solvent A: water with 0.1% TFA; solvent B: acetonitrile): 
0 min: 10% B, 30 min: 90% B, 5 min constant; or using a Agilent Technologies 1200 
Series system (Merck Chromolith column), detection: 210 and 254 nm, flow rate: 4.0 
ml/min. The following method was used: (solvent A: water with 0.1% TFA; solvent B: 
methanol): 0 min: 10% B, 15 min: 100% B, 5 min constant. 
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8.2.2. Individual Procedures 
2-(5-(2-Chloroethyl)-2-hydroxybenzyl)-4-(2-chloroethyl)phenol118 41 
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Paraformaldehyde (1.18 g, 39.36 mmol) was added to a stirring suspension of 4-(2-
chloroethyl)phenol 42 (5.14 g, 32.81 mmol) in sulfuric acid (100 ml, 25% v/v aqueous 
solution) and the reaction mixture was stirred at 70 °C for two hours. The suspension 
was cooled to room temperature, and the solid residue collected by filtration. The 
crude product was purified by flash chromatography (gradient elution: 3:1 to 1:1 
hexane:ethyl acetate) to give the known diphenol118 42 as white plates (3.11 g, 58%). 
M.p. 165-167 °C (hexane-ethyl acetate); RF 0.15 (4:1 hexane-ethyl acetate); νmax/cm-1 
3258, 2928, 1501, 1431, 1258, 1236, 1111; δH (300 MHz; (CD3)2CO) 8.48 (2H, s, 
OH), 7.10 (2H, d, J 2.0, 6-ArH and 6ʼ-ArH), 6.95 (2H, d, J 8.1, 4-ArH and 4ʼ-ArH), 
6.79 (2H, d, J 8.1, 3-ArH and 3ʼ-ArH), 3.91 (2H, s, ArCH2Ar), 3.66 (4H, t J 7.5, 
CH2Cl), 2.89 (4H, t J 7.5, CH2Ar); δC (75 MHz; (CD3)2CO) 154.2 (1-ArC), 132.0, 
130.5, 128.5, 128.1, 116.1, 46.1 and 39.1; m/z (CI) found [M+H]+ 325.0753; 
C17H18Cl2O2 requires [M+H]+ 325.0762. 
 
4-(2-Chloroethyl)phenol209 42 
 
OH
Cl
1
2
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4
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6
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Method A 
A solution of thionyl chloride (3.70 ml, 51.56 mmol) in toluene (20 ml) was added via 
cannula to a stirring solution of 4-(2-hydroxyethyl)phenol (7.00 g, 50.66 mmol) and 
triethylamine (7.05 ml, 50.58 mmol) in toluene (40 ml) at 0 °C. The suspension was 
warmed to room temperature and stirred for 17 hours. Water (40 ml) was added 
cautiously, and the organic and aqueous layers were separated. The aqueous layer 
was extracted with ethyl acetate (3 × 60 ml), and the combined organic fractions were 
dried (MgSO4) and concentrated under vacuum to give the crude product, which was 
purified by passing through a short plug of silica, eluting with chloroform, to give the 
known phenol209 42 as an orange oil (7.14 g, 90%).  
Method B 
Boron tribromide-dimethyl sulfide complex (1.25 g, 4.00 mmol) was added to a 
stirring solution of 4-(2-chloroethyl)-methoxybenzene 47 (171 mg, 1.00 mmol) in 1,2-
dichloroethane (25 ml). The solution was heated at 85 °C for 17 hours, at which point 
a further portion of boron tribromide-dimethyl sulfide complex (1.25 g, 4.00 mmol) 
was added. The solution was stirred for a further 5 hours at 85 °C and cooled to room 
temperature. Water (25 ml) was added, and the aqueous and organic layers were 
separated. The aqueous layer was extracted with dichloromethane (3 × 25 ml), and 
the combined organic fractions were dried (MgSO4) and concentrated under vacuum 
to give the crude product, which was purified by flash chromatography (gradient 
elution: hexane-ethyl acetate 9:1 to 4:1) to give the known phenol209 42 as a pale 
orange oil (109 mg, 69%). RF 0.19 (4:1 hexane-ethyl acetate); νmax/cm-1 3333, 1612, 
1598; δH (300 MHz; CDCl3) 7.09 (2H, d, J 8.4, 5-ArH and 3-ArH), 6.79 (2H, d, J 8.4, 
6-ArH and 2-ArH), 5.03 (1H, s, OH), 3.67 (2H, t, J 7.4, CH2Cl), 3.00 (2H, t, J 7.4, 
CH2Ar); δC (75 MHz; CDCl3) 154.4 (1-ArC), 130.4, 130.1, 115.5, 45.3 and 38.3; m/z 
(CI) found [M+H]+ 157.0428; C8H9ClO requires [M+H]+ 157.0420. 
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1-(2-Chloroethyl)-4-methoxybenzene118 47 
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Trimethylsillyldiazomethane (2.0 M solution in diethyl ether, 2.57 ml, 5.14 mmol) was 
added to a stirring solution of 4-(2-chloroethyl)phenol 42 (153 mg, 0.98 mmol) and 
diisopropylethylamine (0.34 ml, 1.97 mmol) in a 9:1 mixture of acetonitrile:methanol 
(5 ml). The solution was stirred at room temperature for 21 hours. Saturated aqueous 
sodium hydrogen carbonate solution (5 ml) was added, and the solution stirred 
vigorously for 10 minutes. The solution was extracted with diethyl ether (3 × 20 ml) 
and the combined organics dried (MgSO4) and concentrated under vacuum to give 
the known ether118 47 as a pale yellow oil (173 mg, 96%). RF 0.35 (9:1 hexane-ethyl 
acetate); νmax/cm-1 2956, 2836, 1611, 1512; δH (300 MHz; CDCl3) 7.16 (2H, d, J 8.6, 
5-ArH and 3-ArH), 6.88 (2H, d, J 8.6, 6-ArH and 2-ArH), 3.80 (3H, s, ArOCH3), 3.69 
(2H, t, J 7.4, CH2Cl), 3.04 (2H, t, J 7.4, CH2Ar); δC (75 MHz; CDCl3) 158.6 (4-ArC), 
130.2, 129.8, 114.0, 55.3 (CH3O), 45.3 and 38.4; m/z (EI) 170 [M]+ (100%). 
 
1-(5-(2-Chloroethyl)-2-hydroxyphenyl)ethanone118 49 
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Acetyl chloride (5.0 ml, 70.32 mmol) was added to a stirring solution of aluminium 
chloride (9.70 g, 72.75 mmol) and 1-(2-chloroethyl)-4-methoxybenzene 47 (10.0 ml, 
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66.22 mmol) in dichloromethane (125 ml). The solution was heated to 55 °C and 
stirred for 16 hours, then cooled to room temperature. Water (125 ml) was added, 
and the aqueous layer extracted with dichloromethane (3 × 125 ml). The combined 
organic fractions were dried (Na2SO4) and concentrated under vacuum to give the 
known phenol118 49 as a pale yellow oil (12.84 g, 99%). RF 0.28 (9:1 hexane-ethyl 
acetate); νmax/cm-1 2963, 1636, 1209, 1150; δH (300 MHz; CDCl3) 7.84 (1H, s, 6-ArH), 
7.34 (1H, d, J 8.4, 4-ArH), 6.93 (1H, d, J 8.4, 3-ArH), 3.71 (2H, t, J 7.1, CH2Cl), 3.03 
(2H, t, J 7.1 CH2Ar), 2.64 (1H, s, COCH3); δC (75 MHz; CDCl3) 204.3 (C=O), 161.4 (2-
ArC), 137.0, 130.8, 128.5, 119.5, 118.7, 45.0, 38.1 and 26.7 (CH3CO); m/z (CI) found 
[M+H]+ 199.0526; C10H11ClO2 requires [M+H]+ 199.0519. 
 
Methyl-5-(2-chloroethyl)-2-methoxybenzene 50 
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13% Aqueous sodium hypochlorite solution (37 ml, 77.53 mmol) was added dropwise 
to a stirring solution of 1-(5-(2-chloroethyl)-2-methoxyphenyl)ethanone 62 (1.14 g, 
5.36 mmol) in methanol (112 ml) at 0 °C. This reaction only proceeded successfully 
when 13% aqueous sodium hypochloride solution from Acros Organics was used. 
The solution was warmed to room temperature, and stirred for 5.5 hours, aqueous 
sodium bisulfite solution (1M, 125 ml) was added, and the solution stirred for a further 
15 minutes. The solution was extracted with dichloromethane (3 × 125 ml) and the 
combined organics dried (MgSO4) and concentrated under vacuum to give the crude 
product, which was purified by flash chromatography, eluting with 4:1 hexane-ethyl 
acetate, to give the ester 50 as a pale yellow oil (725 mg, 59%). RF 0.17 (4:1 hexane-
ethyl acetate); νmax/cm-1 2951, 2838, 1727, 1614, 1583, 1500; δH (300 MHz; CDCl3) 
7.64 (1H, s, 6-ArH), 7.32 (1H, d, J 8.5, 4-ArH), 6.93 (1H, d, J 8.5, 3-ArH), 3.88 (6H, s, 
ArOCH3 and COCH3), 3.65 (2H, t, J 7.3, CH2Cl), 3.04 (2H, t, J 7.3, CH2Ar); δC (75 
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MHz; CDCl3) 166.6 (C=O), 158.1 (2-ArC), 133.9, 131.9, 129.8, 120.0, 112.3, 56.1. 
(CH3O), 52.1, 44.9 and 38.0; m/z (ES) found [M+Na]+ 251.0462; C11H13ClO3 requires 
[M+Na]+ 251.0451.  
Safety Note: this reaction should be performed behind a blast shield with the 
exclusion of light, due to the potential formation of explosive methyl hypochlorite. 
 
(5-(2-Chloroethyl)-2-methoxyphenyl)methanol 51 
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Diisobutylaluminium hydride (1.0M solution in hexane, 2.20 ml, 2.20 mmol) was 
added dropwise to a stirring solution of methyl-5-(2-chloroethyl)-2-methoxybenzene 
50 (229 mg, 1.00 mmol) in toluene (30 ml) at -78 °C. After 15 minutes the reaction 
was placed in an ice bath and warmed to 0 °C. After 2 hours a large excess of 
sodium sulfate decahydrate was cautiously added. The suspension was warmed to 
room temperature and stirred vigorously for 30 minutes. The resulting white 
suspension was filtered, and the salts washed with copious amounts of diethyl ether. 
The filtrate was concentrated under vacuum to give the crude product, which was 
purified by flash chromatography, eluting with 7:3 hexane-ethyl acetate, to give the 
alcohol 51 as a colourless oil (178 mg, 88%). RF 0.27 (7:3 hexane-ethyl acetate); 
νmax/cm-1 3357, 2953, 2837, 1612, 1500, 893, 811; δH (300 MHz; CDCl3) 7.14-7.09 
(2H, m, ArH), 6.82 (1H, d, J 8.1, 3-ArH), 4.65 (2H, s, ArCH2OH), 3.82 (3H, m, 
ArOCH3), 3.66 (2H, t, J 7.4, CH2Cl), 3.01 (2H, t, J 7.4, CH2Ar), 2.69 (1H, s, OH); δC 
(75 MHz; CDCl3) 156.3 (2-ArC), 130.2, 129.3, 129.0, 128.5, 110.3, 61.6, 55.4 
(CH3OAr), 45.3 and 38.4; m/z (ES) found [M]+ 200.0602; C10H13ClO2 requires [M]+ 
200.0599. 
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4-(2-Chloroethyl)phenyldiethylcarbamate 53 
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N,N,-Diethyl carbamoyl chloride (0.52 ml, 4.14 mmol) was added to a stirring solution 
of 4-(2-chloroethyl)phenol 42 (540 mg, 3.45 mmol) and potassium carbonate (572 
mg, 4.14 mmol) in acetonitrile (10 ml). The suspension was stirred at 90 °C for 20 
hours and cooled to room temperature. Water (20 ml) was added, and the solution 
diluted with dichloromethane (20 ml). The organic and aqueous layers were 
separated, and the aqueous layer extracted with dichloromethane (3 × 20 ml). The 
combined organic fractions were dried (MgSO4) and concentrated under vacuum to 
give the crude product, which was purified by flash chromatography, eluting with 
chloroform, to give the carbamate 53 as a yellow oil (621 mg, 70%). RF 0.27 
(chloroform); νmax/cm-1 2974, 2935, 1711; δH (300 MHz; CDCl3) 7.20 (2H, d, J 8.5, 6-
ArH and 3-ArH), 7.07 (2H, d, J 8.5, 5-ArH and 2-ArH), 3.68 (2H, t, J 7.4, CH2Cl), 3.40 
(4H, q, J 6.7, N(CH2CH3)2), 3.05 (2H, t, J 7.4, CH2Ar), 1.26-1.17 (6H, m, 
N(CH2CH3)2); δC (75 MHz; CDCl3) 154.2 (C=O), 150.5 (2-ArC), 134.8, 129.6, 121.9, 
44.9, 42.2, 41.9, 38.6, 14.2 and 13.4; m/z (CI) found [M+H]+ 256.1098; C11H13ClNO2 
requires [M+H]+ 256.1104. 
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2-Bromo-4-(2-chloroethyl)-1-methoxybenzene 54 
 
Cl
OMe
Br1
3
4
5
6 2
 
 
Bromine (80 μl, 1.56 mmol) was added to a stirring solution of 1-(2-chloroethyl)-4-
methoxybenzene 47 (250 mg, 1.47 mmol) in 1,4-dioxane (10 ml) at 0 ºC. The solution 
was warmed to room temperature and stirred for 3 days. Saturated sodium hydrogen 
carbonate solution (10 ml) was added, and the solution extracted with ethyl acetate 
(3 × 20 ml). The combined organic fractions were dried (MgSO4) and concentrated 
under vacuum to give the aryl bromide 54 as pale yellow plates (357 mg, 97%). M.p. 
33-34 ºC (ethyl acetate); RF 0.50 (4:1 hexane-ethyl acetate); νmax/cm-1 2974, 2942, 
2843, 1600, 1497; δH (300 MHz; CDCl3) 7.31 (1H, s, 3-ArH), 7.13 (1H, d, J 8.5, 6-
ArH), 6.89 (1H, d, J 8.5, 5-ArH), 3.88 (3H, s, ArOCH3), 3.67 (2H, t, J 7.3 CH2Cl), 2.98 
(2H, t, J 7.3, CH2Ar); δC (75 MHz; CDCl3) 154.9 (1-ArC), 133.6, 131.7, 128.9, 111.9, 
111.6, 56.3 (CH3O), 44.9 and 37.8; m/z (ES) found [M+H]+ 248.9671; C9H10Cl79BrO 
requires [M+H]+ 248.9682. 
 
2-Iodo-4-(2-chloroethyl)-1-methoxybenzene 55 
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Selectfluor® (521 mg, 1.47 mmol) was added to a stirring solution of iodine (373 mg, 
1.46 mmol) and 1-(2-chloroethyl)-4-methoxybenzene 47 (251 mg, 1.47 mmol) in 
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acetonitrile (25 ml). The solution was stirred for 17 hours at room temperature and 
10% v/v aqueous sodium thiosulfate solution (10 ml) was added. The solution was 
extracted with dichloromethane (3 × 35 ml), and the combined organic fractions were 
dried (MgSO4) and concentrated under vacuum to give the crude product, which was 
purified by flash chromatography, eluting with 9:1 hexane-ethyl acetate, to give the 
aryl iodide 55 as an orange oil (232 mg, 53%). RF 0.27 (9:1 hexane-ethyl acetate); 
νmax/cm-1 2969, 2926, 2845, 1593, 1564; δH (300 MHz; CDCl3) 7.64 (1H, s, 3-ArH), 
7.16 (2H, d, J 8.4, 5-ArH), 6.76 (1H, d, J 8.4, 6-ArH), 3.79 (2H, s, ArOCH3), 3.63 (2H, 
t, J 7.2, CH2Cl), 2.96 (2H, t, J 7.2, CH2Ar); δC (75 MHz; CDCl3) 157.1, 139.7, 132.3, 
130.0, 110.9, 86.1, 56.4 (CH3OAr), 45.0 and 37.7; m/z (CI) found [M+H]+ 296.9531; 
C9H10ClIO requires [M+H]+ 296.9543. 
 
5-(2-Chloroethyl)-2-methoxybenzaldehyde 61 
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Activated manganese dioxide (1.48 g, 12.76 mmol) was added to a stirring solution of 
(5-(2-chloroethyl)-2-methoxyphenyl)methanol 51 (128 mg, 0.64 mmol) in diethyl ether 
(10 ml). The solution was stirred at room temperature for 16 hours, filtered through a 
short pad of Celite®, eluting with diethyl ether, and concentrated under vacuum to 
give the aldehyde 61 as a pale yellow oil (115 mg, 91%). RF 0.26 (4:1 hexane-ethyl 
acetate); νmax/cm-1 2948, 2866, 1678, 1610, 1582; δH (300 MHz; CDCl3) 10.45 (1H, s, 
CHO), 7.67 (1H, s, 6-ArH), 7.42 (1H, d, J 8.6, 3-ArH), 6.96 (1H, d, J 8.6, 4-ArH), 3.92 
(3H, s, ArOCH3), 3.69 (2H, t, J 7.1, CH2Cl), 3.33 (2H, t, J 7.1, CH2Ar); δC (75 MHz; 
CDCl3) 189.5 (C=O), 160.9 (2-ArC), 136.5, 130.4, 128.4, 124.7, 111.9, 55.8 
(CH3OAr), 44.9 and 37.8; m/z (CI) found [M+H]+ 199.0521; C10H101ClO2 requires 
[M+H]+ 199.0526. 
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1-(5-(2-Chloroethyl)-2-methoxyphenyl)ethanone 62 
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Methyl iodide (1.30 ml, 20.84 mmol) was added to a stirring solution of 1-(5-(2-
chloroethyl)-2-hydroxyphenyl)ethanone 49 (415 mg, 2.09 mmol) and potassium 
carbonate (1.44 g, 10.45 mmol) in acetone (10 ml) in a pressure tube. Additional 
acetone was added until the tube was filled. The tube was sealed and the solution 
heated at 60 °C for 17 hours. The solution was cooled to room temperature, filtered, 
and concentrated under vacuum. To remove residual amounts of potassium 
carbonate, the resulting residue was dissolved in a small volume of dichloromethane, 
filtered and concentrated under vacuum, to give the ether 62 as a yellow oil (433 mg, 
97%). A small sample was purified by short-path vacuum distillation b.p. 200-210 °C 
(3 mm/Hg) for analytical purposes. RF 0.23 (4:1 hexane-ethyl acetate); νmax/cm-1 
2946, 1670, 1608, 1576, 1496; δH (300 MHz; CDCl3) 7.57 (1H, s, 6-ArH), 7.31 (1H, d, 
J 8.5, 3-ArH), 6.91 (1H, d, J 8.5, 4-ArH), 3.88 (3H, s, ArOCH3), 3.65 (2H, t, J 7.4, 
CH2Cl), 2.99 (2H, t, J 7.4, CH2Ar), 2.61 (3H, s, COCH3); δC (75 MHz; CDCl3) 199.6 
(C=O), 158.0 (2-ArC), 134.2, 130.5, 130.2, 128.1, 111.8, 55.6 (CH3O), 45.0, 37.9 and 
31.9; m/z (CI) found [M+H]+ 213.0689; C11H13ClO2 requires [M+H]+ 213.0682. 
 
4-(2-Chloroethyl)-2-ethynyl-1-methoxybenzene 64 
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Triphenylphosphine (5.28 g, 20.14 mmol) was added to a stirring solution of carbon 
tetrabromide (3.34 g, 10.07 mmol) and 5-(2-chloroethyl)-2-methoxybenzaldehyde 61 
(1.00 g, 5.03 mmol) in dichloromethane (25 ml) at 0 ºC. The solution was stirred for 1 
hour at 0 ºC and warmed to room temperature. The solution was passed through a 
short pad of Celite®, eluting with 9:1 petroleum ether-ethyl acetate, and concentrated 
under vacuum. The residue was dissolved in stirring THF (25 ml) and cooled to -78 
ºC. n-BuLi (8.45 ml, 1.19 M solution in THF, 10.3 mmol) was cautiously added, and 
the solution stirred at -78 ºC for 1 hour. The solution was warmed to room 
temperature and 1M HCl solution (20 ml) added. The solution was extracted with 
ethyl acetate (3 × 50 ml), and the combined organic fractions were dried (MgSO4) 
and concentrated under vacuum to give the crude product, which was purified by 
flash chromatography, eluting with 9:1 petroleum ether-ethyl acetate, to give the 
alkyne 64 as a pale yellow oil (563 mg, 58%). RF 0.59 (1:1 hexane-ethyl acetate); 
νmax/cm-1 3386, 2959, 1605, 1497; δH (500 MHz; CDCl3) 7.32 (1H, d, J 2.3, 3-ArH), 
7.18 (1H, dd, J 2.3, 8.5, 5-ArH), 6.84 (1H, d, J 8.5, 6-ArH), 3.89 (3H, s, ArOCH3), 
3.67 (2H, t, J 7.3, CH2Cl), 3.31 (1H, s, C≡CH), 2.98 (2H, t, J 7.3, ArCH2); δC (75 MHz; 
CDCl3) 159.6 (1-ArC), 134.5, 130.8, 130.2, 111.3, 110.8, 81.3 (ArC≡C), 80.0 (C≡CH), 
56.0 (CH3O), 45.0, 38.0 and 29.8; m/z (CI) found [M+H]+ 195.0576; C11H12OCl 
requires [M+H]+ 195.0577. 
 
2-(Bromomethyl)4-(2-chloroethyl)-1-methoxybenzene 65 
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Triphenylphosphine (200 mg, 0.763 mmol) was added to a stirring solution of carbon 
tetrabromide (253 mg, 0.763 mmol) and (5-(2-chloroethyl)-2-
methoxyphenyl)methanol 51 (102 mg, 0.508 mmol) in dichloromethane (3 ml). The 
solution was heated at 55 °C for two hours, cooled to room temperature and 
concentrated under vacuum to give the crude product, which was purified by flash 
chromatography, eluting with 20:1 hexane-ethyl acetate, to give the bromide 65 as a 
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pale yellow oil (110 mg, 82%). RF 0.24 (20:1 hexane-ethyl acetate); νmax/cm-1 2861, 
1613, 1033; δH (300 MHz; CDCl3) 7.19-7.11 (2H, m, ArH), 6.84 (1H, d, J 8.3, 6-ArH), 
4.55 (2H, s, ArCH2Br), 3.88 (3H, s, ArOCH3), 3.65 (2H, t, J 7.4, CH2Cl), 3.00 (2H, t, J 
7.4, CH2Ar); δC (75 MHz; CDCl3) 156.4 (1-ArC), 131.3, 130.5, 130.3, 126.2, 111.1, 
55.7 (CH3O), 45.1, 38.2 and 28.9 (ArCH2Br); m/z (CI) found [M+H]+ 262.9833; 
C10H1279BrClO requires [M+H]+ 262.9838. 
 
2-(5-(2-Chloroethyl)-2-methoxybenzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
66 
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Tetrakis(triphenylphosphine)palladium(0) (20 mg, 0.02 mmol) was added to a stirring 
solution of 2-(bromomethyl)4-(2-chloroethyl)-1-methoxybenzene 65 (100 mg, 0.38 
mmol), bis(pinacolato)diboron (116 mg, 0.46 mmol) and potassium carbonate (157 
mg, 1.14 mmol) in 1,4 dioxane (3 ml). The solution was heated to 80 °C and stirred 
for 17 hours, cooled to room temperature and diluted with water (10 ml). The solution 
was extracted with ethyl acetate (3 × 15 ml), and the combined organic fractions were 
dried (MgSO4) and concentrated under vacuum to give the crude product, which was 
purified by flash chromatography, eluting with 9:1 hexane-ethyl acetate, to give the 
boronate 66 as a pale yellow oil (33 mg, 28%). RF 0.24 (9:1 hexane-ethyl acetate); 
νmax/cm-1 2977, 2927, 1684, 1611; δH (300 MHz; CDCl3) 6.98-6.95 (2H, m, ArH), 6.74 
(1H, d, J 8.8, 3-ArH), 3.78 (3H, s, ArOCH3), 3.66 (2H, t, J 7.6, CH2Cl), 2.96 (2H, t, J 
7.6, CH2Ar), 2.15 (2H, s, ArCH2BO2), 1.24 (12H, s, C(CH3)2); δC (75 MHz; CDCl3) 
156.2 (2-ArC), 131.1, 129.8, 128.2, 126.5, 109.8, 83.2 (OC(CH3)2), 55.2 (CH3OAr), 
45.3, 38.6 and 24.7; m/z (EI) found [M]+ 310.1502; C16H24BClO3 requires [M]+ 
310.1503. 
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2-(Azidomethyl)-4-(2-chloroethyl)-1-methoxybenzene 68 
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Sodium azide (49 mg, 0.75 mmol) was added to a stirring solution of 2-
(bromomethyl)4-(2-chloroethyl)-1-methoxybenzene 65 (132 mg, 0.50 mmol) in DMF 
(8 ml). The solution was heated at 60 °C for 18 hours and an additional portion of 
sodium azide (277 mg, 4.26 mmol) was added. The solution was heated at 60 °C for 
a further 2 days and cooled to room temperature. The solution was diluted with water 
(10 ml) and extracted with diethyl ether (3 × 20 ml). The combined organic fractions 
were dried (MgSO4) and concentrated under vacuum to give the azide 68 as a yellow 
oil (93 mg, 82%). RF 0.24 (20:1 hexane-ethyl acetate); νmax/cm-1 2933, 2097, 1614, 
1504; δH (500 MHz; CDCl3) 7.16 (1H, d, J 8.3, 5-ArH), 7.11 (1H, s, 3-ArH), 6.87 (1H, 
d, J 8.3, 6-ArH), 4.35 (2H, s, CH2N3), 3.85 (3H, s, ArOCH3), 3.48 (2H, t, CH2Cl), 2.84 
(2H, t, ArCH2); δC (75 MHz; CDCl3) 156.6 (1-ArC), 130.4, 130.1, 130.0, 124.2, 110.8, 
55.6, 52.7, 50.2 and 34.5. 
 
5-(2-Chloroethyl)-2-methoxyphenyl acetate 69 
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meta-Chloroperoxybenzoic acid (2.41 g, 13.98 mmol) was added to a stirring solution 
of 5-(2-chloroethyl)-2-methoxybenzene 62 (1.49 g, 6.99 mmol) in chloroform (70 ml). 
The solution was stirred at 50 ºC for 4 hours, cooled to room temperature, and 
concentrated under vacuum. The residue was dissolved in diethyl ether (120 ml) and 
washed with saturated sodium carbonate solution (120 ml). The organic and aqueous 
layers were separated and the organic layer dried (MgSO4) and concentrated under 
vacuum to give the crude product, which was purified by flash chromatography, 
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eluting with 4:1 hexane-ethyl acetate, to give the acetate 69 as a pale yellow oil (1.08 
g, 68%). RF 0.26 (4:1 hexane-ethyl acetate); νmax/cm-1 1764, 1764, 1673, 1619, 1512; 
δH (500 MHz; CDCl3) 7.05 (1H, dd, J 2.2, 8.4, 6-ArH), 6.95-6.87 (2H, m, 3-ArH and 4-
ArH), 3.82 (3H, s, ArOCH3), 3.67 (2H, t, J 7.4, CH2Cl), 3.00 (2H, t, J 7.4, ArCH2), 2.31 
(3H, s, COCH3); δC (75 MHz; CDCl3) 169.1 (OC=O), 150.1 (2-ArC), 139.7, 134.2, 
130.7, 127.2, 123.3, 112.5, 56.0 (CH3O), 44.9, 38.3 and 20.8 (COCH3); m/z (CI) 
found [M+H]+ 229.0626; C11H13O3Cl requires [M+H]+ 229.0632. 
 
5-(2-Chloroethyl)-2-methoxybenzene-1-sulfonyl chloride 70 
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1-(2-Chloroethyl)-4-methoxybenzene 47 (0.76 ml, 5.03 mmol) was added to a stirring 
solution of chlorosulfonic acid (2.67 ml, 40.24 mmol) and dichloromethane (5 ml) at 0 
ºC. The solution was stirred for 1 hour at 0 ºC and poured cautiously onto crushed ice 
(20 g). The solution was extracted with dichloromethane (3 × 50 ml), and the 
combined organic fractions were dried (MgSO4) and concentrated under vacuum to 
give the chlorosulfonic acid 70 as pale pink plates (1.12 g, 82%). M.p. 49-50 ºC 
(chloroform); RF 0.38 (1:1 hexane-ethyl acetate); νmax/cm-1 2951, 2845, 1608, 1568, 
1497, 1365; δH (500 MHz; CDCl3) 7.80 (1H, s, 6-ArH), 7.56 (1H, d, J 8.6, 4-ArH), 7.09 
(1H, d, J 8.6, 3-ArH), 4.04 (3H, s, ArOCH3), 3.71 (2H, t, J 6.8, CH2Cl), 3.07 (2H, t, J 
6.8, ArCH3); δC (75 MHz; CDCl3) 156.3 (2-ArC), 137.9, 131.7, 130.4, 129.8, 113.5, 
56.7 (CH3OAr), 44.5 and 37.6; m/z (ES) found [M(-Cl)(+O)]- 248.9988; C9H10O3SCl2 
requires [M(-Cl)(+O)]- 248.9984. 
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4-(2-Chloroethyl)-1-methoxy-2-nitrobenzene210 72 
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Methyl iodide (1.30 ml, 20.84 mmol) was added to a stirring solution of 4-hydroxy-3-
nitrophenylethyl chloride 73 (421 mg, 2.09 mmol) and potassium carbonate (1.44 g, 
10.45 mmol) in acetone (10 ml) in a pressure tube. Additional acetone was added 
until the tube was filled. The tube was sealed and the solution heated at 60 °C for 17 
hours. The solution was cooled to room temperature, filtered and concentrated under 
vacuum. To remove residual amounts of potassium carbonate, the resulting residue 
was dissolved in a small amount of dichloromethane, filtered and concentrated under 
vacuum. The crude product was purified by flash chromatography, eluting with 4:1 
hexane-ethyl acetate, to give the known ether210 72 as a pale yellow oil (338 mg, 
75%). RF 0.28 (4:1 hexane-ethyl acetate); νmax/cm-1 2930, 1623, 1574, 1527; δH (300 
MHz; CDCl3) 7.70 (1H, s, 3-ArH), 7.38 (1H, d, J 8.4, 5-ArH), 7.13 (1H, d, J 8.4, 6-
ArH), 3.86 (3H, s, ArOCH3), 3.70 (2H, t, J 6.9, CH2Cl), 3.04 (2H, t, J 6.9, ArCH2); δC 
(150 MHz; CDCl3) 152.0 (1-ArC), 134.8, 130.4, 129.5, 126.0, 113.7, 56.6 (OCH3), 
44.6 and 37.5; m/z (EI) found [M]+ 215.0354; C9H10NO3Cl requires [M]+ 215.0344. 
 
 
4-Hydroxy-3-nitrophenylethyl chloride210 73 
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4-(2-Chloroethyl)phenol 42 (3.13 g, 20.00 mmol) was added to a stirring solution of 
tetrabutylammonium bromide (650 mg, 2.00 mmol), 6 wt% nitric acid (29.5 ml) and 
dichloromethane (50 ml). The solution was stirred at room temperature for 4.5 hours 
and the organic and aqueous layers were separated. The organic layer was washed 
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with water (3 × 50 ml), dried (MgSO4) and concentrated under vacuum to give the 
crude product, which was purified by flash chromatography, eluting with 20:1 hexane-
ethyl acetate, to give the known nitrophenol210 73 as yellow needles (2.72 g, 68%). 
M.p. 44-46 ºC (chloroform); RF 0.24 (10:1 hexane-ethyl acetate); νmax/cm-1 3183, 
3083, 1531, 1488, 1430, 1320; δH (300 MHz; CDCl3) 7.95 (1H, s, 2-ArH), 7.45 (1H, d, 
J 8.6, 6-ArH), 7.10 (1H, d, J 8.6, 5-ArH), 7.10 (1H, d, J 8.6, 5-ArH), 3.71 (2H, t, J 6.9, 
CH2Cl), 3.04 (2H, t, J 6.9, CH2Ar); δC (75 MHz; CDCl3) 154.0 (4-ArC), 138.4, 133.4, 
130.5, 124.8, 120.1, 44.5 and 37.5; m/z (CI) 202 [M]+ (100%). 
 
4-(2-Chloroethyl)-2-nitrophenyl acetate 76 
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4-Hydroxy-3-nitrophenylethyl chloride 72 (333 mg, 1.65 mmol) was added to a 
stirring solution of 4-dimethylaminopyridine (catalytic amount), acetic anhydride (186 
μl, 1.98 mmol) and triethylamine (3 ml). The solution was stirred at room temperature 
for 16 hours and concentrated under vacuum to give the crude product, which was 
purified by flash chromatography, eluting with 4:1 hexane-ethyl acetate, to give the 
acetate 76 as pale yellow plates (103 mg, 26%). M.p. 68-70 ºC (chloroform); RF 0.21 
(4:1 hexane-ethyl acetate); νmax/cm-1 1770, 1615, 1580, 1524; δH (500 MHz; CDCl3) 
7.99 (1H, d, J 2.1, 3-ArH), 7.55 (1H, dd, J 2.2, 8.3, 6-ArH), 7.22 (1H, d, J 8.3, 5-ArH), 
3.77 (2H, t, J 6.9, CH2Cl), 3.16 (2H, t, J 6.9, ArCH2), 2.39 (3H, s, OCH3); δC (75 MHz; 
CDCl3) 168.8 (C=O), 143.0, 141.6, 137.3, 135.3, 126.1, 125.4, 44.1, 37.9 and 20.9 
(COCH3); m/z (CI) found [M+H]+ 244.0367; C10H11O4NCl requires [M+H]+ 244.0377. 
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2-(2-Acetoxy-5-(2-chloroethyl)-3-iodobenzyl)-4-(2-chloroethyl)phenyl acetate 85 
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4-(2-Chloro-ethyl)-2-[5-2(chloro-ethyl)-2-hydroxy-benzyl]-6-iodo-phenol 78 (97 mg, 
0.22 mmol) was added to a stirring solution of 4-dimethylaminopyridine (catalytic 
amount), acetic anhydride (45 μl, 0.48 mmol) and triethylamine (5 ml). The solution 
was stirred at room temperature for 16 hours and partioned between ethyl acetate 
(10 ml) and water (10 ml). The aqueous layer was extracted with ethyl acetate (3 × 
10 ml) and the combined organic fractions were dried (MgSO4) and concentrated 
under vacuum to give the crude product, which was purified by flash 
chromatography, eluting with 4:1 hexane-ethyl acetate, to give the acetate 85 as a 
yellow oil (90 mg, 78%). RF 0.23 (4:1 hexane-ethyl acetate); νmax/cm-1 2961, 2924, 
2853, 1767; δH (300 MHz; CDCl3) 7.56 (1H, s, 4ʼ-ArH), 7.15 (1H, d, J 8.2, 6-ArH), 
7.03 (1H, d, J 8.2, 5-ArH), 6.81 (1H, s, 3-ArH), 6.77 (1H, s, 6ʼ-ArH), 3.76 (2H, s, 
ArCH2Ar), 3.70-3.59 (4H, m, CH2Cl), 3.03-2.89 (4H, m, ArCH2), 2.32-2.27 (3H, m, 
CH3C=O), 2.19-2.10 (3H, m CH3C=O); δC (75 MHz; CDCl3) 169.3 (C=O), 168.2 
(C=O), 148.5, 147.9, 138.0, 137.8, 136.2, 133.5, 131.4, 131.0, 130.8, 128.7, 122.7, 
91.7, 44.8, 44.4, 38.4, 37.9, 31.3, 21.1 (OCH3) and 20.8 (OCH3); m/z (ES) found 
[M+Na]+ 556.9747; C21H21O4Cl2I requires [M+Na]+ 556.9759. 
 
Di-tertbutyl-N-5-hexenyliminodicarboxylate211 86 
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6-Bromohex-1-ene (0.80 ml, 6.00 mmol) was added to a stirring solution of di-tert-
butyliminodicarboxylate (868 mg, 4.00 mmol) and caesium carbonate (2.61 g, 8.00 
mmol) in 2-butanone (20 ml) and heated at reflux (90 ºC) for 16.5 hours. The solution 
was cooled to room temperature and brine (40 ml) added. The organic and aqueous 
layers were separated, and the aqueous layer extracted with diethyl ether (3 × 20 ml). 
The combined organic fractions were dried (MgSO4) and concentrated under vacuum 
to give the known amide211 86 as a yellow oil (1.19 g, quantitative yield). RF 0.35 (4:1 
hexane-ethyl acetate); νmax/cm-1 2980, 2937, 1716, 1630, 1252; δH (300 MHz; CDCl3) 
5.85-5.78 (1H, m, CH2=CHCH2), 5.00-4.90 (2H, m, CH2=CHCH2), 3.53 (2H, t, J 7.4, 
NCH2CH2), 2.04 (2H, q, J 6.7, CH2=CHCH2), 1.58-1.41 (20H, m, OC(CH3)3 and 
CH2=CHCH2CH2); δC (75 MHz; CDCl3) 152.7 (C=O), 138.5 (H2C=CH), 114.6 
(H2C=CH), 82.0, 46.3, 33.4, 32.2, 28.5, 28.1, 26.0 and 25.0; m/z (ES) found 
[2M+Na]+ 621.4072; C16H29NO4 requires [2M+Na]+ 621.4085. 
 
Di-tertbutyl-N-5-phenylhexenyliminodicarboxylate 88 
 
 
 
Palladium acetate (2 mg, 0.01 mmol) was added to a stirring solution of sodium 
carbonate (54 mg, 0.51 mmol), tetrabutylammonium bromide (55 mg, 0.19 mmol), 
iodobenzene (20 μl, 0.18 mmol) and di-tertbutyl-N-5-hexenyliminodicarboxylate 86 
(49 mg, 0.16 mmol) in DMF (2 ml). The solution was heated at 100 °C for 23 hours, 
cooled to room temperature, passed through a short pad of Celite®, eluting with ethyl 
acetate, and concentrated under vacuum to give the crude product, which was 
purified by flash chromatography, eluting with 12:1 hexane-ethyl acetate, to give the 
alkene 88 as a yellow oil (60 mg, 98%). RF 0.25 (12:1 hexane-ethyl acetate); νmax/cm-
1 2980, 2932, 1782, 1736, 1693, 1456; δH (300 MHz; CDCl3) 7.51-7.18 (6H, m, ArH), 
6.40-6.36 (1H, m, ArCH=CH), 6.25-6.15 (1H, m, CH=CHCH2), 3.57 (2H, t, J 7.4 
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NCH2CH2), 1.63-1.57 (2H, m, CH=CHCH2), 1.50-1.41 (20H, m, NCH2CH2CH2 and 
(OC(CH3)3)2), 1.28-1.23 (2H, m, NCH2CH2CH2); δC (75 MHz; CDCl3) 152.8 (C=O), 
137.8, 130.5, 130.1, 128,7, 128.5, 128.3, 127.2, 126.8, 126.6, 126.1, 125.9, 82.1, 
46.3, 32.7, 29.7, 28.6, 28.1 and 26.5; m/z (FAB) found [M+Na]+ 398.2306; C22H33NO4 
requires [M+Na]+ 398.2307. 
 
4-(2-Chloroethyl)-2-iodophenylacetate 89 
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Acetic anhydride (0.22 ml, 2.33 mmol) was added to a stirring solution of 4-(2-
chloroethyl)-2-iodophenol (536 mg, 1.90 mmol) and 4-dimethylaminopyridine 
(catalytic amount) in triethylamine (10 ml). The solution was stirred for 16.5 hours at 
room temperature and concentrated under vacuum. The resulting residue was 
dissolved in ethyl acetate (20 ml) and water (20 ml) added. The organic and aqueous 
layers were separated, and the aqueous layer extracted with ethyl acetate (3 × 20 
ml). The combined organic fractions were dried (MgSO4) and concentrated under 
vacuum to give the acetate 89 as a pale yellow oil (560 mg, 91%). RF 0.38 (4:1 
hexane-ethyl acetate); νmax/cm-1 2960, 1767; δH (300 MHz; CDCl3) 7.68 (1H, s, 3-
ArH), 7.21 (1H, d, J 8.2, 5-ArH), 7.03 (1H, d, J 8.2, 6-ArH), 3.66 (2H, t, J 7.2, CH2Cl), 
2.99 (2H, t, J 7.2, CH2Ar), 2.35 (3H, s, COCH3); δC (75 MHz; CDCl3) 168.7 (C=O), 
150.1 (1-ArC), 139.6, 137.8, 122.9, 121.7, 90.7, 44.5, 37.9 and 21.3 (OCH3); m/z (CI) 
found [M+H]+ 324.9485; C10H10ClIO2 requires [M+H]+ 324.9492. 
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2-(3-Iodo-4-methoxyphenyl)ethanol 94 
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Iodine (295 mg, 1.16 mmol) was added to a stirring suspension of 2-(4-
methoxyphenyl)ethanol (177 mg, 1.16 mmol) and Brij® 35 (28 mg, 0.02 mmol) in 
water (10 ml). After five minutes SelectFluor™ (413 mg, 1.16 mmol) was added, and 
the solution was stirred at room temperature for 21 hours. 10% v/v aqueous sodium 
thiosulfate solution (10 ml) was added, and the solution extracted with 
dichloromethane (3 × 20 ml), dried (MgSO4) and concentrated under vacuum to give 
the crude product, which was purified by flash chromatography (gradient elution: 
hexane-ethyl acetate 7:3 to 6:4) to give the aryl iodide 94 as a yellow oil (181 mg, 
56%). RF 0.19 (7:3 hexane-ethyl acetate); νmax/cm-1 3387, 3008, 2941, 1599, 1493; δH 
(300 MHz; CDCl3) 7.62 (1H, s, 2-ArH), 7.14 (1H, d, J 8.3, 6-ArH), 6.73 (1H, d, J 8.3, 
5-ArH), 3.84-3.81 (3H, m, ArOCH3), 3.74 (2H, t, J 6.5, CH2OH), 2.73 (2H, t, J 6.5, 
CH2Ar), 1.92 (1H, s, OH); δC (75 MHz; CDCl3) 156.8 (4-ArC), 139.8, 132.9, 130.1, 
111.0, 86.1, 63.5, 56.5 and 37.7; m/z (EI) found [M]+ 277.9804; C9H11IO2 requires 
[M]+ 277.9798. 
 
1-((3-Iodo-4-methoxyphenethyloxy)methyl)benzene 95 
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Sodium hydride (60% mineral oil dispersion, 35 mg, 0.88 mmol) was added 
cautiously to a solution of 2-(3-iodo-4-methoxyphenyl)ethanol 94 (176 mg, 0.63 
mmol) in THF (5 ml) at 0 ºC. Tetrabutylammonium iodide (12 mg, 0.03 mmol) was 
added, followed by the dropwise addition of benzyl bromide (75 µl, 0.63 mmol). The 
solution was warmed to room temperature and stirred for 16 hours, cooled to 0 ºC 
and aqueous hydrochloric acid (1M, 5 ml) added. The solution was concentrated 
under vacuum and the resulting residue was dissolved in dichloromethane (10 ml) 
and washed with water (10 ml). The aqueous and organic layers were separated, 
and the aqueous layer extracted with dichloromethane (3 × 10 ml). The combined 
organic fractions were dried (MgSO4) and concentrated under vacuum to give the 
crude product, which was purified by flash chromatography, eluting with 12:1 hexane-
ethyl acetate, to give the ether 95 as a colourless oil (206 mg, 88%). RF 0.28 (12:1 
hexane-ethyl acetate); νmax/cm-1 3018, 2928, 2855, 1520, 1493; δH (300 MHz; CDCl3) 
7.65 (1H, s, 2-ArH), 7.43-7.26 (5H, m, OCH2ArH), 7.17 (1H, d, J 8.3, 6-ArH), 6.74 
(1H, d, J 8.3, 5-ArH), 4.52 (2H, s, OCH2Ph), 3.86 (3H, s, OCH3), 3.64 (2H, t, J 6,9, 
CH2OBn), 2.83 (2H, t, J 6.9, CH2Ar); δC (75 MHz; CDCl3) 156.7 (4-ArC), 139.8, 138.4, 
133.4, 130.1, 128.5, 127.7, 110.8, 85.9, 73.1, 71.1, 56.5, 35.0 and 29.8; m/z (CI) 
found [M]+ 368.0270; C16H17IO2 requires [M]+ 368.0268. 
 
1-((4-Methoxyphenethyloxy)methyl)benzene 96 
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Sodium hydride (60% mineral oil dispersion, 63 mg, 1.58 mmol) was added 
cautiously to a solution of 2-(4-methoxyphenyl)ethanol (200 mg, 1.31 mmol) in 
tetrahydrofuran (10 ml) at 0 ºC. Tetrabutylammonium iodide (20 mg, 0.05 mmol) was 
added, followed by the dropwise addition of benzyl bromide (0.16 ml, 1.35 mmol). 
The solution was allowed to warm to room temperature and stirred for 19 hours, 
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cooled to 0 ºC and aqueous hydrochloric acid (1M, 5 ml) added. The solution was 
concentrated under vacuum and the resulting residue dissolved in dichloromethane 
(20 ml) and washed with water (20 ml). The aqueous and organic layers were 
separated, the aqueous layer extracted with dichloromethane (3 × 20 ml) and the 
combined organics fractions dried (MgSO4) and concentrated under vacuum to give 
the crude product, which was purified by flash chromatography, eluting with 15:1 
hexane-ethyl acetate, to give the ether 86 as a pale yellow oil (258 mg, 81%). RF 0.33 
(20:1 hexane-ethyl acetate); νmax/cm-1 3031, 2934, 2856, 1612, 1584, 1511; δH (300 
MHz; CDCl3) 7.38-7.26 (5H, m, OCH2ArH), 7.17 (2H, d, J 8.5, 2-ArH and 6-ArH), 6.85 
(2H, d, J 8.5, 3-ArH and 5-ArH), 4.47 (2H, s, OCH2Ph), 3.80 (3H, s, OCH3), 3.67 (2H, 
t, J 7.2, CH2OBn), 2.90 (2H, t, J 7.2, OCH2Ar); δC (75 MHz; CDCl3) 158.1 (4-ArC), 
138.5, 131.1, 129.9, 128.4, 127.6, 127.5, 113.8, 73.0, 71.5, 55.3 and 35.5; m/z (CI) 
found [M]+ 242.1312; C16H18O requires [M]+ 242.1301. 
 
1-(Allyloxy)-4-(2-chloroethyl)benzene 99 
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Allyl bromide (1.70 ml, 20.00 mmol) was added to a stirring solution of 4-(2-
chloroethyl)phenol 42 (1.72 g, 10.00 mmol), potassium carbonate (2.80 g, 20.00 
mmol) and caesium carbonate (660 mg, 2.00 mmol) in DMF (50 ml). The solution 
was stirred at 40 °C for 20 hours, cooled to room temperature, and concentrated 
under vacuum. Water (30 ml) and dichloromethane (30 ml) were added to the 
resulting residue, and the organic and aqueous layers were separated. The aqueous 
layer was extracted with dichloromethane (3 × 60 ml), and the combined organic 
fractions were dried (MgSO4) and concentrated under vacuum to give the allyl ether 
99 as a yellow oil (1.94 g, 90%). RF 0.57 (4:1 hexane-ethyl acetate); νmax/cm-1 2957, 
2928, 2864, 1612, 1512, 1456; δH (300 MHz; CDCl3) 7.14 (2H, d, J 8.2, 5-ArH and 3-
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ArH), 6.88 (2H, d, J 8.2, 6-ArH and 2-ArH), 6.13-6.00 (1H, m, CH2CH=CH2), 5.41 
(1H, d, J 5.4, CHtransH=CH), 5.29 (1H, d, J 10.4, CHcisH=CH), 4.54-4.50 (2H, d, J 5.4, 
ArOCH2CH), 3.68 (2H, t, J 7.5, CH2Cl), 3.01 (2H, t, J 7.5, CH2Ar); δC (75 MHz; CDCl3) 
157.6 (1-ArC), 133.3, 130.4, 129.8, 129.7, 127.4, 117.7, 114.8, 68.9, 45.3 and 38.4; 
m/z (CI) found [M+H]+ 197.0725; C11H13ClO requires [M+H]+ 197.0733. 
 
2-Allyl-4-(2-chloroethyl)phenol 100 
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Stirring 1-(allyoxy)-4-(2-chloroethyl)benzene 99 (587 mg, 2.98 mmol) was heated at 
190 °C for 18 hours, then at 250 °C for a further 13 hours. The resulting residue was 
cooled to room temperature and purified by flash chromatography (gradient elution: 
hexane-ethyl acetate 10:1 to 7:3) to give the phenol 100 as a brown oil (34 mg, 6%). 
RF 0.27 (4:1 hexane-ethyl acetate); νmax/cm-1 3427, 2959, 1638, 1508, 1437; δH (300 
MHz; CDCl3) 6.99-6.88 (2H, m, 3-ArH and 5-ArH), 6.76 (1H, d, J 7.8, 6-ArH), 6.08-
5.95 (1H, m, CH2CH=CH2), 5.17 (2H, d, J 13.8, CH2=CH), 4.97 (1H, s, ArOH), 3.67 
(2H, t, J 7.5, CH2Cl), 3.39 (2H, d, J 6.3, ArCH2CH), 2.98 (2H, t, J 7.5, CH2Ar); δC (75 
MHz; CDCl3) 153.0 (1-ArC), 136.3, 130.8, 130.5, 128.1, 125.5, 116.6, 115.9, 45.3, 
38.4 and 35.1; m/z (EI) found [M]+ 196.0643; C11H13ClO requires [M]+ 196.0649. 
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2-(5-(2-Chloroethyl)-2-hydroxy-3-nitrobenzyl)-4-(2-chloroethyl)-6-nitrophenol 
103 
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4-(2-Chloro-ethyl)-2-[5-2(chloro-ethyl)-2-hydroxy-benzyl]-6-iodo-phenol 78 (159 mg, 
0.49 mmol) was added to a stirring solution of 6 wt% nitric acid (0.5 ml) and 
acetonitrile (2 ml). The solution was stirred at room temperature for 3 hours, at which 
point at yellow precipitate had formed. The precipitate was collected by filtration, 
washed with water and dried under vacuum to give the crude product, which was 
purified by flash chromatography, eluting with 9:1 hexane-ethyl acetate, to give the 
di-nitrophenol 103 as pale yellow needles (84 mg, 41%). M.p. 122-124 ºC 
(chloroform); RF 0.21 (9:1 hexane-ethyl acetate); νmax/cm-1 3242, 1740, 1621, 1532; 
δH (300 MHz; CDCl3) 7.88 (2H, s, 4-ArH and 4ʼ-ArH), 7.46 (2H, s, 6-ArH and 6ʼ-ArH), 
4.12 (2H, s, ArCH2Ar), 3.70 (2H, t, J 6.9, CH2Cl), 3.02 (2H, t, J 6.9, ArCH2); δC (75 
MHz; CDCl3) 152.5 (2-ArC), 139.4, 133.5, 130.1, 129.7, 123.4, 44.6, 37.6 and 29.9; 
m/z (CI) found [M+H]+ 415.0467; C17H17O6N2Cl2 requires [M+H]+ 415.0464. 
 
(9-H-Fluoren-9-yl)methyl-6-(5-(2-chloroethyl)-2-hydroxyphenyl)-6-
oxohexylcarbamate 105 
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4-(2-Chloroethyl)phenol 42 (332 mg, 1.95 mmol) in nitrobenzene (10 ml) was added 
to a stirring solution of (9-H-fluoren-9-yl)methyl-5-(chlorocarbonyl) pentylcarbamate 
106 (724 mg, 1.95 mmol) in nitrobenzene (15 ml). The solution was cooled to 0 °C 
and aluminium chloride (910 mg, 6.83 mmol) added in small portions. The solution 
was heated at 60 °C for 16 hours and cooled to room temperature, water (25 ml) was 
added and the solution extracted with diethyl ether (3 × 50 ml). The combined organic 
fractions were dried (MgSO4) and concentrated under vacuum to give the crude 
product, which was purified by flash chromatography (gradient elution: hexane-ethyl 
acetate 7:3 to 6:4) to give the ketone 105 as brown plates (459 mg, 48%). M.p. 110-
112 °C (chloroform); RF 0.39 (6:4 hexane:ethyl acetate); νmax/cm-1 3338, 2935, 2863, 
1701, 1640, 1517; δH (300 MHz; CDCl3) 7.77 (2H, d, J 7.4, ArH), 7.60-7.58 (3H, m, 
ArH), 7.34-7.28 (5H, m, ArH), 6.95 (1H, d, J 8.5, 3-ArH), 4.83 (1H, s, NHCO), 4.41 
(2H, d, J 6.9, (CO)OCH2), 4.22 (1H, t, J 6.9, OCH2CH), 3.68 (2H, t, J 7.1, CH2Cl), 
3.20 (2H, q, J 6.6, NHCH2CH2), 3.04-2.95 (4H, m, CH2Ar and COCH2), 1.80-1.37 (6H, 
m, COCH2CH2, NHCH2CH2 and NHCH2CH2CH2); δC (75 MHz; CDCl3) 206.3 (ArC=O), 
161.5, 156.5, 144.0, 141.3, 136.8, 130.1, 128.4, 127.7, 127.0, 125.0, 120.0, 119.1, 
118.8, 76.6, 66.5 (OCH2), 47.3, 45.1, 40.8, 38.1, 29.9, 26.3 and 23.8; m/z (ES) found 
[M+Na]+ 514.1778; C29H30ClNO4 requires [M+Na]+ 514.1761. 
 
(9-H-Fluoren-9-yl)methyl-5-(chlorocarbonyl)pentylcarbamate 106 
 
 
 
Thionyl chloride (0.46 ml, 6.31 mmol) was added to a stirring solution of (9-H-fluroen-
9-yl)aminohexanoic acid (1.48 g, 4.18 mmol) in dichloromethane (20 ml). The 
solution was heated at 55 °C for 16 hours, cooled to room temperature and 
concentrated under vacuum to give the acyl chloride 106 as white plates (1.46 g, 
94%). M.p. 88-90 °C (chloroform); RF 0.24 (1:1 hexane-ethyl acetate); νmax/cm-1 3344, 
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2941, 2866, 1685, 1526; δH (300 MHz; CDCl3) 7.77 (2H, d, J 7.4, ArH), 7.59 (2H, d, J 
7.4, ArH), 7.41-7.26 (4H, m, ArH), 4.82 (1H, s, NHCO), 4.52 (2H, d, J 7.1, 
(CO)OCH2), 4.20 (1H, t, J 7.1, OCH2CH), 3.18 (2H, m, NHCH2CH2), 2.89 (2H, t, J 
7.1, CH2COCl), 1.73-1.69 (2H, m, CH2CH2COCl), 1.51-1.35 (4H, m, 
CH2CH2CH2COCl and NHCH2CH2CH2); δC (75 MHz; CDCl3) 173.7 (C=OCl), 156.5 
(C=ONH), 144.0, 141.4, 127.7, 127.1, 125.0, 120.0, 66.6 (OCH2), 47.3, 47.0, 40.7, 
29.6, 25.5 and 24.7; m/z (ES) found [M+Na]+ 376.1535; C21H22NO4 requires [M+Na]+ 
376.1525. 
 
4-(2-Chloroethyl)-2-(1-hydroxyethyl)phenol 108 
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Lithium aluminium hydride (78 mg, 2.06 mmol) was added cautiously to a stirring 
solution of aluminium chloride (275 mg, 2.06 mmol) in THF (20 ml). The solution was 
stirred at room temperature for 30 minutes, and a solution of 1-(5-(2-chloro-ethyl)-2-
hydroxyphenyl)ethanone 49 (82 mg, 0.41 mmol) in THF (5 ml) was added dropwise. 
The solution was heated at 55 °C for one hour, cooled to 0 °C and water (25 ml) 
added dropwise. The solution was extracted with diethyl ether (3 × 25 ml), and the 
combined organic fractions were dried (MgSO4) and concentrated under vacuum to 
give the diol 108 as brown needles (65 mg, 78%). M.p. 72-74 ºC (chloroform). RF 
0.13 (4:1 hexane-ethyl acetate); νmax/cm-1 3341, 2927, 1614, 1498; δH (300 MHz; 
CDCl3) 7.99 (1H, s, OH), 7.01 (1H, d, J 8.2, 5-ArH), 6.83-6.75 (2H, m, 3-ArH and 6-
ArH), 5.03 (1H, q, J 6.6, ArCH(OH)CH3), 3.65 (2H, t, J 7.4, CH2Cl), 2.95 (2H, t, J 7.4, 
CH2Ar), 1.56 (3H, d, J 6.6, ArCH(OH)CH3); δC (75 MHz; CDCl3) 154.2 (1-ArC), 129.5, 
129.1, 128.6, 126.9, 117.2, 62.8 (CH(OH)CH3), 45.3, 38.4 and 23.5 (CH(OH)CH3). 
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4-(2-Chloroethyl)-2-(hydroxymethyl)phenol 109 
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Method A 
Borane-dimethyl sulfide complex (2.0 M solution in hexane, 1.73 ml, 3.46 mmol) was 
added to a stirring solution of 5-(2-chloroethyl)-2-hydroxybenzaldehyde 159 (319 mg, 
1.73 mmol) in THF (10 ml). The solution was stirred for one hour at room temperature 
and 5% aqueous HCl (5 ml) added dropwise. The solution was stirred vigorously for 5 
minutes and partitioned between water (50 ml) and ethyl acetate (50 ml), the organic 
and aqueous layers were separated and the aqueous layer extracted with ethyl 
acetate (3 × 50 ml). The combined organic fractions were dried (MgSO4) and 
concentrated under vacuum to give the crude product, which was purified by flash 
chromatography, eluting with 3:2 hexane:ethyl acetate, to give the give the diol 109 
as white needles (187 mg, 58%). 
Method B 
Diisobutylaluminium hydride (1.0M solution in hexane, 1.90 ml, 1.90 mmol) was 
added dropwise to a stirring solution of methyl-5-(2-chloroethyl)-2-hydroxybenzoate 
133 (187 mg, 0.87 mmol) in toluene (25 ml) at 0 °C. After 15 minutes the solution 
was warmed to room temperature and was stirred for 24 hours. A large excess of 
sodium sulfate decahydrate was cautiously added and the suspension was stirred 
vigorously for 30 minutes. The resulting white suspension was filtered, and the salts 
washed with copious amounts of diethyl ether. The filtrate was concentrated under 
vacuum to give the crude product, which was purified by flash chromatography, 
eluting with 6:4 hexane-ethyl acetate, to give the diol 109 as pale yellow plates (11 
mg, 7%). M.p. 66-68 ºC (chloroform); RF 0.25 (6:4 hexane-ethyl acetate); νmax/cm-1 
3258, 2872, 2928, 1614; δH (300 MHz; CDCl3) 7.22 (1H, s, OH), 7.05 (1H, d, J 8.2, 5-
ArH), 6.89 (1H, s, 3-ArH), 6.84 (1H, d, J 8.2, 6-ArH), 4.85 (2H, s, ArCH2OH), 3.66 
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(2H, t, J 7.4, CH2Cl), 2.97 (2H, t, J 7.4, CH2Ar), 2.17 (1H, s, OH); δC (75 MHz; CDCl3) 
155.0 (1-ArC), 129.8, 129.7, 128.2, 124.7, 116.7, 64.6 (ArCH2OH), 45.2 and 38.3, 
m/z (ES) found [M-H]- 185.0371; C9H11ClO2 requires [M-H]- 185.0369. 
 
6-Triisopropylsilyloxy-1-hexanol212 113 
 
HO O Si
 
 
Triisopropylsilylchloride (2.23 ml, 10.52 mmol) was added dropwise to a stirring 
solution of 1,6-hexanediol (1.24 g, 10.51 mmol) and N,N-diisopropylethylamine (18.3 
ml, 100.10 mmol) in DMF (60 ml). The solution was stirred at room temperature for 
18 hours and water (200 ml) was added. The solution was extracted with diethyl 
ether (3 × 250 ml) and the combined organic fractions washed with 1M hydrochloric 
acid (2 × 100 ml), saturated aqueous sodium hydrogen carbonate solution (100 ml) 
and saturated brine (100 ml), dried (MgSO4) and concentrated under vacuum to give 
the crude product, which was purified by flash chromatography, eluting with 7:1 
hexane-acetone, to give the known silyl ether212 113 as a colourless oil (1.62 g, 
56%). RF 0.26 (7:1 hexane-acetone); νmax/cm-1 3333, 2938, 2865; δH (300 MHz; 
CDCl3) 3.69-3.62 (4H, m, CH2CH2OSi and CH2CH2OH), 1.60-1.35 (11H, m, 
OSi(CH(CH3)2)3, HOCH2CH2, HOCH2CH2CH2, SiOCH2CH2 and SiOCH2CH2CH2), 
1.08-1.03 (18H, m, OSi(CH(CH3)2)3), 0.88 (1H, s, OH); δC (75 MHz; CDCl3) 63.4, 
63.0, 33.0, 32.8, 25.7, 25.6, 18.0, 17.7 and 12.1; m/z (FAB) found [M+Na]+ 297.2229; 
C15H34O2Si requires [M+Na]+ 297.2226. 
6-Bromohexan-1-ol167 115 
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Hydrobromic acid (9M, 1.10 ml, 10.15 mmol) was added to a stirring solution of 1,6-
hexanediol (1.00 g, 8.46 mmol) in toluene (30 ml). The solution was heated at 110 °C 
for 36 hours, cooled to room temperature and diluted with diethyl ether (150 ml). The 
solution was washed with 1M sodium hydroxide (200 ml), saturated brine (200 ml), 
phosphate-citric acid buffer (pH 7.0, 200 ml), dried (MgSO4) and concentrated under 
vacuum to give known bromide167 115 as a colourless oil (1.33 g, 80%). RF 0.55 
(diethyl ether); νmax/cm-1 3339, 2933, 2859; δH (300 MHz; CDCl3) 3.64 (2H, t, J 6.7, 
HOCH2CH2), 3.41 (2H, t, J 6.7, CH2CH2Br), 1.87 (2H, quin, J 6.7, BrCH2CH2), 1.60-
1.35 (6H, m, HOCH2CH2, BrCH2CH2CH2 and HOCH2CH2CH2); δC (75 MHz; CDCl3) 
62.7, 33.9, 32.7, 32.5, 27.9 and 24.9; m/z (CI) 181 (M)+ (100%). 
 
2-(5-(2-Chloroethyl)-2-hydroxybenzyl)-4-(2-chloroethyl)-6-ethylphenol 134 
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4-(2-Chloroethyl)-2-ethylphenol 42 (9 mg, 0.05 mmol) and 4-(2-chloroethyl)-2-
(hydroxymethyl)phenol 130 (9 mg, 0.05 mmol) were suspended in 25% v/v aqueous 
sulfuric acid (3 ml). The suspension was stirred at 100 °C for 4 hours, cooled to room 
temperature, diluted with water (15 ml) and extracted with diethyl ether (3 × 20 ml). 
The combined organic fractions were dried (MgSO4) and concentrated under vacuum 
to give the crude product, which was purified by flash chromatography, (gradient 
elution: hexane-ethyl acetate 6:1 to 4:1) to give the diarylmethane 134 as white 
needles (7 mg, 41%). M.p. 115-116 °C (chloroform); RF 0.26 (4:1 hexane-ethyl 
acetate); νmax/cm-1 3320, 2961, 2927, 2870, 1610; δH (300 MHz; CDCl3) 7.11 (1H, s, 
ArH), 6.97-6.93 (2H, m, 4-ArH and ArH), 6.86 (1H, s, 5ʼ-ArH), 6.74 (1H, d, J 8.2, 5-
ArH), 6.23 (1H, s, OH), 6.07 (1H, s, OH), 3.89 (2H, s, ArCH2Ar), 3.68-3.62 (4H, m, 
CH2Cl), 2.99-2.94 (4H, m, CH2Ar), 2.60 (2H, q, J 7.6, ArCH2CH3), 1.22 (3H, t, J 7.6, 
ArCH2CH3); δC (75 MHz; CDCl3) 151.5, 149.9, 131.4, 131.3, 130.7, 130.6, 128.7, 
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128.4, 128.1, 126.9, 126.5, 116.1, 45.5, 45.4, 38.7, 38.5, 31.1, 23.3 and 14.1 
(CH2CH3). 
 
2-(2-Acetoxy-5-(2-chloroethyl)-3-ethylbenzyl)-4-(2-chloroethyl)phenyl acetate 
137 
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Acetic anhydride (2 μl, 0.02 mmol) was added to a stirring solution of 2-(5-(2-
chloroethyl)-2-hydroxybenzyl)-4-(2-chloroethyl)-6-ethylphenol 134 (3 mg, 0.01 mmol) 
and 4-dimethylaminopyridine (catalytic amount) in triethylamine (1 ml). The solution 
was stirred for 16 hours at room temperature and concentrated under vacuum to give 
the crude product, which was purified by reverse phase HPLC to give the acetate 127 
as a pale yellow oil (2 mg, 54%). δH (300 MHz; CDCl3) 7.12 (1H, d, J 8.2, 5-ArH), 
7.00 (2H, m, ArH), 6.92 (1H, s, ArH), 6.69 (1H, s, ArH), 3.71-3.61 (6H, m, ArCH2Ar 
and CH2Cl), 3.01-2.93 (4H, m, ArCH2), 2.50 (2H, q, J 7.5, ArCH2CH3) 2.24 (3H, s, 
COCH3), 2.17 (3H, s, COCH3), 1.19 (3H, t, J 7.5, CH2CH3). 
 
4-(2-Chloroethyl)-2-ethyl-1-methoxybenzene 128 
 
Cl
OMe
1
2
345
6
 
183 
 
Sodium hydride (60% mineral oil dispersion, 432 mg, 10.80 mmol) was added to a 
stirring solution of methyltriphenylphosphonium bromide (3.86 g, 10.79 mmol) in THF 
(100 ml). The solution was stirred for 2.5 hours at room temperature, cooled to 0 °C, 
and a solution of 5-(2-chloroethyl)-2-methoxybenzaldehyde 61 (932 mg, 4.69 mmol) 
in THF (20 ml) was added. The solution was warmed to room temperature and stirred 
for 20 hours. Saturated ammonium chloride solution (120 ml) was added, and the 
organic and aqueous layers were separated. The aqueous layer was extracted with 
diethyl ether (3 × 120 ml) and the combined organic fractions were dried (MgSO4) 
and concentrated under vacuum, to give the crude product, which was partially 
purified by flash chromatography, eluting with 10:1 hexane-ethyl acetate, to give the 
intermediate alkene, which was used without further purification. The residue was 
dissolved in THF and 10% activated palladium on carbon (200 mg) added. The 
solution was stirred for 22 hours under a hydrogen atmosphere, filtered through a 
short pad of Celite®, eluting with copious amounts of diethyl ether, and concentrated 
under vacuum to give the crude product, which was purified by flash 
chromatography, eluting with 20:1 hexane-ethyl acetate, to give the phenol 128 as a 
pale yellow oil (336 mg, 66%). RF 0.29 (20:1 hexane-ethyl acetate); νmax/cm-1 2961, 
2835, 1610, 1500; δH (300 MHz; CDCl3) 7.03-6.91 (2H, m, ArH), 6.79 (1H, d, J 8.0, 6-
ArH), 3.81 (3H, s, ArOCH3), 3.65 (2H, t, J 7.7, CH2Cl), 2.99 (2H, t, J 7.7, CH2Ar), 2.62 
(2H, q, J 7.5, ArCH2CH3), 1.19 (3H, t, J 7.5, ArCH2CH3); δC (75 MHz; CDCl3) 156.4 
(1-ArC), 132.8, 130.0, 129.5, 127.0, 110.2, 55.4 (CH3OAr), 45.4, 38.6, 23.3 and 14.2 
(CH2CH3); m/z (CI) found [M+H]+ 199.0891; C11H15ClO requires [M+H]+ 199.0890. 
 
4-(2-Chloroethyl)-2-ethylphenol 130 
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Boron tribromide-dimethyl sulfide complex (623 mg, 2.00 mmol) was added to a 
stirring solution of 4-(2-chloroethyl)-2-ethyl-1-methoxybenzene 128 (99 mg, 0.50 
mmol) in 1,2-dichloroethane (12.5 ml). The solution was heated at 85 °C for two days 
and cooled to room temperature. Water (12.5 ml) was added, and the aqueous and 
organic layers were separated. The aqueous layer was extracted with diethyl ether (3 
× 12.5 ml) and the combined organic fractions dried (MgSO4) and concentrated under 
vacuum to give the crude product, which was purified by flash chromatography, 
eluting with 9:1 hexane-ethyl acetate, to give the phenol 130 as a pale orange oil (39 
mg, 43%). RF 0.20 (9:1 hexane-ethyl acetate); νmax/cm-1 3416, 2965, 2933, 2872, 
1611, 1502; δH (300 MHz; CDCl3) 6.99 (1H, s, 3-ArH), 6.94 (1H, d, J 8.1, 5-ArH), 6.71 
(1H, d, J 8.1, 6-ArH), 4.79 (1H, s, ArOH), 3.65 (2H, t, J 7.6, CH2Cl), 2.99 (3H, t, J 7.6, 
CH2Ar), 2.63 (2H, q, J 7.6, ArCH2CH3), 1.24 (3H, t, J 7.6, ArCH2CH3); δC (75 MHz; 
CDCl3) 152.3 (1-ArC), 130.5, 130.1, 129.8, 127.2, 115.2, 45.4, 38.6, 23.0 and 14.0 
(CH2CH3); m/z (CI) found [M+H]+ 185.0734; C10H13ClO requires [M+H]+ 185.0733. 
 
5-(2-Chloroethyl)-2-hydroxybenzoic acid 131 
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S-Methyl 5-(2-chloroethyl)-2-hydroxybenzothioate 132 
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Boron tribromide-dimethyl sulfide complex (2.33 g, 7.44 mmol) was added to a 
stirring solution of methyl-5-(2-chloroethyl)-2-methoxybenzene 50 (425 mg, 1.86 
mmol) in 1,2-dichloroethane (50 ml). The solution was heated at 85 °C for 17 hours 
and cooled to room temperature. Water (50 ml) was added, and the aqueous and 
organic layers were separated. The aqueous layer was extracted with 
dichloromethane (3 × 50 ml) and the combined organic layers were dried (MgSO4) 
and concentrated under vacuum to give the crude product, which was purified by 
flash chromatography (gradient elution: hexane-ethyl acetate 4:1 to 1:1) to give the 
acid 131 as orange needles (208 mg, 56%). M.p. 106-108 °C (chloroform); RF 0.39 
(4:1 hexane-ethyl acetate); νmax/cm-1 2849, 2607, 1661, 1617, 1590; δH (300 MHz; 
CDCl3) 8.03 (1H, s, 6-ArH), 7.40 (1H, d, J 8.5, 4-ArH), 6.98 (1H, d, J 8.5, 3-ArH), 3.70 
(2H, d, J 7.2, CH2Cl), 3.02 (2H, d, J 7.2, CH2Ar); δC (75 MHz; CDCl3) 174.6 (C=OOH), 
161.1 (2-ArC), 137.6, 130.8, 129.3, 118.1, 111.3, 44.9 and 37.9. m/z (ES) found [M-
H]- 199.0171; C9H9ClO3 requires [M-H]- 199.0167. 
Also isolated from the above procedure was the thioester 132 as yellow needles (19 
mg, 4%). M.p. 58-60 °C (chloroform); RF 0.19 (4:1 hexane-ethyl acetate); νmax/cm-1 
2930, 1634, 1589; δH (300 MHz; CDCl3) 7.70 (1H, s, 6-ArH), 7.32 (1H, d, J 8.5, 4-
ArH), 6.94 (1H, d, J 8.5, 3-ArH), 3.69 (2H, d, J 7.2, CH2Cl), 3.02 (2H, d, J 7.2, 
CH2Ar), 2.48 (3H, s, SCH3); δC (75 MHz; CDCl3) 197.4 (C=O), 158.2 (2-ArC), 136.4, 
129.0, 128.7, 119.9, 118.4, 44.9, 38.1 and 11.5 (SCH3); m/z (CI) found [M+H]+ 
231.0241; C10H11ClO2S requires [M+H]+ 231.0247. 
 
Methyl 5-(2-chloroethyl)-2-hydroxybenzoate 133 
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Thionyl chloride (3 ml) was added cautiously to 5-(2-chloroethyl)-2-hydroxybenzoic 
acid 131 (203 mg, 1.01 mmol) at 0 °C. The solution was warmed to room 
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temperature and stirred for 2.5 hours. The solution was concentrated under vacuum 
and methanol (3 ml) added to the resulting residue at 0 °C. The solution was warmed 
to room temperature, stirred for 17 hours and concentrated under vacuum to give the 
ester 133 as an orange oil (196 mg, 90%). RF 0.52 (7:3 hexane-ethyl acetate); 
νmax/cm-1 3196, 2955, 1677, 1615, 1595; δH (300 MHz; CDCl3) 7.69 (1H, s, 6-ArH), 
7.32 (1H, d, J 8.5, 4-ArH), 6.94 (1H, d, J 8.5, 3-ArH), 3.94 (3H, s, (CO)OCH3), 3.70 
(2H, t, J 7.2, CH2Cl), 2.99 (2H, t, J 7.2, CH2Ar); δC (75 MHz; CDCl3) 170.4 
(C=OOCH3), 160.5 (2-ArC), 136.3, 128.9, 128.8, 117.8, 112.3, 52.3 (CH3OAr), 45.0 
and 38.1; m/z (EI) found [M]+ 214.0386; C10H11ClO3 requires [M]+ 214.0391. 
 
1-(5-(2-Chloroethyl)-2-methoxybenzyl)benzene 137 
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A solution of 2-bromo-4-(2-chloroethyl)-1-methoxybenzene 54 (250 mg, 1.00 mmol) 
in THF (2 ml) was added to a stirring solution of B-benzyl-9-borabicyclo[3.3.1]nonane 
135 (4 ml of a 0.5 M solution in THF, 2.0 mmol), palladium acetate (5 mg, 0.02 
mmol), potassium phosphate (637 mg, 3.00 mmol) and SPhos 67 (16 mg, 0.04 
mmol) in THF (1 ml). The solution was heated for 16 hours at 60 °C, cooled to room 
temperature, and diluted with ethyl acetate (20 ml). The solution was passed through 
a short pad of Celite®, eluting with ethyl acetate, and concentrated under vacuum to 
give the crude product, which was purified by flash chromatography, eluting with 20:1 
hexane-ethyl acetate, to give the diarylmethane 137 as a pale yellow oil (67 mg, 
26%). RF 0.53 (4:1 hexane-ethyl acetate); νmax/cm-1 3027, 2926, 2835, 1602, 1501; δH 
(300 MHz; CDCl3) 7.31-7.17 (5H, m, ArH), 7.06 (1H, d, J 8.3, ArH), 6.93 (1H, d, J 8.3, 
3-ArH), 6.82 (1H, d, J 8.3, 4-ArH), 3.97 (2H, s, ArCH2Ar), 3.81 (3H, s ArOCH3), 3.64 
(2H, t, J 7.5, CH2Cl), 2.96 (2H, t, J 7.5, CH2Ar); δC (75 MHz; CDCl3) 156.4 (2-ArC), 
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140.9, 130.8, 130.0, 129.8, 128.9, 128.3, 127.6, 125.9, 110.5, 55.5 (CH3OAr), 45.3, 
38.5 and 35.9; m/z (EI) found [M]+ 260.0958; C16H17ClO requires [M]+ 260.0962. 
 
2-Benzyl-4-(2-chloroethyl)phenol 138 
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Boron tribromide-dimethyl sulfide complex (273 mg, 0.87 mmol) was added to a 
stirring solution of 1-(5-(2-chloroethyl)-2-methoxybenzyl)benzene 137 (57 mg, 0.28 
mmol) in 1,2-dichloroethane (10 ml). The solution was heated at 85 °C for 36 hours 
and cooled to room temperature. The solution was diluted with dichloromethane (15 
ml) and water (25 ml) was added. The aqueous and organic layers were separated 
and the aqueous layer extracted with dichloromethane (3 × 25 ml). The combined 
organic layers were dried (MgSO4) and concentrated under vacuum to give the crude 
product, which was purified by flash chromatography eluting with 4:1 hexane-ethyl 
acetate to give the phenol 138 as a pale orange oil (35 mg, 65%). RF 0.35 (4:1 
hexane-ethyl acetate); δH (300 MHz; CDCl3) 7.32-7.31 (5H, m, ArH), 7.00-6.97 (2H, 
m, ArH), 6.73 (1H, d, J 8.8, 6-ArH), 4.62 (1H, s, OH), 3.98 (2H, s, ArCH2Ar), 3.65 
(2H, t, J 7.4, CH2Cl), 2.97 (2H, t, J 7.4, ArCH2). 
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2-Benzyl-4-(2-chloroethyl)phenyl acetate 139 
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2-Benzyl-4-(2-chloroethyl)phenol 138 (35 mg, 0.14 mmol) was added to a stirring 
solution of 4-dimethylaminopyridine (catalytic amount), acetic anhydride (16 μl, 0.17 
mmol) and triethylamine (3 ml). The solution was stirred at room temperature for 18 
hours and concentrated under vacuum to give the crude product, which was purified 
by flash chromatography, eluting with 9:1 hexane-ethyl acetate, to give the acetate 
139 as a yellow oil (16 mg, 40%). RF 0.24 (9:1 hexane-ethyl acetate); νmax/cm-1 1764, 
1512, 1442; δH (300 MHz; CDCl3) 7.35-6.94 (9H, m, ArH), 3.88 (2H, s, ArCH2Ar), 3.66 
(2H, t, J 7.5, CH2Cl), 3.01 (2H, t, J 7.5, ArCH2), 2.19 (3H, s, COCH3); δC (75 MHz; 
CDCl3) 169.3 (C=O), 147.9 (1-ArC), 139.6, 135.9, 133.0, 131.4, 128.8, 128.5, 127.8, 
126.3, 122.6, 44.8, 38.6, 36.4 and 20.8 (COCH3); m/z (CI) found [M+H]+ 229.0626; 
C17H17ClO2 requires [M+H]+ 229.0632. 
 
5-(2-Chloroethyl)biphenyl-2-yl acetate 140 
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Phenylboronic acid (95 mg, 0.78 mmol) was added to a stirring solution of 4-(2-
chloroethyl)-2-iodophenylacetate 89 (127 mg, 0.39 mmol), palladium acetate (2 mg, 
0.01 mmol), potassium phosphate (249 mg, 1.17 mmol) and SPhos 67 (6 mg, 0.01 
mmol) in THF (3 ml). The solution was heated for 16 hours at 60 °C, cooled to room 
temperature, and. diluted with ethyl acetate (20 ml) The solution was passed through 
a short pad of Celite®, eluting with ethyl acetate. The filtrate was concentrated under 
vacuum to give the crude product, which was partially purified by flash 
chromatography, eluting with 6:1 hexane-ethyl acetate, to give an inseparable 2.5:1 
mixture of the biaryl 140 and the iodide 89 as a pale yellow oil (52 mg). A small 
sample of analytically pure biaryl 140 was obtained by reverse phase HPLC 
purification. RF 0.26 (6:1 hexane-ethyl acetate); νmax/cm-1 1760, 1601, 1504; δH (600 
MHz; CDCl3) 7.43-7.41 (4H, m, ArH), 7.38-7.35 (1H, m, ArH), 7.29-7.28 (2H, m, ArH), 
7.24 (1H, dd, J 2.2, 8.2, 3-ArH), 7.10 (1H, d, J 8.2, 4-ArH), 3.76 (2H, t, J 7.4, CH2Cl), 
3.13 (2H, t, J 7.4, ArCH2), 2.10 (3H, s, COCH3); δC (150 MHz; CDCl3) 169.6 (C=O), 
146.6 (2-ArC), 137.4, 136.2, 134.9, 131.3, 128.9, 128.8, 128.7, 128.5, 128.4, 127.6, 
123.0, 44.8, 38.6 and 20.9; m/z (CI) found [M+H]+ 275.0845; C16H15O235Cl requires 
[M+H]+ 275.0839. 
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(5-(2-Chloroethyl)-2-hydroxyphenyl)(phenyl)methanone 141 
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(5-(2-Chloroethyl)-2-methoxyphenyl)(phenyl)methanone 142 
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Aluminium chloride (977 mg, 7.33 mmol) was added to a stirring solution of benzoyl 
chloride (0.85 ml, 7.33 mmol) and 1-(2-chloroethyl)-4-methoxybenzene 47 (1.00 ml, 
6.66 mmol) in dichloromethane (25 ml). The solution was heated at 55 °C for 18 
hours and cooled to room temperature. Water (25 ml) was cautiously added, the 
organic and aqueous layers were separated and the aqueous layer extracted with 
dichloromethane (3 × 60 ml). The combined organic fractions were dried (MgSO4) 
and concentrated under vacuum to give the crude product, which was purified by 
flash chromatography (gradient elution: hexane-ethyl acetate 9:1 to 4:1) to give the 
phenol 138 as pale yellow plates (868 mg, 50%). M.p. 80-82 °C (chloroform); RF 0.42 
(4:1 hexane-ethyl acetate); νmax/cm-1 3054, 2959, 2864, 1626, 1597; δH (500 MHz; 
CDCl3) 11.91 (1H, s, OH), 7.72-7.67 (2H, m, ArH), 7.64-7.58 (1H, m, ArH), 7.55-7.49 
(2H, m, ArH), 7.44 (1H, d, J 2.3, 6-ArH), 7.38 (1H, dd, J 2.3, 8.5, 4-ArH), 7.05 (1H, d, 
J 8.5, 3-ArH), 3.65 (2H, t, J 7.1, CH2Cl), 2.97 (2H, t, J 7.1, ArCH2); δC (125 MHz; 
CDCl3) 201.5 (C=O), 162.2 (2-ArC), 137.9, 136.9, 133.7, 132.1, 129.3, 128.5, 128.3, 
119.0, 118.7, 45.2 and 38.1; m/z (CI) found [M+H]+ 261.0678; C16H15O2Cl requires 
[M+H]+ 261.0682. 
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Also isolated from the above procedure was the ether 142 as a pale yellow oil (638 
mg, 35%); RF 0.33 (4:1 hexane-ethyl acetate); νmax/cm-1 2959, 2837, 1659, 1608, 
1596, 1579; δH (500 MHz; CDCl3) 7.85-7.78 (2H, m, ArH), 7.58-7.53 (1H, m, ArH), 
7.43 (2H, t, J 7.8, ArH), 7.33 (1H, dd, J 2.3, 8.5, 4-ArH), 7.22 (1H, d, J 2.3, 6-ArH), 
6.95 (1H, d, J 8.5, 3-ArH), 3.71 (6H, s, ArOCH3 and CH2Cl), 3.04 (2H, t, J 7.3, 
ArCH3); δC (125 MHz; CDCl3) 196.3 (C=O), 156.4 2-ArC), 137.8, 133.1, 132.3, 130.3, 
130.0, 129.9, 129.0, 128.3, 111.7, 55.8 (ArOCH3), 45.1, 38.1; m/z (CI) found [M-
OMe+H]+ 261.0694; C16H15O2Cl requires [M-OMe+H]+ 261.0682. 
 
(5-(2-Chloroethyl)-2-acetoxyphenyl)(phenyl)methanone 143 
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Acetic anhydride (0.13 ml, 1.20 mmol) was added to a stirring solution of (5-(2-
chloroethyl)-2-hydroxyphenyl)(phenyl)methanone 141 (261 mg, 1.00 mmol) and 4-
dimethylaminopyridine (catalytic amount) in triethylamine (3 ml). The solution was 
stirred for 16 hours at room temperature and concentrated under vacuum. The crude 
product was purified by flash chromatography, eluting with 4:1 hexane-ethyl acetate, 
to give the acetate 143 as a pale yellow oil (214 mg, 71%). RF 0.26 (4:1 hexane-ethyl 
acetate); νmax/cm-1 2958, 1762, 1662, 1596, 1580; δH (500 MHz; CDCl3) 7.84-7.72 
(2H, m, ArH), 7.59 (1H, t, J 7.4, ArH), 7.44 (4H, m, ArH), 7.15 (1H, d, J 8.2, 4-ArH), 
3.72 (2 H, t, J 7.2, CH2Cl), 3.10 (2H, t, J 7.2, ArCH2), 1.92 (3H, s, COCH3); δC (125 
MHz; CDCl3) 194.7 (ArC=OAr), 169.2 (OC=O), 147.7 (2-ArC), 137.5, 135.8, 133.2, 
132.7, 131.6, 130.9, 129.9, 128.5, 123.4, 53.5, 44.7, 38.3 and 20.6; m/z (ES) found 
[M+Na]+ 325.0595; C17H15ClO3 requires [M+Na]+ 325.0607. 
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4-(2-Chloroethyl)-2-(hydroxy(phenyl)methyl)phenol 144  
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Borane-dimethyl sulfide complex (2M solution in THF, 1.00 ml, 2.00 mmol) was 
added to a stirring solution of (5-(2-chloroethyl)-2-hydroxyphenyl)(phenyl)methanone 
141 (261 mg, 1.00 mmol) in THF (7 ml). The solution was stirred at room temperature 
for 2.5 hours. HCl (5% aqueous solution, 5 ml) was added dropwise and the solution 
stirred vigorously for 5 minutes. The solution was partitioned between water (50 ml) 
and ethyl acetate (50 ml), the aqueous and organic layers were separated and the 
aqueous layer extracted with ethyl acetate (3 × 50 ml). The combined organic 
fractions were dried (MgSO4) and concentrated under vacuum to give the crude 
product, which was purified by flash chromatography, eluting with 1:1 hexane-ethyl 
acetate, to give the alcohol 144 (152 mg) as a pale yellow oil in approximately 90% 
purity. δH (300 MHz; CDCl3) 7.83 (1H, s, OH), 7.38-7.31 (5H, m, ArH), 7.04 (1H, d, J 
8.3, 3-ArH), 6.87-6.72 (2H, m, ArH), 5.99 (1H, s, ArCH(OH)Ar), 3.61 (2H, t, J 7.4, 
CH2Cl), 2.98-2.91 (3H, m, ArCH2, OH); δC (75 MHz; CDCl3) 171.8, 154.4, 141.8, 
129.6, 129.5, 128.8, 128.6, 128.4, 127.4, 126.8, 128.6, 117.5, 45.2, 38.3 and 22.7. 
The compound was used immediately without further purification. 
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Acetic anhydride (54 μl, 0.58 mmol) was added to a stirring solution of 4-(2-
chloroethyl)-2-(hydroxy(phenyl)methyl)phenylacetate 144 (152 mg, 0.58 mmol), 
pyridine (47 μl, 0.58 mmol) and 4-dimethylaminopyridine (catalytic amount) in 
dichloromethane (3 ml). The solution was stirred for 16 hours and concentrated under 
vacuum to give the crude product, which was purified by flash chromatography 
(gradient elution: hexane-ethyl acetate 5:1 to 4:1) to give the acetate 145 as a 
colourless oil (11 mg, 1%). RF 0.31 (4:1 hexane-ethyl acetate); νmax/cm-1 2923, 1763, 
1737, 1605; δH (500 MHz; CDCl3) 7.37-7.25 (6H, m, ArH), 7.19 (1H, dd, J 2.2, 8.2, 3-
ArH), 7.04 (1H, d, J 8.2, 6-ArH), 3.68 (2H, t, J 7.5, CH2Cl), 3.05 (2H, t, J 7.5, ArCH2), 
2.19 (3H, s, COCH3), 2.14 (3H, s, COCH3); δC (125 MHz; CDCl3) 169.8 (C=O), 169.1 
(C=O), 147.2 (1-ArC), 138.9, 136.0, 132.1, 129.5, 129.0, 128.6, 128.2, 127.1, 123.3, 
71.8 (CH(OAc)), 44.7, 38.7, 21.2 and 20.9; m/z (ES) found [M+Na]+ 369.0870; 
C19H19O4Cl requires [M+Na]+ 369.0885. 
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Tetrakis(triphenylphosphine)palladium(0) (catalytic amount) was added to a stirring 
solution of 4-(2-chloroethyl)-2-iodophenylacetate 89 (68 mg, 0.21 mmol), 
phenylacetylene (46 μl, 0.48 mmol) and copper iodide (catalytic amount) in 
triethylamine (2 ml). The solution was stirred at room temperature overnight and 
filtered through a short pad of Celite®, eluting with diethyl ether, and concentrated 
under vacuum to give the crude product, which was purified by flash chromatography 
(gradient elution: hexane-ethyl acetate 9:1 to 4:1) to give the alkyne 147 as a pale 
yellow oil (49 mg, 79%). RF 0.29 (4:1 hexane-ethyl acetate); νmax/cm-1 2960, 1764, 
194 
1597; δH (600 MHz; CDCl3) 7.51-7.46 (2H, m, ArH), 7.46 (1H, d, J 2.1, 3-ArH), 7.39-
7.36 (3H, m, ArH), 7.24 (1H, d, J 8.2, 6-ArH), 7.10 (1H, d, J 8.2, 5-ArH), 3.74 (2H, t, J 
7.4, CH2Cl), 3.08 (2H, t, J 7.4, ArCH2), 2.38 (3H, s, COCH3); δC (150 MHz; CDCl3) 
150.4 (1-ArC), 135.9, 133.2, 131.6, 130.0, 128.7, 128.4, 128.3, 126.9, 122.9, 122.8, 
122.4, 117.5, 94.3, 84.1, 44.6 and 38.3; m/z (CI) found [M+H]+ 299.0844; 
C18H16O235Cl requires [M+H]+ 299.0839. 
 
(Z)-4-(2-Chloroethyl)-2-styrylphenyl acetate 148 
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Sodium hydride (60% mineral oil dispersion, 24 mg, 1.00 mmol) was added to a 
stirring solution of benzyltriphenylphosphonium bromide (256 mg, 0.59 mmol) in THF 
(4 ml). The solution was stirred for 2 hours at room temperature, cooled to 0 °C, and 
a solution of 4-(2-chloroethyl)-2-formylphenylacetate 150 (67 mg, 0.59 mmol) in THF 
(8 ml) was added. The solution was heated to 60 °C and stirred for 24 hours, at 
which point the temperature was increased to 80 °C hours. After a further 3 days, 
saturated ammonium chloride solution (12 ml) was added, and the organic and 
aqueous layers were separated. The aqueous layer was extracted with diethyl ether 
(3 × 20 ml) and the combined organic fractions were dried (MgSO4) and concentrated 
under vacuum. The resulting residue was partially purified by flash chromatography, 
eluting with 9:1 hexane-ethyl acetate, to give the (Z)-alkene 148 (9 mg) in 
approximately 90% purity. RF 0.25 (9:1 hexane-ethyl acetate); νmax/cm-1 2922, 2851, 
1763, 1600, 699; δH (600 MHz; CDCl3) 7.22-7.19 (4H, m, ArH), 7.12-7.10 (1H, m, 
ArH), 7.06 (1H, m, ArH), 7.03 (1H, d, J 8.2, 5-ArH), 6.69 (1H, d, J 12.1, 
ArCH=CHPh), 6.46 (1H, d, J 12.1, ArCH=CHPh), 3.76 (2H, t, J 7.4, CH2Cl), 3.51 (2H, 
t, J 7.4, ArCH2), 2.25 (3H, s, COCH3); δC (150 MHz; CDCl3) 169.4 (C=O), 147.5 (1-
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ArC), 136.5, 135.6, 132.5, 130.8, 130.6, 129.0, 128.9, 128.2, 127.5, 124.2, 122.5, 
44.7, 38.4 and 20.1; m/z (EI) found [M]+ 300.0907; C18H17O2Cl requires [M]+ 
300.0912. 
 
4-(2-Chloroethyl)-2-formylphenylacetate 150 
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Acetic anhydride (1.0 ml) was added to a stirring solution of 5-(2-chloroethyl)-2-
hydroxybenzaldehyde 159 (276 mg, 1.22 mmol) and 4-dimethylaminopyridine 
(catalytic amount) in pyridine (3 ml). The solution was stirred for 24 hours and 
concentrated under vacuum to give the crude product, which was purified by flash 
chromatography, eluting with 5:1 hexane-ethyl acetate, to give the acetate 150 as a 
pale orange oil (75 mg, 22%). RF 0.18 (5:1 hexane-ethyl acetate); νmax/cm-1 2866, 
1766, 1692, 1656, 1606, 1586; δH (300 MHz; CDCl3) 10.10 (1H, s, CHO), 7.73 (1H, d, 
J 2.6, 3-ArH), 7.49 (1H, dd, J 2.6, 8.2, 6-ArH), 7.14 (1H, d, J 8.2, 5-ArH), 3.73 (2H, t, 
J 7.1, CH2Cl), 3.11 (2H, t, J 7.1, ArCH2), 2.38 (3H, s, COCH3); δC (75 MHz; CDCl3) 
188.5 (CHC=O), 169.3 (OC=O), 150.5 (1-ArC), 136.6, 135.8, 131.1, 128.0, 123.6, 
44.4, 38.1, 22.7 and 20.9; m/z (ES) found [M-COCH3]- 183.0227; C11H11ClO3 requires 
[M-COCH3]- 183.0213. 
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4-(2-Chloroethyl)-2-(phenoxymethyl)phenylacetate 153 
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Potassium carbonate (61 mg, 0.44 mmol) was added to a stirring solution of 2-
(bromomethyl)-4-(2-chloroethyl)phenylacetate 154 (107 mg, 0.37 mmol) and phenol 
(41 mg, 0.37 mmol) in DMF (3 ml). After 16 hours TLC analysis indicated the 
presence of unreacted starting material, therefore sodium iodide (catalytic amount) 
was added. The solution was stirred for a further 7 days and concentrated under 
vacuum. The resulting residue was partially purified by flash chromatography 
(gradient elution: hexane-ethyl acetate 5:1 to 4:1) to give the ether 153 (6 mg) in 
approximately 90% purity. A small sample of analytically pure ether 153 was 
obtained by reverse phase HPLC purification. RF 0.28 (4:1 hexane-ethyl acetate); 
νmax/cm-1 2925, 1762, 1599, 1587; δH (600 MHz; CDCl3) 7.38 (1H, s, 3-ArH), 7.33-
7.30 (2H, m, 3ʼ-ArH and 5ʼ-ArH), 7.23 (1H, dd, J 8.2, 2.2, 5-ArH), 7.09 (1H, d, J 8.2, 
6-ArH), 7.00-6.96 (3H, m, 2ʼ-ArH, 4ʼ-ArH and 6ʼ-ArH), 5.01 (2H, s, ArCH2O), 3.71 (2H, 
t, J 7.4, CH2Cl), 3.08 (2H, t, J 7.4, ArCH2), 2.28 (3H, s, COCH3); δC (150 MHz; CDCl3) 
169.4 (C=O), 158.5 (1-ArC), 147.5, 136.2, 129.7, 129.6, 129.2, 122.7, 121.2, 114.8, 
65.3, 44.7, 38.6, 20.9; m/z (EI) found [M]+ 304.0868; C17H17ClO3 requires [M]+ 
304.0861. 
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2-(Bromomethyl)-4-(2-chloroethyl)phenylacetate 154 
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Acetyl bromide (110 μl, 1.52 mmol) was added to a stirring solution of 4-(2-
chloroethyl)-2-(hydroxymethyl)phenol 109 (225 mg, 1.20 mmol) in glacial acetic acid 
(6 ml). After one hour a further portion of acetyl bromide (110 μl, 1.52 mmol) was 
added. The solution was stirred for a further hour and concentrated under vacuum to 
give the crude product, which was purified by flash chromatography, eluting with 4:1 
hexane-ethyl acetate, to give the bromide 154 as a pale yellow oil (196 mg, 56%). RF 
0.30 (4:1 hexane-ethyl acetate); νmax/cm-1 2959, 1762, 1613, 1516; δH (500 MHz; 
CDCl3) 7.28 (1H, s, 3-ArH), 7.21 (1H, d, J 8.3, 6-ArH), 7.10 (1H, d, J 8.3, 5-ArH), 4.36 
(2H, s, ArCH2Br), 3.71 (2H, t, J 7.3, CH2Cl), 3.06 (2H, t, J 7.3, ArCH2), 2.37 (3H, s, 
COCH3); δC (125 MHz; CDCl3) 169.1, (C=O), 147.9 (1-ArC), 136.3, 131.3, 130.3, 
129.7, 123.3, 44.6, 38.4, 27.6 and 21.1; m/z (ES) found [M+NH4]+ 310.0028; 
C11H1281BrClO2 requires [M+NH4]+ 310.0025. 
 
2-((N-Phenylacetamido)methyl)-4-(2-chloroethyl)phenylacetate 157  
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N-(5-(2-Chloroethyl)-2-hydroxybenzyl)-N-phenylacetamide 158 
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Aniline (91 μl, 1.00 mmol) was added to a stirring solution of 5-(2-chloroethyl)-2-
hydroxybenzaldehyde 159 (185 mg, 1.00 mmol) in methanol (5 ml). The solution was 
heated at 65 °C for 90 minutes and cooled to room temperature. Sodium borohydride 
(87 mg, 2.50 mmol) was added cautiously, the solution was stirred at room 
temperature for 2 hours and 1M HCl (2 ml) was added to adjust the pH to 3.7. 
Saturated sodium carbonate solution (20 ml) was added and the intermediate sodium 
phenolate salt collected by filtration. The sodium phenolate salt (143 mg) was 
dissolved in acetic anhydride (2 ml) and stirred at room temperature for 16 hours. 
The solution was concentrated under vacuum to give the crude product, which was 
purified by flash chromatography (gradient elution: toluene-acetone 20:1 to 9:1) to 
give the acetate 157 as a colourless viscous oil (158 mg, 46%). RF 0.29 (20:1 
toluene-acetone); νmax/cm-1 1760, 1653, 1596; δH (300 MHz; CDCl3) 7.30 (3H, m, 
ArH), 7.10 (1H, dd, J 2.1, 8.2, 6-ArH), 7.03-6.90 (3H, m, ArH), 6.83 (1H, d, J 2.0, 3-
ArH), 4.87 (2H, s, ArCH2Ar), 3.51 (2H, t, J 7.4, CH2Cl), 2.90 (2H, t, J 7.4, ArCH2), 
2.19 (3H, s, ArCOCH3), 1.82 (3H, s, NCOCH3); δC (75 MHz; CDCl3) 170.1 (NC=O), 
169.8 (OC=O), 148.3 (1-ArC), 142.2, 135.6, 132.4, 129.6, 129.4, 129.2, 129.1, 128.6, 
128.3, 128.1, 122.8, 47.2, 44.8, 38.4, 22.7 and 21.0; m/z (CI) found [M+H]+ 346.1228; 
C19H21O3NCl requires [M+H]+ 346.1210. 
Also isolated from the above procedure was the amide 158 as a pale yellow oil (638 
mg, 35%); RF 0.33 (4:1 hexane-ethyl acetate); νmax/cm-1 2959, 2837, 1659, 1608, 
1596, 1579; δH (500 MHz; CDCl3) 9.58 (1H, s, OH), 7.43-7.41 (3H, m, ArH), 7.06-7.01 
(3H, m, ArH), 6.92 (1H, d, J 8.3, 3-ArH), 6.44 (1H, s, 6-ArH), 4.73 (2H, s, ArCH2N), 
3.52 (2H, t, J 7.3, CH2Cl), 2.81 (2H, t, J 7.3, ArCH2), 1.87 (3H, s, N(CO)CH3); δC (125 
MHz; CDCl3) 172.9 (C=O), 155.0 (2-ArC), 142.1, 132.3, 130.6, 130.0, 128.8, 128.7, 
199 
128.1, 122.2, 118.1, 50.7, 45.5, 38.1 and 22.4; m/z (EI) found [M]+ 303.1019; 
C17H18NO2Cl requires [M]+ 303.1021. 
 
5-(2-Chloroethyl)-2-hydroxybenzaldehyde 159 
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Triethylamine (1.04 ml, 7.50 mmol) was added to a stirring solution of 4-(2-
chloroethyl)phenol 42 (313 mg, 2.00 mmol), magnesium chloride (286 mg, 3.00 
mmol) and paraformaldehyde (375 mg, 13.50 mmol) in acetonitrile (10 ml). The 
solution was heated at 70 °C for 16 hours, cooled to room temperature and HCl (5% 
aqueous solution, 50 ml) was added to adjust the solution to pH 1. The solution was 
extracted with diethyl ether (3 × 60 ml), and the combined organic fractions dried 
(MgSO4) and concentrated under vacuum to give the crude product, which was 
purified by flash chromatography, eluting with chloroform, to give the aldehyde 159 
as a colourless oil (343 mg, 93%). RF 0.51 (chloroform); νmax/cm-1 3208, 2960, 2849, 
1651, 1625, 1590; δH (500 MHz; CDCl3) 10.92 (1H, s, CHO), 9.88 (1H, s, ArOH), 
7.43-7.36 (2H, m, 5-ArH and 6-ArH), 6.95 (1H, d, J 8.4, 3-ArH), 3.71 (2H, t, J 7.0, 
CH2Cl), 3.05 (2H, t, J 7.0, ArCH2); δC (75 MHz; CDCl3) 196.5 (C=O), 160.7 (2-ArH), 
137.7, 133.7, 129.7, 120.5, 118.0, 45.0 and 37.9; m/z (CI) found [M+H]+ 185.0365; 
C9H10O2Cl requires [M+H]+ 185.0369. 
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N-(5-ethyl-2-hydroxybenzyl)-N-phenylacetamide 162 
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Benzyl chloroformate (20 μl, 0.13 mmol) was added to a stirring solution of 4-(2-
chloroethyl)-2-((phenylamino)methyl)phenol 155 (34 mg, 0.13 mmol) and 
triethylamine (34 μl, 0.24 mmol) in dichloromethane (3 ml) at 0 °C. After 15 minutes 
the solution was warmed to room temperature. After six hours HCl (5% aqueous 
solution, 3 ml) was added, the solution was stirred for 30 minutes, partitioned 
between dichloromethane (20 ml) and water (20 ml) and the aqueous layer extracted 
with dichloromethane (3 × 20 ml). The combined organic fractions were dried 
(MgSO4) and concentrated under vacuum. The residue was dissolved in pyridine (3 
ml) and acetic anhydride (1 ml) and 4-dimethylaminopyridine (catalytic amount) were 
added. The solution was stirred for 19 hours and concentrated under vacuum to give 
the intermediate carbamate, which was used without further purification. The residue 
was dissolved in methanol (5 ml) and 10% activated palladium on carbon (25 mg) 
added. The solution was stirred for 17 hours under a hydrogen atompsohere, filtered 
through a short pad of Celite®, eluting with copious amounts of diethyl ether and 
concentrated under vacuum to give the crude product, which was purified by flash 
chromatography, eluting with 4:1 hexane-ethyl acetate, to give the amide 162 as a 
pale yellow oil (6 mg, 18%). RF 0.23 (4:1 hexane-ethyl acetate); νmax/cm-1 2961, 2928, 
1764, 1627, 1593; δH (500 MHz; CDCl3) 7.44-7.41 (3H, m, ArH), 7.04-7.01 (3H, m, 
ArH), (1H, d, J 8.2, 3-ArH), 6.40 (1H, s, 6-ArH), 4.74 (ArCH2N), 2.42 (2H, q, J 7.6, 
CH2CH3), 1.86 (3H, s, COCH3), 1.05 (3H, t, J 7.6, CH2CH3); δC (125 MHz; CDCl3) 
172.8 (C=O), 153.9 (2-ArC), 142.3, 135.0, 131.1, 129.9, 129.6, 128.7, 128.1, 121.9, 
117.7, 50.8, 27.8, 22.3 and 16.1; m/z (CI) found [M+H]+ 270.1495; C17H19NO2 
requires [M+H]+ 270.1494. 
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2-(Azidomethyl)-4-(2-chloroethyl)phenylacetate 164 
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Sodium azide (194 mg, 2.98 mmol) was added to a stirring solution of 2-
(bromomethyl)-4-(2-chloroethyl)phenylacetate 154 (87 mg, 0.30 mmol) in DMF (5 ml). 
The solution was heated at 100 °C for 16 hours and cooled to room temperature, 
diluted with water (15 ml) and extracted with diethyl ether (3 × 20 ml). The combined 
organic fractions were dried (MgSO4) and concentrated under vacuum to give the 
intermediate phenol as a pale yellow oil. The oil was dissolved in acetic anhydride 
(500 μl) and pyridine (1.5 ml) and stirred at room temperature for 16 hours. The 
solution was concentrated under vacuum to give the crude product, which was 
purified by flash chromatography, eluting with 4:1 hexane-ethyl acetate, to give the 
azide 164 as a pale yellow oil (12 mg, 16%). RF 0.24 (4:1 hexane-ethyl acetate); 
νmax/cm-1 2925, 2096, 1764, 1499; δH (500 MHz; CDCl3) 7.23-7.21 (2H, m, ArH), 7.09 
(1H, dd, J 2.9, 8.9, 5-ArH), 4.43 (2H, s, ArCH2N3), 3.54 (2H, t, J 7.2, CH2Cl), 2.90 
(2H, t, J 7.2, ArCH2), 2.32 (3H, s, COCH3); δC (125 MHz; CDCl3) 169.3 (C=O), 147.8 
(1-ArC), 136.4, 130.4, 130.0, 127.8, 123.0, 52.3, 50.1, 34.8 and 21.0; m/z (CI) found 
[M+H]+ 218.0924; C11H12O2N3 requires [M+H]+ 218.0930. 
 
1-(5-(2-Chloroethyl)-2-methoxyphenylsulfonylamino)benzene 167 
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Aniline (37 μl, 0.37 mmol) was added to a stirring solution of 5-(2-chloroethyl)-2-
methoxybenzene-1-sulfonyl chloride 70 (100 mg, 0.37 mmol) in dichloromethane (3 
ml) and 1M sodium carbonate solution (3 ml). The solution was stirred for 16 hours at 
room temperature, and diluted with dichloromethane (20 ml) and water (20 ml). The 
organic and aqueous layers were separated, and the aqueous layer extracted with 
dichloromethane (3 × 20 ml). The combined organic layers were dried (MgSO4) and 
concentrated under vacuum to give the crude product, which was purified by flash 
chromatography, eluting with 20:1 toluene-acetone, to give the sulfonamide 167 as 
white needles (52 mg, 43%). M.p. 90-92 °C (chloroform); RF 0.47 (1:1 hexane-ethyl 
acetate); νmax/cm-1 3250, 1598, 1486; δH (500 MHz; CDCl3) 7.66 (1H, d, J 2.3, 6-ArH), 
7.34 (1H, dd, J 2.3, 8.5, 3-ArH), 7.22-7.15 (2H, m, ArH), 7.06 (3H, m, ArH), 7.00-6.84 
(2H, m, ArH), 4.02 (3H, s, ArOCH3), 3.60 (2H, t, J 7.1, CH2Cl), 2.97 (2H, t, J 7.1, 
ArCH3); δC (125 MHz; CDCl3) 155.1 (2-ArC), 136.7, 135.4, 131.1, 130.8, 129.3, 
126.4, 125.5, 121.6, 112.3, 56.6 (ArOCH3), 44.7 and 37.8; m/z (CI) found [M+H]+ 
326.0620; C15H16O3NSCl requires [M+H]+ 326.0618. 
 
1-(5-(2-Chloroethyl)-2-hydroxyphenylsulfonylamino)benzene 168 
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Boron tribromide-dimethyl sulfide complex (180 mg, 0.56 mmol) was added to a 
stirring solution of 1-(5-(2-chloroethyl)-2-methoxyphenylsulfonylamino)benzene 167 
(47 mg, 0.14 mmol) in 1,2-dichloroethane (5 ml). The solution was heated at 85 °C 
for 24 hours, at which point a further portion of boron tribromide-dimethyl sulfide 
complex (180 g, 0.56 mmol) was added. The solution was stirred for a further 16 
hours at 85 °C, cooled to room temperature and diluted with dichloromethane (20 ml) 
Water (25 ml) was added, and the aqueous and organic layers were separated. The 
aqueous layer was extracted with dichloromethane (3 × 25 ml) and the combined 
organic layers dried (MgSO4) and concentrated under vacuum to give the crude 
product, which was purified by flash chromatography, eluting with 1:1 hexane-ethyl 
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acetate, to give the phenol 168 as white needles (20 mg, 45%). M.p. 116-118 °C 
(chloroform); RF 0.10 (4:1 hexane-ethyl acetate); νmax/cm-1 3386, 3248, 2959, 1599, 
1507, 913; δH (500 MHz; CDCl3) 8.40 (1H, s, OH or NH), 7.27 (5H, m, ArH), 7.20 (1H, 
m, 6-ArH), 7.06 (2H, d, J 7.2, 2ʼ-ArH and 6ʼ-ArH), 6.92 (1H, d, J 8.6, 3-ArH), 6.66 (1H, 
s, OH or NH), 3.54 (2H, t, J 6.9, CH2Cl), 2.90 (2H, t, J 6.9, CH2Ar), 1.64 (1H, s, NH); 
δC (125 MHz; CDCl3) 154.0 (2-ArC), 136.3, 135.3, 130.3, 129.6, 128.6, 126.9, 123.7, 
121.5, 119.0, 44.8 and 37.7; m/z (EI) found [M]+ 311.0384; C14H14O3NSCl requires 
[M]+ 311.0377. 
 
2-(N-Acetyl-N-phenylsulfamoyl)-4-(2-chloroethyl)phenylacetate 169 
 
O
Cl
1
2
3
4
5 6
1' 2' 3'
4'
5'
6'
S N
O
O
O
O
 
 
Acetic anhydride (1 ml) was added to a stirring solution of 1-(5-(2-chloroethyl)-2-
hydroxyphenylsulfonylamino)benzene 168 (18 mg, 0.06 mmol) and 4-
dimethylaminopyridine (catalytic amount) in pyridine (3 ml). The solution was stirred 
for 16 hours at room temperature and concentrated under vacuum to give the crude 
product, which was purified by flash chromatography, eluting with 6:4 hexane-ethyl 
acetate, to give the acetate 169 as a colourless oil (17 mg, 75%). RF 0.33 (1:1 
hexane-ethyl acetate); νmax/cm-1 1774, 1696, 1592; δH (500 MHz; CDCl3) 8.12 (1H, d, 
J 2.2, 6-ArH), 7.62-7.37 (6H, m, ArH), 7.14 (1H, d, J 8.2, 3-ArH), 3.76 (2H, t, J 7.1, 
CH2Cl), 3.17 (2H, t, J 7.1, ArCH2), 1.92 (3H, s, OCOCH3), 1.86 (3H, s, NCOCH3); 
170.3 (C=O), 168.6 (C=O), 147.0, 136.4, 136.3, 135.8, 133.9, 131.3, 130.8, 130.0, 
129.6, 125.2, 44.4, 38.2, 25.2 and 20.8; m/z (CI) found [M+H]+ 396.0685; 
C18H19O5NSCl requires [M+H]+ 396.0673. 
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2-(2-Chlorobenzyl)-4-(2-chloroethyl)phenylacetate 176 
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2-Chlorophenylboronic acid (54 mg, 0.35 mmol) was added to a stirring solution of 2-
(bromomethyl)-4-(2-chloroethyl)phenyl acetate 154 (50 mg, 0.17 mmol), trans-
bromo(N-succinimidyl)bis(triphenylphosphine)palladium(II)bromo (bistriphenyl-
phosphine) (14 mg, 0.02 mmol) and sodium carbonate (54 mg, 0.51 mmol) in THF (5 
ml). The solution was stirred for five minutes at room temperature and heated at 80 
°C for 17 hours. The solution was cooled to room temperature and passed through a 
short pad of Celite®, eluting with ethyl acetate. The filtrate was concentrated under 
vacuum to give the crude product, which was purified by flash chromatography, 
eluting with 12:1 cyclohexane:ethyl acetate, to give the diarylmethane 176 as a 
colourless oil (18 mg, 33%). RF 0.21 (12:1 cyclohexane-ethyl acetate); νmax/cm-1 
2927, 1760, 1571; δH (400 MHz; CDCl3) 7.42-7.40 (1H, m, 3ʼ-ArH), 7.21-7.14 (3H, m, 
6-ArH, 4ʼ-ArH and 5ʼ-ArH), 7.07-7.05 (2H, m, 5-ArH and 6ʼ-ArH), 6.99 (1H, d, J 1.9, 3-
ArH), 4.03 (2H, s, ArCH2Ar), 3.68 (2H, t, J 7.5, CH2Cl), 3.03 (2H, t, J 7.5, ArCH2), 
2.24 (3H, s, COCH3); δC (101 MHz; CDCl3) 169.7 (C=O), 148.3 (1-ArC), 137.5, 136.3, 
134.4, 132.0, 131.6, 131.1, 129.8, 128.4, 128.2, 127.3, 123.0, 45.2, 39.0, 33.9 and 
21.2; m/z (ES) found [M+NH4]+ 340.0869; C17H16O2Cl2 requires [M+NH4]+ 340.0866. 
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3-Chlorophenylboronic acid (54 mg, 0.35 mmol) was added to a stirring solution of 2-
(bromomethyl)-4-(2-chloroethyl)phenyl acetate 154 (50 mg, 0.17 mmol), trans-
bromo(N-succinimidyl)bis(triphenylphosphine)palladium(II)bromo (bistriphenyl-
phosphine) (14 mg, 0.02 mmol) and sodium carbonate (54 mg, 0.51 mmol) in THF (5 
ml). The solution was stirred for five minutes at room temperature and heated at 80 
°C for 17 hours. The solution was cooled to room temperature and passed through a 
short pad of Celite®, eluting with ethyl acetate. The filtrate was concentrated under 
vacuum to give the crude product, which was partially purified by flash 
chromatography, eluting with 12:1 cyclohexane:ethyl acetate, to give an 
approximately 1:1 mixture of the title compound and 2-(bromomethyl)-4-(2-
chloroethyl)phenyl acetate 154. The mixture was purified by reverse phase HPLC to 
give the diarylmethane 177 as a pale yellow oil (6 mg, 11%). RF 0.30 (4:1 
cyclohexane-ethyl acetate); νmax/cm-1 2924, 2853, 1760, 1596; δH (400 MHz; CDCl3) 
7.23-7.21 (2H, m, 2ʼ-ArH and 4ʼ-ArH), 7.16-7.14 (2H, m, 3-ArH and 5ʼ-ArH), 7.05-7.03 
(3H, m, 5-ArH, 6-ArH and 6ʼ-ArH), 3.87 (2H, s, ArCH2Ar), 3.70 (2H, t, J 7.4, CH2Cl), 
3.04 (2H, t, J 7.4, ArCH2), 2.23 (3H, s, COCH3); δC (101 MHz; CDCl3) 142.0 (1-ArC), 
129.3, 127.5, 127.3, 126.9, 123.2, 45.1, 38.9, 36.5, 21.3; m/z (CI) found [M+H]+ 
323.0600; C17H10Cl2O2 requires [M+H]+ 323.0600. 
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O
CF3
O
Cl
1
2
3
45
6 1'
2'
3'
4'
5'
6'
 
 
4-(Trifluoromethyl)phenylboronic acid (66 mg, 0.35 mmol) was added to a stirring 
solution of 2-(bromomethyl)-4-(2-chloroethyl)phenyl acetate 154 (50 mg, 0.17 mmol), 
trans-bromo(N-succinimidyl)bis(triphenylphosphine)- palladium(II) 
bromo(bistriphenyl-phosphine) (14 mg, 0.02 mmol) and sodium carbonate (54 mg, 
0.51 mmol) in THF (5 ml). The solution was stirred for five minutes at room 
temperature and heated at 80 °C for 17 hours. The solution was cooled to room 
temperature and passed through a short pad of Celite®, eluting with ethyl acetate. 
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The filtrate was concentrated under vacuum to give the crude product, which was 
partially purified by flash chromatography, eluting with 12:1 cyclohexane:ethyl 
acetate, to give an approximately 3:1 mixture of the title compound and 2-
(bromomethyl)-4-(2-chloroethyl)phenyl acetate 154 (25 mg). The mixture was further 
purified by reverse phase HPLC to give the diarylmethane 178 as white needles (13 
mg, 21%). RF 0.30 (4:1 cyclohexane-ethyl acetate); νmax/cm-1 2926, 1758, 1617; δH 
(400 MHz; CDCl3) 7.56 (2H, d, J 8.1, 2ʼ-ArH and 4ʼ-ArH), 7.28 (2H, m, 1ʼ-ArH and 6ʼ-
ArH), 7.17 (1H, dd, J 8.2, 2.0, 6-ArH), 7.09-7.02 (2H, m, 3-ArH and 5-ArH), 3.96 (2H, 
s, ArCH3Ar), 3.70 (2H, t, J 7.4, CH2Cl), 3.04 (2H, t, J 7.4, ArCH2), 2.22 (3H, s, 
COCH3), δC (101 MHz; CDCl3) 166.6 (C=O), 148.2 (1-ArC), 144.2, 136.6, 132.3, 
131.8, 129.4, 129.2, 128.9, 128.69, 125.8, 125.8, 125.8, 123.2, 45.2, 38.9, 36.6 and 
21.2; m/z (CI) found [M+H]+ 357.0858; C18H16ClF3O2 requires [M+H]+ 357.0864. 
 
4-(2-Chloroethyl)-2-(naphthalen-1-ylmethyl)phenylacetate 179 
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2-Napthylboronic acid (59 mg, 0.35 mmol) was added to a stirring solution of 2-
(bromomethyl)-4-(2-chloroethyl)phenyl acetate 154 (50 mg, 0.17 mmol), trans-
bromo(N-succinimidyl)bis(triphenylphosphine)palladium(II)-bromo(bistriphenyl-
phosphine) (14 mg, 0.02 mmol) and sodium carbonate (54 mg, 0.51 mmol) in THF (5 
ml). The solution was stirred for five minutes at room temperature and heated at 80 
°C for 17 hours. The solution was cooled to room temperature and passed through a 
short pad of Celite®, eluting with ethyl acetate. The filtrate was concentrated under 
vacuum to give the crude product, which was purified by flash chromatography, 
eluting with 12:1 cyclohexane:ethyl acetate, to give the diarylmethane 179 as a 
yellow oil (27 mg, 47%). RF 0.53 (4:1 cyclohexane-ethyl acetate); νmax/cm-1 3046, 
1759, 1599; δH (400 MHz; CDCl3) 7.92 (2H, m, 6ʼ-napthylH, 9ʼ-napthylH), 7.81 (1H, d, 
J 8.2, 4ʼ-napthylH), 7.55-7.40 (3H, m, 3ʼ-napthylH, 7ʼ-napthylH and 8ʼ-napthylH), 7.24 
(1H, d, J 7.0, 2ʼ-napthylH), 7.13 (1H, dd, J 8.2, 1.9, 6-ArH), 7.08 (1H, d, J 8.2, 5-ArH), 
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6.83 (1H, s, 3-ArH), 4.34 (2H, s, ArCH2Ar), 3.57 (2H, t, J 7.5, CH2Cl), 2.92 (2H, t, J 
7.5, ArCH2), 2.22 (3H, s, COCH3); δC (101 MHz; CDCl3) 169.9 (C=O), 148.2 (1-ArC), 
136.4, 135.4, 134.2, 133.1, 132.4, 131.3, 129.1, 128.2, 127.8, 127.7, 126.5, 126.1, 
126.0, 124.4, 122.8, 45.1, 38.9, 33.4 and 21.2; m/z (CI) found [M+H]+ 338.1067; 
C21H19ClO2 requires [M+H]+ 338.1068. 
 
4-(2-Chloroethyl)-2-(furan-2-ylmethyl)phenylacetate 180 
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Furan-2-ylboronic acid (38 mg, 0.35 mmol) was added to a stirring solution of 2-
(bromomethyl)-4-(2-chloroethyl)phenyl acetate 154 (50 mg, 0.17 mmol), trans-
bromo(N-succinimidyl)bis(triphenylphosphine)palladium(II)bromo-(bistriphenyl-
phosphine) (14 mg, 0.02 mmol) and sodium carbonate (54 mg, 0.51 mmol) in THF (5 
ml). The solution was stirred for five minutes at room temperature and heated at 80 
°C for 40 hours. The solution was cooled to room temperature and passed through a 
short pad of Celite®, eluting with ethyl acetate. The filtrate was concentrated under 
vacuum to give the crude product, which was partially purified by flash 
chromatography, eluting with 12:1 cyclohexane:ethyl acetate, to give an 
approximately 9:1 mixture of the title compound and 2-(bromomethyl)-4-(2-
chloroethyl)phenyl acetate 154 (18 mg). The mixture was purified by reverse phase 
HPLC to give the diarylmethane 180 as a yellow oil (12 mg, 25%). RF 0.30 (4:1 
cyclohexane-ethyl acetate); νmax/cm-1 2958, 1761, 1680; δH (400 MHz; CDCl3) 7.34 
(1H, d, J 1.7, 4ʼ-furylH), 7.15 (1H, dd, J 8.2, 2.0, 6-ArH), 7.09 (1H, d, J 1.7, 3-ArH), 
7.04 (1H, d, J 8.2, 5-ArH), 6.31 (1H, m, 3ʼ-furylH), 6.01 (1H, d, J 2.5, 2ʼ-furylH), 3.90 
(2H, s, ArCH3Ar), 3.70 (2H, t, J 7.5, CH2Cl), 3.05 (2H, t, J 7.5, ArCH2), 2.28 (3H, s, 
COCH3); δC (101 MHz; CDCl3) 169.6 (C=O), 152.3 (1-ArC), 148.1, 142.0, 136.4, 
131.4, 130.6, 128.6, 123.1, 110.8, 106.9, 45.2, 39.0, 29.5 and 21.3; m/z (CI) found 
[M+H]+ 279.0781; C15H15ClO3 requires [M+H]+ 279.0782. 
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4-(2-Chloroethyl)-2-(2,3,4-trimethoxybenzyl)phenylacetate 181 
 
O
OMe
OMe
OMe
O
Cl
1
2
3
45
6 1'
2' 3'
4'
5'
6'
 
 
2,3,4-Trimethoxphenylboronic acid (73 mg, 0.35 mmol) was added to a stirring 
solution of 2-(bromomethyl)-4-(2-chloroethyl)phenyl acetate 154 (50 mg, 0.17 mmol), 
trans-bromo(N-succinimidyl)bis(triphenylphosphine)- palladium(II) 
bromo(bistriphenyl-phosphine) (14 mg, 0.02 mmol) and sodium carbonate (54 mg, 
0.51 mmol) in THF (5 ml). The solution was stirred for five minutes at room 
temperature and heated at 80 °C for 17 hours. The solution was cooled to room 
temperature and passed through a short pad of Celite®, eluting with ethyl acetate. 
The filtrate was concentrated under vacuum to give the crude product, which was 
partially purified by flash chromatography (gradient elution: with cyclohexane:ethyl 
acetate 12:1 to 9:1) to give the diarylmethane 181 in approximately 90% purity (14 
mg). The mixture was purified by reverse phase HPLC to give the diarylmethane 181 
as a yellow oil (6 mg, 9%). RF 0.13 (12:1 cyclohexane-ethyl acetate); νmax/cm-1 2937, 
1760, 1601; δH (400 MHz; CDCl3) 7.10 (1H, dd, J 8.2, 2.0, 6-ArH), 7.02-7.00 (2H, m, 
3-ArH and 5-ArH), 6.73 (1H, d, J 8.5, 6ʼ-ArH), 6.61 (1H, d, J 8.5, 5ʼ-ArH), 3.89 (2H, s, 
ArOCH3), 3.86 (3H, s, ArOCH3), 3.83 (2H, s, ArCH3Ar), 3.75 (3H, s, 3ʼ-ArOCH3), 3.67 
(2H, t, J 7.5, CH2Cl), 3.01 (2H, t, J 7.5, ArCH2), 2.27 (3H, s, OCH3); δC (101 MHz; 
CDCl3) 169.9 (C=O), 152.8, 152.2, 148.2, 136.2, 133.7, 131.6, 127.9, 125.9, 124.8, 
122.8, 107.5, 61.2, 56.3, 45.2, 39.0, 30.3 and 21.3; m/z (CI) found [M+H]+ 379.1288; 
C20H23ClO5 requires [M+H]+ 379.1307. 
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2-(2-Chlorobenzoyl)-4-(2-chloroethyl)phenylacetate 183 
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Aluminium chloride (244 mg, 1.83 mmol) was added to a stirring solution of 2-
chlorobenzoyl chloride (250 μl, 1.83 mmol) and 1-(2-chloroethyl)-4-methoxybenzene 
47 (250 μl, 1.83 mmol) in dichloromethane (5 ml). The solution was heated at 55 °C 
for 17 hours and cooled to room temperature. The solution was diluted with 
dichloromethane (5 ml) and water (10 ml) was cautiously added. The organic and 
aqueous layers were separated, and the aqueous layer extracted with 
dichloromethane (3 × 10 ml). The combined organic layers were dried (MgSO4) and 
concentrated under vacuum. The resulting residue was dissolved in pyridine (3 ml). 
Acetic anhydride (1 ml) and 4-dimethylaminopyridine (catalytic amount) were added, 
and the solution stirred at room temperature for 15 hours. The solution was 
concentrated under vacuum to give the crude product, which was purified by flash 
chromatography, eluting with 7:1 cyclohexane-ethyl acetate, to give the diarylketone 
183 as a viscous colourless oil (331 mg, 59%); RF 0.29 (7:1 cyclohexane-ethyl 
acetate); νmax/cm-1 3064, 1764, 1668; δH (400 MHz; CDCl3) 7.49 (1H, s, 3-ArH), 7.44-
7.39 (4H, m, ArH), 7.35-7.31 (1H, m, ArH), 7.08 (1H, d, J 8.2, 5-ArH), 3.68 (2H, t, J 
7.2, CH2Cl), 3.06 (2H, t, J 7.2, CH2Ar), 1.92 (3H, s, COCH3); δC (101 MHz; CDCl3) 
193.5 (C=O), 169.7 (1-ArC), 148.9, 134.8, 132.2, 132.2, 130.9, 130.7, 130.4, 127.2, 
124.2, 44.9, 38.6 and 20.8; m/z (CI) found [M+H]+ 337.0409; C17H14Cl2O3 requires 
[M+H]+ 337.0393. 
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2-(3-Chlorobenzoyl)-4-(2-chloroethyl)phenylacetate 184 
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Thionyl chloride (1 ml) was added cautiously to 2-chlorobenzoic acid (285 mg, 1.82 
mmol) at 0 C. The solution was stirred at room temperature for 13 hours and 
concentrated under vacuum. The resulting residue was dissolved in 1,2-
dichloroethane (5 ml). Aluminium chloride (244 mg, 1.83 mmol) and 1-(2-chloroethyl)-
4-methoxybenzene 47 (200 μl, 1.45 mmol) were added to the stirring solution. The 
solution was heated at 85 °C for 19 hours and cooled to room temperature. The 
solution was diluted with dichloromethane (5 ml) and water (10 ml) was cautiously 
added. The organic and aqueous layers were separated, and the aqueous layer 
extracted with dichloromethane (3 × 10 ml). The combined organic layers were dried 
(MgSO4) and concentrated under vacuum. The resulting residue was dissolved in 
pyridine (3 ml). Acetic anhydride (1 ml) and 4-dimethylaminopyridine (catalytic 
amount) were added, and the solution stirred at room temperature for 17 hours. The 
solution was concentrated under vacuum to give the crude product, which was 
purified by flash chromatography (gradient elution cyclohexane-ethyl acetate 7:1 to 
4:1) to give the diarylketone 184 as a colourless oil (109 mg, 24%); RF 0.15 (7:1 
cyclohexane-ethyl acetate); νmax/cm-1 3066, 1765, 1668; δH (400 MHz; CDCl3) 7.81-
7.79 (1H, m, 2ʼ-ArH), 7.65 (1H, d, J 7.8, 4ʼ-ArH), 7.58 (1H, m, 6ʼ-ArH), 7.47-7.39 (3H, 
m, ArH), 7.18 (1H, d, J 8.3, 5-ArH), 3.74 (2H, t, J 7.0, CH2Cl), 3.11 (2H, t, J 7.0, 
ArCH2), 2.01 (3H, s, COCH3); δC (101 MHz; CDCl3) 193.6 (C=O), 169.5 (1-ArC), 
148.0, 139.4, 136.3, 135.1, 133.4, 131.2, 130.3, 130.0, 128.4, 123.9, 45.0, 38.5 and 
21.0; m/z (ES) found [M+Na]+ 359.0214; C17H14Cl2O3 requires [M+Na]+ 359.0212.  
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4-(2-Chloroethyl)-2-(2-methoxybenzoyl)phenylacetate 185 
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Thionyl chloride (1 ml) was added cautiously to 2-methoxybenzoic acid (277 mg, 1.82 
mmol) at 0 C. The solution was stirred at room temperature for 16 hours and 
concentrated under vacuum. The resulting residue was dissolved in 1,2-
dichloroethane (5 ml). Aluminium chloride (244 mg, 1.83 mmol) and 1-(2-chloroethyl)-
4-methoxybenzene 47 (200 μl, 1.45 mmol) were added to the stirring solution. The 
solution was heated at 85 °C for 16 hours and cooled to room temperature. The 
solution was diluted with dichloromethane (5 ml) and water (10 ml) was cautiously 
added. The organic and aqueous layers were separated, and the aqueous layer 
extracted with dichloromethane (3 × 10 ml). The combined organic layers were dried 
(MgSO4) and concentrated under vacuum. The resulting residue was dissolved in 
pyridine (3 ml). Acetic anhydride (1 ml) and 4-dimethylaminopyridine (catalytic 
amount) were added, and the solution stirred at room temperature for 19 hours. The 
solution was concentrated under vacuum to give the crude product, which was 
purified by flash chromatography, eluting with 7:1 cyclohexane-ethyl acetate, to give 
the diarylketone 185 as a yellow oil, obtained as a 1:1 mixture of rotamers α and β 
(338 mg, 56%); RF 0.26 (4:1 cyclohexane-ethyl acetate); νmax/cm-1 2943, 1764, 1655, 
1600; δH (400 MHz; CDCl3) 7.68-7.65 (1H, m, ArH), 7.57-7.46 (4H, m, ArH), 7.41-
7.30 (4H, m, ArH), 7.13 (1H, d, J 8.1, ArH), 7.08-7.03 (2H, m, ArH), 6.97-6.90 (2H, m, 
ArH), 3.75-3.70 (4H, m, CH2Clα and CH2Clβ), 3.68 (3H, s, OCH3α), 3.67 (3H, s, 
OCH3β), 3.10 (2H, t, J 7.2, ArCH2α), 3.04 (2H, t, J 7.2, ArCH2β), 1.88 (3H, s, 
COCH3α), 1.85 (3H, s, COCH3β); δC (101 MHz; CDCl3) 194.2 (C=O), 169.7, 169.6, 
158.6, 157.6, 149.4, 148.3, 136.1, 133.9, 133.5, 133.4, 133.1, 133.0, 132.8, 131.4, 
131.3, 131.0, 130.9, 130.6, 129.6, 129.4, 126.2, 123.5, 123.4, 121.0, 111.9, 111.8, 
56.1, 56.0, 45.5, 45.0, 38.7, 38.3, 20.8 and 20.7; m/z (CI) found [M+H]+ 333.0882; 
C18H17ClO4 requires [M+H]+ 333.0888. 
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4-(2-Chloroethyl)-2-(3-methoxybenzoyl)phenylacetate 186 
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Thionyl chloride (1 ml) was added cautiously to 3-methoxybenzoic acid (277 mg, 1.82 
mmol) at 0 C. The solution was stirred at room temperature for 13 hours and 
concentrated under vacuum. The resulting residue was dissolved in 1,2-
dichloroethane (5 ml). Aluminium chloride (244 mg, 1.83 mmol) and 1-(2-chloroethyl)-
4-methoxybenzene 47 (200 μl, 1.45 mmol) were added to the stirring solution. The 
solution was heated at 85 °C for 19 hours and cooled to room temperature. The 
solution was diluted with dichloromethane (5 ml) and water (10 ml) was cautiously 
added. The organic and aqueous layers were separated, and the aqueous layer 
extracted with dichloromethane (3 × 10 ml). The combined organic layers were dried 
(MgSO4) and concentrated under vacuum. The resulting residue was dissolved in 
pyridine (3 ml). Acetic anhydride (1 ml) and 4-dimethylaminopyridine (catalytic 
amount) were added, and the solution stirred at room temperature for 17 hours. The 
solution was concentrated under vacuum to give the crude product, which was 
purified by flash chromatography, eluting with 7:1 cyclohexane-ethyl acetate, to give 
the diarylketone 186 as a pale yellow oil (67 mg, 15%); RF 0.26 (7:1 cyclohexane-
ethyl acetate); νmax/cm-1 2938, 1765, 1664, 1582; δH (400 MHz; CDCl3) 7.45-7.32 (5H, 
m, ArH), 7.19-7.14 (2H, m, ArH), 3.86 (3H, s, OCH3), 3.75 (2H, t, J 7.2, CH2Cl), 3.12 
(2H, t, J 7.2, CH2Ar), 1.99 (3H, s, COCH3); δC (101 MHz; CDCl3) 194.8 (C=O), 169.5, 
160.0, 148.0, 139.2, 136.1, 133.0, 131.1, 129.8, 123.8, 123.1, 120.4, 113.8, 55.9, 
44.9, 38.6 and 20.9; m/z (ES) found [M+H]+ 333.0891; C18H17ClO4 requires [M+H]+ 
333.0888. 
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4-(2-Chloroethyl)-2-(4-methoxybenzoyl)phenylacetate 187 
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Aluminium chloride (244 mg, 1.83 mmol) was added to a stirring solution of 4-
methoxybenzoyl chloride (250 μl, 1.83 mmol) and 1-(2-chloroethyl)-4-
methoxybenzene 47 (250 μl, 1.83 mmol) in 1,2-dichloroethane (5 ml). The solution 
was heated at 85 °C for 16 hours and cooled to room temperature. The solution was 
diluted with dichloromethane (5 ml) and water (10 ml) was cautiously added. The 
organic and aqueous layers were separated, and the aqueous layer extracted with 
dichloromethane (3 × 10 ml). The combined organic layers were dried (MgSO4) and 
concentrated under vacuum. The resulting residue was dissolved in pyridine (3 ml). 
Acetic anhydride (1 ml) and 4-dimethylaminopyridine (catalytic amount) were added, 
and the solution stirred at room temperature for 19 hours. The solution was 
concentrated under vacuum to give the crude product, which was purified by flash 
chromatography (gradient elution cyclohexane-ethyl acetate 7:1 to 4:1) to give the 
diarylketone 187 as a yellow oil (414 mg, 75%); RF 0.10 (7:1 cyclohexane-ethyl 
acetate); νmax/cm-1 2932, 1764, 1656, 1597; δH (400 MHz; CDCl3) 7.80 (2H, d, J 8.9, 
2ʼ-ArH and 6ʼ-ArH), 7.48-7.33 (2H, m, 3-ArH and 6-ArH), 7.17 (1H, d, J 8.3, 5-ArH), 
6.96 (2H, d, J 8.9, 3ʼArH and 5ʼArH), 3.90 (3H, s, OCH3), 3.75 (2H, t, J 7.2, CH2Cl), 
3.12 (2H, t, J 7.2, ArCH2), 2.02 (3H, s, COCH3); δC (101 MHz; CDCl3) 193.6 (C=O), 
169.6 (1-ArC), 164.1, 147.7, 136.0, 132.7, 130.8, 130.4, 123.7, 114.1, 56.0, 45.0, 
38.7, 27.3 and 21.1; m/z (CI) found [M+H]+ 333.0880; C18H17ClO4 requires [M+H]+ 
333.0888. 
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OO
OMe
OMe
OMe
O
Cl
1
2
3
45
6 1'
2' 3'
4'
5'
6'
 
 
Thionyl chloride (1 ml) was added cautiously to 2,3,4-trimethoxybenzoic acid (386 
mg, 1.82 mmol) at 0 C. The solution was stirred at room temperature for 13 hours 
and concentrated under vacuum. The resulting residue was dissolved in 1,2-
dichloroethane (5 ml). Aluminium chloride (244 mg, 1.83 mmol) and 1-(2-chloroethyl)-
4-methoxybenzene 47 (200 μl, 1.45 mmol) were added to the stirring solution. The 
solution was heated at 85 °C for 19 hours and cooled to room temperature. The 
solution was diluted with dichloromethane (5 ml) and water (10 ml) was cautiously 
added. The organic and aqueous layers were separated, and the aqueous layer 
extracted with dichloromethane (3 × 10 ml). The combined organic layers were dried 
(MgSO4) and concentrated under vacuum. The resulting residue was dissolved in 
pyridine (3 ml). Acetic anhydride (1 ml) and 4-dimethylaminopyridine (catalytic 
amount) were added, and the solution stirred at room temperature for 17 hours. The 
solution was concentrated under vacuum to give the crude product, which was 
purified by flash chromatography (gradient elution: cyclohexane-ethyl acetate 7:1 to 
3:1) to give the diarylketone 188 as a yellow oil (309 mg, 60%); RF 0.35 (3:1 
cyclohexane-ethyl acetate); νmax/cm-1 2938, 1765, 1664, 1582; δH (400 MHz; CDCl3) 
7.44 (1H, d, J 8.8, 6-ArH), 7.31 (1H, dd, J 8.5, 2.2, 6ʼ-ArH), 7.22 (1H, d, J 2.2, 3-ArH), 
6.91 (1H, d, J = 8.5, 5ʼ-ArH), 6.83 (1H, d, J 8.8, 5-ArH), 3.95 (3H, s, 2ʼ-ArOCH3), 3.84 
(3H, s, 4ʼ-ArOCH3), 3.75-3.66 (5H, m, 3ʼ-ArOCH3 and CH2Cl), 3.02 (3H, t, J 7.1, 
ArCH2), 2.00 (3H, s, COCH3); δC (101 MHz; CDCl3) 193.3 (C=O), 169.2 (1-ArC), 
157.5, 157.0, 144.3, 141.6, 133.0, 130.5, 130.4, 127.7, 125.7, 111.8, 109.2, 61.3, 
56.5, 56.2, 45.5, 38.3 and 20.6; m/z (ES) found [M+H]+ 393.1096; C20H21ClO6 
requires [M+H]+ 393.1099. 
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2-(1-Naphthoyl)-4-(2-chloroethyl)phenylacetate 189 
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Aluminium chloride (244 mg, 1.83 mmol) was added to a stirring solution of 1-
napthoyl chloride (243 μl, 1.83 mmol) and 1-(2-chloroethyl)-4-methoxybenzene 47 
(250 μl, 1.83 mmol) in 1,2-dichloroethane (5 ml). The solution was heated at 85 °C 
for 16 hours and cooled to room temperature. The solution was diluted with 
dichloromethane (5 ml) and water (10 ml) was cautiously added. The organic and 
aqueous layers were separated, and the aqueous layer extracted with 
dichloromethane (3 × 10 ml). The combined organic layers were dried (MgSO4) and 
concentrated under vacuum. The resulting residue was dissolved in pyridine (3 ml). 
Acetic anhydride (1 ml) and 4-dimethylaminopyridine (catalytic amount) were added, 
and the solution stirred at room temperature for 19 hours. The solution was 
concentrated under vacuum to give the crude product, which was purified by flash 
chromatography, eluting with 7:1 cyclohexane-ethyl acetate, to give the diarylketone 
189 as a yellow oil (565 mg, 97%); RF 0.22 (7:1 cyclohexane-ethyl acetate); νmax/cm-1 
3051, 1763, 1659; δH (400 MHz; CDCl3) 8.44 (1H, d, J 7.6, 4ʼ-napthylH), 8.04 (1H, d, 
J 8.2, 6-ArH), 7.94 (1H, dd, J 7.0, 2.3, 2ʼ-napthylH), 7.65-7.43 (6H, m, 3-ArH and 
napthylH), 7.14 (1H, d, J 8.2, 5-ArH), 3.72 (2H, t, J 7.2, CH2Cl), 3.10 (3H, t, J 7.2, 
ArCH2), 1.75 (3H, s, COCH3); ); δC (101 MHz; CDCl3) 196.4 (C=O), 169.7 (1-ArC), 
148.9, 136.3, 134.1, 133.9, 133.1, 132.9, 132.2, 131.0, 129.8, 128.8, 128.3, 127.0, 
126.0, 124.8, 124.0, 45.0, 38.6, 27.3 and 20.7; m/z (ES) found [M+H]+ 353.0942; 
C21H17ClO3 requires [M+H]+ 353.0939. 
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4-(2-Chloroethyl)-2-(furan-2-carbonyl)phenylacetate 190 
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Aluminium chloride (244 mg, 1.83 mmol) was added to a stirring solution of furan-2-
carbonyl chloride (179 μl, 1.83 mmol) and 1-(2-chloroethyl)-4-methoxybenzene 47 
(250 μl, 1.83 mmol) in dichloromethane (5 ml). The solution was heated at 55 °C for 
21 hours and cooled to room temperature. The solution was diluted with 
dichloromethane (5 ml) and water (10 ml) was cautiously added. The organic and 
aqueous layers were separated, and the aqueous layer extracted with 
dichloromethane (3 × 10 ml). The combined organic layers were dried (MgSO4) and 
concentrated under vacuum. The resulting residue was dissolved in pyridine (3 ml). 
Acetic anhydride (1 ml) and 4-dimethylaminopyridine (catalytic amount) were added, 
and the solution stirred at room temperature for 15 hours. The solution was 
concentrated under vacuum to give the crude product, which was purified by flash 
chromatography (gradient elution cyclohexane-ethyl acetate 7:1 to 4:1) to give the 
diarylketone 190 as a yellow oil (196 mg, 40%); RF 0.31 (4:1 cyclohexane-ethyl 
acetate); νmax/cm-1 3133, 1763, 1650, 1564, 1974; δH (400 MHz; CDCl3) 7.68 (1H, d, J 
0.9, 4ʼ-furylH), 7.51 (1H, d, J 2.2, 3-ArH), 7.41 (1H, dd, J 8.3, 2.2, 6-ArH), 7.15 (1H, d, 
J 8.3, 5-ArH), 7.11 (1H, d, J 3.6, 2ʼ-furylH), 6.57 (1H, m, 3ʼ-furylH), 3.74 (2H, t, J 7.1, 
CH2Cl), 3.10 (2H, t, J 7.1, CH2Ar), 2.16 (3H, s, COCH3); δC (101 MHz; CDCl3) 181.2 
(C=O), 170.0 (1-ArC), 152.4, 148.2, 147.9, 147.8, 136.1, 130.7, 124.0, 121.6, 121.4, 
120.2, 112.9, 112.6, 45.1, 38.5 and 21.2; m/z (CI) found [M+H]+ 293.0569; 
C15H13ClO4 requires [M+H]+ 293.0575. 
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4-(2-Chloroethyl)-2-(cyclohexanecarbonyl)phenylacetate 191 
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Aluminium chloride (244 mg, 1.83 mmol) was added to a stirring solution of 
cyclohexanecarbonyl chloride (244 μl, 1.83 mmol) and 1-(2-chloroethyl)-4-
methoxybenzene 47 (250 μl, 1.83 mmol) in dichloromethane (5 ml). The solution was 
heated at 55 °C for 17 hours and cooled to room temperature. The solution was 
diluted with dichloromethane (5 ml) and water (10 ml) was cautiously added. The 
organic and aqueous layers were separated, and the aqueous layer extracted with 
dichloromethane (3 × 10 ml). The combined organic layers were dried (MgSO4) and 
concentrated under vacuum. The resulting residue was dissolved in pyridine (3 ml). 
Acetic anhydride (1 ml) and 4-dimethylaminopyridine (catalytic amount) were added, 
and the solution stirred at room temperature for 15 hours. The solution was 
concentrated under vacuum to give the crude product, which was purified by flash 
chromatography (gradient elution cyclohexane-ethyl acetate 9:1 to 4:1) to give the 
diarylketone 191 as a viscous colourless oil (310 mg, 61%); RF 0.55 (4:1 
cyclohexane-ethyl acetate); νmax/cm-1 2930, 2854, 1765, 1683; δH (400 MHz; CDCl3) 
7.49 (1H, d, J 2.1, 3-ArH), 7.33 (1H, dd, J 8.3, 2.1, 6-ArH), 7.06 (1H, d, J 8.3, 5-ArH), 
3.70 (2H, t, J 7.2, CH2Cl), 3.08 (2H, t, J 7.2, CH2Ar), 3.02-2.95 (1H, m, COCH(CH2)2) 
2.29 (3H, s, COCH2), 1.83-1.62 (4H, m, cyclohexyl), 1.44-1.20 (5H, m, cyclohexyl); δC 
(101 MHz; CDCl3) 204.5 (C=O), 169.9 (1-ArC), 148.1, 136.3, 133.2, 131.6, 130.2, 
124.3, 49.1, 45.0, 38.7, 29.3, 26.3, 26.2 and 21.5; m/z (CI) found [M+H]+ 309.1257; 
C17H21ClO3 requires [M+H]+ 309.1252.  
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4-(2-Chloroethyl)-2-bromophenylacetate 192 
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Acetic anhydride (1 ml) was added to a stirring solution of 4-(2-chloroethyl)-2-
bromophenol (1.24 g, 5.27 mmol) and 4-dimethylaminopyridine (catalytic amount) in 
triethylamine (3 ml). The solution was stirred for 18 hours at room temperature, 
concentrated under vacuum and the resulting residue purified by flash 
chromatography, eluting with 9:1 hexane-ethyl acetate, to give the acetate 192 as a 
pale yellow oil (1.01 g, 69%). RF 0.25 (9:1 hexane-ethyl acetate); νmax/cm-1 2961, 
1764; δH (500 MHz; CDCl3) 7.51 (1H, s, 3-ArH), 7.18 (1H, d, J 8.2, 6-ArH), 7.07 (1H, 
d, J 8.2, 5-ArH), 3.69 (2H, t, J 7.2, CH2Cl), 3.02 (2H, t, J 7.2, ArCH2), 2.35 (3H, s, 
COCH3); δC (125 MHz; CDCl3) 168.7 (C=O), 147.2 (1-ArC), 137.7, 133.6, 129.1, 
123.8, 116.3, 44.5, 38.2 and 20.9; m/z (EI) found [M]+ 275.9544; C10H1079BrClO2 
requires [M]+ 275.9542. 
 
2ʼ-Chloro-5-(2-chloroethyl)biphenyl-2-yl acetate 193 
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2-Chlorophenylboronic acid (122 mg, 0.78 mmol) was added to a stirring solution of 
4-(2-chloroethyl)-2-bromophenylacetate 192 (108 mg, 0.39 mmol), palladium acetate 
(2 mg, 0.01 mmol), potassium phosphate (249 mg, 1.17 mmol) and SPhos 67 (6 mg, 
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0.01 mmol) in THF (3 ml). The solution was heated for 16 hours at 85 °C and cooled 
to room temperature. The filtrate was passed through a short pad of Celite®, eluting 
with ethyl acetate, and concentrated under vacuum to give the crude product, which 
was partially purified by flash chromatography, eluting with 6:1 hexane-ethyl acetate, 
to give an approximately 2.5:1 chromatographically inseparable mixture of biaryl 193 
and bromide 192 as a yellow oil (73 mg). RF 0.36 (4:1 hexane-ethyl acetate); νmax/cm-
1 2958, 1762, 1566; δH (300 MHz; CDCl3) 7.48-7.45 (1H, m, ArH), 7.32-7.13 (6H, m, 
ArH), 3.74 (2H, t, J 7.4, CH2Cl), 3.08 92H, t, J 7.4, ArCH2), 2.00 (3H, s, COCH3); δC 
(75 MHz; CDCl3) 169.2 (C=O), 147.0, 137.6, 136.1, 135.7, 133.5, 132.4, 131.6, 
129.6, 129.0, 126.5, 123.7, 122.6, 44.7, 38.6 and 20.7; m/z (EI) found [M]+ 308.0356; 
C16H14O2Cl2 requires [M]+ 308.0365. 
 
3ʼ-Chloro-5-(2-chloroethyl)biphenyl-2-yl acetate 194 
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3-Chlorophenylboronic acid (122 mg, 0.78 mmol) was added to a stirring solution of 
4-(2-chloroethyl)-2-bromophenylacetate 192 (108 mg, 0.39 mmol), palladium acetate 
(2 mg, 0.01 mmol), potassium phosphate (249 mg, 1.17 mmol) and SPhos 67 (6 mg, 
0.01 mmol) in THF (3 ml). The solution was heated for 16 hours at 85 °C and cooled 
to room temperature. The filtrate was passed through a short pad of Celite®, eluting 
with ethyl acetate, and concentrated under vacuum to give the crude product, which 
was partially purified by flash chromatography, eluting with 6:1 hexane-ethyl acetate, 
to give an approximately 8:1 chromatographically inseparable mixture of biaryl 194 
and bromide 192 as a pale yellow oil (95 mg). RF 0.36 (4:1 hexane-ethyl acetate); 
νmax/cm-1 2959, 1762, 1595, 1565; δH (300 MHz; CDCl3) 7.36 (1H, s, 6-ArH), 7.33-
7.25 (5H, m, 4-ArH), 7.10 (1H, d, J 8.7, 6-ArH), 3.76 (2H, t, J 7.3, CH2Cl), 3.08 (2H, t, 
J 7.3, ArCH3), 2.12 (3H, s, COCH3); δC (75 MHz; CDCl3) 169.4 (C=O), 146.6, 139.1, 
136.5, 134.8, 134.2, 133.5, 130.4, 129.6, 129.5, 128.9, 127.2, 44.7, 38.5 and 20.9; 
m/z (EI) found [M]+ 308.0353; C16H14O2Cl2 requires [M]+ 308.0365. 
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5-(2-Chloroethyl)-4ʼ-(trifluoromethyl)biphenyl-2-yl acetate 195 
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4-(Trifluoromethyl)phenylboronic acid (149 mg, 0.78 mmol) was added to a stirring 
solution of 4-(2-chloroethyl)-2-bromophenylacetate 192 (108 mg, 0.39 mmol), 
palladium acetate (2 mg, 0.01 mmol), potassium phosphate (249 mg, 1.17 mmol) and 
SPhos 67 (6 mg, 0.01 mmol) in THF (3 ml). The solution was heated for 16 hours at 
85 °C and cooled to room temperature. The filtrate was passed through a short pad 
of Celite®, eluting with ethyl acetate, and concentrated under vacuum to give the 
crude product, which was partially purified by flash chromatography, eluting with 6:1 
hexane-ethyl acetate, to give an approximately 5.5:1 chromatographically 
inseparable mixture of biaryl 195 and bromide 192 as a pale yellow oil (95 mg). RF 
0.36 (4:1 hexane-ethyl acetate); νmax/cm-1 2965, 1763, 1619; δH (300 MHz; CDCl3) 
7.68 (2H, d, J 7.8, 3ʼ-ArH and 5ʼ-ArH), 7.55 (2H, d, J 7.8, 2ʼ-ArH and 6ʼ-ArH), 7.26-
7.18 (2H, m, 3-ArH and 5-ArH), 7.13 (1H, d, J 8.0, 4-ArH), 3.75 (2H, t, J 7.3, CH2Cl), 
3.12 (2H, t, J 7.3, ArCH2), 2.10 (3H, s, COCH3); δC (75 MHz; CDCl3) 169.4 (C=O), 
146.6, 141.1, 137.7, 136.6, 133.6, 131.2, 130.0, 129.7, 129.2, 125.3, 123.2, 115.4, 
44.7, 38.5 and 20.8; m/z (EI) found [M]+ 342.0638; C17H14O2Cl2F3 requires [M]+ 
342.0629. 
 
5-(2-Chloroethyl)-2'-methoxybiphenyl-2-yl acetate 196 
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2-Methoxyphenylboronic acid (119 mg, 0.78 mmol) was added to a stirring solution of 
4-(2-chloroethyl)-2-bromophenylacetate 192 (108 mg, 0.39 mmol), palladium acetate 
(2 mg, 0.01 mmol), potassium phosphate (249 mg, 1.17 mmol) and SPhos 67 (6 mg, 
0.01 mmol) in THF (3 ml). The solution was heated for 16 hours at 85 °C and cooled 
to room temperature. The filtrate was passed through a short pad of Celite®, eluting 
with ethyl acetate, and concentrated under vacuum to give the crude product, which 
was purified by flash chromatography, eluting with 6:1 hexane-ethyl acetate, to give 
the biaryl 196 as a pale yellow oil (53 mg, 45%). RF 0.26 (4:1 hexane-ethyl acetate); 
νmax/cm-1 2933, 1761, 1599, 1579; δH (300 MHz; CDCl3) 7.38-7.36 (1H, m, 6-ArH), 
7.25-7.19 (3H, m, ArH), 7.12 (1H, d, J 8.9, 4-ArH), 7.04-6.95 (2H, m, ArH), 3.74-3.68 
(5H, m, OCH3 and CH2Cl), 3.10 (2H, t, J 7.5, ArCH2), 2.04 (3H, s, COCH3); δC (75 
MHz; CDCl3) 169.3 (C=O), 156.7 (2-ArC), 147.3, 135.5, 132.1, 131.6, 131.2, 129.3, 
128.7, 126.4, 122.7, 120.6, 110.8, 55.5 (OCH3), 44.8, 38.7 and 20.8; m/z (EI) found 
[M]+ 304.0865; C17H17O3Cl requires [M]+ 304.0861. 
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3-Methoxyphenylboronic acid (119 mg, 0.78 mmol) was added to a stirring solution of 
4-(2-chloroethyl)-2-bromophenylacetate 192 (108 mg, 0.39 mmol), palladium acetate 
(2 mg, 0.01 mmol), potassium phosphate (249 mg, 1.17 mmol) and SPhos 67 (6 mg, 
0.01 mmol) in THF (3 ml). The solution was heated for 16 hours at 85 °C and cooled 
to room temperature. The filtrate was passed through a short pad of Celite®, eluting 
with ethyl acetate, and concentrated under vacuum to give the crude product, which 
was purified by flash chromatography, eluting with 6:1 hexane-ethyl acetate, to give 
the biaryl 197 as a pale yellow oil (61 mg, 51%). RF 0.29 (4:1 hexane-ethyl acetate); 
νmax/cm-1 2938, 1761, 1598, 1577; δH (300 MHz; CDCl3) 7.35-7.21 (3H, m, ArH), 7.09 
(1H, d, J 8.2, ArH), 6.99-6.96 (2H, m, ArH), 6.91 (1H, d, J 8.2, ArH), 3.83 (3H, s, 
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OCH3), 3.72 (2H, t, J 7.4, CH2Cl), 3.13 (2H, t, J 7.4, ArCH2), 2.11 (3H, s, COCH3); δC 
(75 MHz; CDCl3) 169.6 (C=O), 159.5 (1-ArC), 146.6, 138.8, 136.2, 134.8, 130.1, 
129.3, 129.0, 123.0, 121.3, 114.4, 113.3, 55.3 (OCH3), 44.7, 38.6 and 20.9; m/z (EI) 
found [M]+ 304.0872; C17H17O3Cl requires [M]+ 304.0861. 
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4-Methoxyphenylboronic acid (119 mg, 0.78 mmol) was added to a stirring solution of 
4-(2-chloroethyl)-2-bromophenylacetate 192 (108 mg, 0.39 mmol), palladium acetate 
(2 mg, 0.01 mmol), potassium phosphate (249 mg, 1.17 mmol) and SPhos 67 (6 mg, 
0.01 mmol) in THF (3 ml). The solution was heated for 16 hours at 85 °C and cooled 
to room temperature. The filtrate was passed through a short pad of Celite®, eluting 
with ethyl acetate, and concentrated under vacuum to give the crude product, which 
was purified by flash chromatography, eluting with 6:1 hexane-ethyl acetate, to give 
the biaryl 198 as a pale yellow oil (67 mg, 57%). RF 0.29 (4:1 hexane-ethyl acetate); 
νmax/cm-1 2934, 1760, 1610, 1517; δH (300 MHz; CDCl3) 7.35 (2H, d, J 6.8, 2ʼ-ArH and 
6ʼ-ArH), 7.24-7.17 (2H, m, ArH), 7.07 (1H, d, J 8.4, 4-ArH), 6.96 (2H, d, J 6.7, 3ʼ-ArH 
and 5ʼ-ArH); δC (75 MHz; CDCl3) 169.5 (C=O), 159.1 (1-ArC), 146.7, 136.2, 134.6, 
131.2, 130.0, 129.8, 128.4, 122.9, 113.8, 55.3 (OCH3), 44.8, 38.6 and 20.9; m/z (EI) 
found [M]+ 304.0857; C17H17O3Cl requires [M]+ 304.0861. 
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8.3. Biological Evaluation of Compounds 
8.3.1. Cell Culture Techniques 
MCF-7 breast cancer cells (ATCC) were cultured on 100 mm tissue culture plates 
(Nunc) in Dulbeccoʼs Modified Eagles Medium (DMEM) (Sigma) supplemented with 
10% foetal bovine serum (FBS) (Sigma) in a humidified incubator at 37 °C with a 
10% carbon dioxide atmosphere. When cells reached approximately 70% confluency 
they were split by aspirating the media, followed by washing once with PBS. Trypsin 
was added, and the cells were incubated at 37 °C for five minutes. The cells were 
resuspended in growth media and the cell suspension added to plates containing a 
further quantity of growth media. All manipulations were conducted aseptically in a 
laminar flow hood. 
 
8.3.2. Determination of Akt Inhibition  
For experimental purposes, cells were plated on 4 cm tissue culture plates (Nunc) in 
DMEM supplemented with 10% FBS (Sigma). Cells were deprived of serum 
overnight and the starved cells were incubated with DMEM supplemented with a 
solution of the corresponding compound dissolved in DMSO (50 μg/ml) and 
incubated at 37 °C for one hour. This was followed by stimulation with insulin (2 
μg/ml) (Sigma) and incubation at 37 °C for a further 15 minutes. After washing twice 
with ice-cold PBS, cells were harvested with 200 μl of lysis buffer (1.6 ml Tris 6.8 
(2M), 6 ml Glycerol (80%), 2.5 ml β-mercaptoethanol, 10 ml 10% SDS, 5 mg 
bromophenol blue, distilled water to 50 ml). The cell lysate was boiled at 100 °C for 
ten minutes. 
 
8.3.3. Western Blot Analysis 
Cell lysate samples were run on 10% polyacrylamide SDS gels at 100 V until the 
samples reached the stacking interface, when the voltage was raised to 150 V. Pre-
stained protein markers of known molecular weight (Biorad) were loaded onto the 
gels for comparison. Following electrophoresis the gel was placed into a cartridge 
sandwiched between two sponges, two pieces of blotting paper and a Whatman 
PROTRAN nitrocellulose membrane. The gels were transferred to the membrane at 
400 mA for 45 minutes in electron transfer buffer (2.9 g glycine, 5.8 g Tris, 370 mg 
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SDS, 200 ml MeOH, distilled water to 1 l) at 4 °C. The membrane was incubated in 
5% dried milk / TBS / 0.1% Tween for 30 minutes, then incubated in 5% dried milk 
powder / TBS / 0.1% Tween with the relevant primary antibody with gentle agitation 
at 4 °C overnight (Table 8.1). The membrane was washed three times in TBS / 0.1% 
Tween for five minutes and three times in TBS for five minutes. The membrane was 
incubated with the relevant secondary antibody with gentle agitation for one hour. 
The previous washing procedure was repeated, the membranes were probed using 
an HRP catalysed chemiluminescence reaction (GE Healthcare) and visualised using 
a Fuji Image Analyser LS3000 apparatus. 
 
Primary antibodies 
Antibody Source Species Dilution 
Akt Upstate Mouse 1:1000 
pAkt Ser473 Cell Signaling (9271S) Rabbit 1:1000 
α-tubulin Sigma (T9026) Mouse 1:1000 
 
Secondary antibodies 
Antibody Source Species Dilution 
Anti-mouse IgG HRP-conjugate Bio-Rad Mouse 1:1000 
Anti-rabbit IgG HRP-conjugate Bio-Rad Rabbit 1:1000 
 
Table 8.1. Antibodies used for Western blot analysis. 
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